|
Inventiva is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, lanifibranor, is an oral PPAR agonist currently undergoing a global Phase III clinical trial to evaluate its efficacy in treating MASH with fibrosis stages F2 and F3. The company holds global development and commercialization rights for lanifibranor, excluding Greater China, Japan, and South Korea, where it has entered licensing agreements with Sino Biopharmaceutical and Hepalys Pharma, respectively. Inventiva was created in 2012 following the divestiture of the research unit by Abbott Laboratories, which had acquired the asset from Fournier. The company's pipeline targets metabolic dysfunction, inflammation, and fibrosis in metabolic liver disease. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage inventivapharma.com |
| Sector Healthcare | IR page inventivapharma.com/investors | |
|
Tags
metabolic dysfunction-associated steatohepatitis, oral small molecules, ppar agonists, liver disease, clinical-stage, cardiometabolic health, fibrosis, inflammation, type 2 diabetes, lanifibranor, NATiV3, NATIVE, LEGEND, Sino Biopharmaceutical, Hepalys Pharma, Abbott Laboratories, Fournier
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | € 636.658M |
| Market cap (USD) | $ 699.623M |
| P/E | -1.73 |
| PEG | — |
| P/BV | 10.79 |
| P/S | 142.02 |
| P/OCF | -6.07 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 1,241.6% |
| ROI | — |
| ROIC | — |
| Profit margin | -7,899.6% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | — |
| Debt/Equity | 113.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -61.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||
| Trade receivables (EUR) | — | 4,000 | 48,000 | 4M | 0.00 | 3.81M | 531,000 | 2.02M |
| ↳ YoY growth | +1,100.0% | +8,233.3% | -100.0% | -86.1% | +279.7% | |||
| ↳ 5y CAGR | +165.8% | +111.2% | ||||||
| Borrowings, current (EUR) | — | 113,000 | 18,000 | 1.28M | 5.85M | — | — | — |
| Borrowings, non-current (EUR) | — | 2,000 | 10M | 8.84M | 28.7M | — | — | — |
| Cash and deposits (EUR) | 56.7M | 35.8M | 106M | 86.6M | 86.7M | 26.9M | 96.6M | 99.3M |
| Intangible assets (EUR) | — | 1.23M | 935,000 | 770,000 | 568,000 | 541,000 | 48,000 | 182,000 |
| Net debt (borrowings + leases - cash) (EUR) | — | -35.7M | -95.6M | -76.4M | -52.2M | — | — | — |
| Cash flow detail | ||||||||
| Operating cash flow (EUR) | — | -28.4M | -30.6M | -47.6M | -44.9M | -81.6M | -85.9M | -105M |
| Change in receivables (cash effect) (EUR) | — | 1.78M | -459,000 | -5.32M | 3.84M | -5.84M | 2.81M | 850,000 |
| Change in inventories (cash effect) (EUR) | — | 22,000 | 68,000 | -72,000 | 19,000 | -44,000 | 417,000 | 0.00 |
| Change in payables (cash effect) (EUR) | — | -2.97M | 1.27M | 7.6M | 3.54M | 20M | -3.34M | 2.56M |
| Interest paid (cash effect) (EUR) | — | — | — | — | — | 0.00 | 0.00 | -248,000 |
| Share-based compensation (EUR) | — | 1.41M | 938,000 | 2.09M | 2.22M | 3.97M | 3.58M | 26.8M |
| Operating cash flow before change in receivables (EUR) | — | -30.2M | -30.1M | -42.3M | -48.8M | -75.8M | -88.7M | -106M |
| Income detail | ||||||||
| Research and development expense (EUR) | — | 33.8M | 23.7M | 48.5M | 60.5M | 110M | 90.9M | 87M |
| ↳ 5y CAGR | +21.9% | +29.7% | ||||||
| Total comprehensive income (EUR) | — | -30.3M | -33.7M | -49.7M | -54M | -110M | -184M | -354M |
| Reported | Mar 11, 2022 | Mar 11, 2022 | Mar 11, 2022 | Mar 11, 2022 | Mar 29, 2023 | Apr 8, 2026 | Apr 8, 2026 | Apr 8, 2026 |
Podcast Mentions
Regulated information filed with the AMF (info-financiere.gouv.fr), newest first, titles as filed. Voting-rights totals, own-share transactions, threshold crossings and availability notices are left out. The link opens the filed document. Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesis
Preclinical data and Phase 2b clinical results showed lanifibranor improved liver sinusoidal endothelial cell alterations and was associated with changes in intrahepatic vascular abnormalities across multiple stages of disease
Analysis of plasma cell-free DNA (cfDNA) identified coordinated epigenetic changes across the PPAR family in patients with MASLD, supporting the biological rationale for targeting multiple PPAR isoforms
Daix (France), New York City (New York, United States), October 6, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of three abstracts at the upcoming AASLD The Liver Meeting® 2026, to be held from November 5-9, 2026, in Denver, Colorado.
Number of Shares and Voting Rights
Statement of total voting rights and shares forming the company’s share capital on September 30, 2026 Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Market: Euronext Paris ISIN code / Mnemo: FR0013233012/ IVA
Web site: www.inventivapharma.com
DATE
NUMBER OF SHARES OUTSTANDING
TOTAL VOTING RIGHTS, GROSS1
TOTAL VOTING RIGHTS, NET2
30 September 2026
237 986 695
246 879 509
246 879 509
- The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
- The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
pg. 1
Registered office: 50, rue de Dijon, 21121 Daix, France
1.
Interim Financial Report
6
1.1.
General overview of activities
6
1.2.
Significant events in the first half of 2026
6
1.3.
Risk factors
11
1.4.
Earnings analysis for the six months ended June 30, 2026
16
1.5.
Analysis of financial situation
23
2.
Cash flow and equity
25
2.1.
Cash and cash equivalents
25
2.2.
Cash flow analysis
27
2.3.
Anticipated sources of funds
29
3.
Unaudited interim condensed consolidated financial statements
31
4.
Other information
77
Table of delegations
77
2
Table of Contents
Definitions
In this first-half report (the “Interim Financial Report”), and unless otherwise specified, the terms Inventiva or the Company are taken to mean the company Inventiva S.A. with its registered office at 50, rue de Dijon, 21121 Daix, France, and which is listed with the Dijon Trade and Companies Register under number 537 530 255 and its subsidiary, 100% owned, Inventiva Inc. with its registered office at 10-34 44th Dr, Long Island City, 11101 New York, USA, created in January 2021.
COMMUNIQUÉ DE PRESSE
Inventiva publie ses résultats financiers non audités du premier semestre 2026 et fait le point sur ses activités • Trésorerie et équivalents de trésorerie à 166,1 millions d’euros et dépôts à court terme 1 à 67,8 millions d’euros au 30 juin 2026 • Horizon de trésorerie inchangé par rapport au 30 juillet 2026 2 • Résultats principaux de l’étude de Phase 3 NATiV3 attendus au quatrième trimestre 2026 • Faits marquants du premier semestre 2026 et actualités récentes de la Société • La Direction organisera un webcast aujourd’hui à 8h00 (heure de New York) pour discuter des résultats financiers du premier semestre 2026 Daix (France), New York (New York, États-Unis), le 28 septembre, 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a publié aujourd’hui ses informations financières pour le premier semestre 2026, clos le 30 juin 2026, notamment sa trésorerie, ses flux de trésorerie et ses revenus, et a fait le point sur ses activités.
Principaux résultats financiers pour le 1er semestre 2026 (en milliers d'euros)
Six mois clos 30 juin 2026
Chiffre d'affaires
Autres produits d'exploitation Frais de recherche et développement Frais de Marketing et de développement commercial Frais généraux et administratifs Autres produits (charges) opérationnels Résultat opérationnel (perte) Résultat financier
30 juin 2025 20
4 454
1 286
1 156
(46 238)
(44 890)
(2 589)
(746)
(22 247)
(14 713)
(619)
(8 202)
(70 388)
(62 940)
907
(113 224)
1 Les dépôts à court terme étaient classés dans la catégorie « autres actifs courants » dans l’état consolidé de la situation financière selon les normes IFRS, et étaient considérés par la Société comme liquides et facilement disponibles. 2 Cf communiqué de presse du 30 juillet 2026.
pg. 1
COMMUNIQUÉ DE PRESSE
Quote-part du résultat des sociétés mises en équivalence et gain de dilution Produit (charge) d'impôt Résultat Net Résultat net de base/dilué par action (euros/actions) Nombre moyen pondéré d'actions en circulation pour le calcul du résultat de base/dilué par action
117
(220)
(104)
503
(69 467)
(175 882)
(0,25)
(1,62)
273 582 870
108 839 636
Aucun chiffre d’affaires n’a été enregistré au premier semestre 2026, contre 4,5 millions d’euros enregistrés au cours de la même période en 2025. Le chiffre d’affaires comptabilisé au premier semestre 2025 était lié à l’accord de licence de 2022 conclu avec Chia Tai Tianging Pharmaceutical Group Co., Ltd., (tel que modifié et cédé à Chia Tai Tianging (Guangzhou) Co., Ltd.) Les autres produits d’exploitation se sont élevés à 1,3 million d’euros au premier semestre 2026, stable par rapport aux 1,2 million d’euros enregistrés au premier semestre 2025. Les autres produits provenaient principalement du crédit d’impôt recherche (« CIR »). Les dépenses de recherche et développement (« R&D ») pour le premier semestre 2026, se sont élevés à 46,2 millions d’euros, principalement en raison du développement clinique de lanifibranor dans la MASH, soit une hausse de 3,0 % par rapport aux 44,9 millions d’euros du premier semestre 2025. Cette augmentation est conforme aux prévisions et ne comprend aucun frais de recherche préclinique à la suite de l’arrêt des activités de R&D préclinique instaure à la mi-2025. Les dépenses de marketing et de développement commercial se sont élevées à 2,6 millions d’euros au premier semestre 2026, contre 0,7 million d’euros au cours de la même période en 2025, reflétant principalement l’augmentation des coûts de personnel ainsi que les dépenses liées à la préparation du potentiel développement commercial de lanifibranor, sous réserve de son approbation. Les frais généraux et administratifs (G&A) se sont élevés à 22,2 millions d’euros au premier semestre 2026, contre 14,7 millions d’euros au premier semestre 2025, soit une augmentation de 7,5 millions d’euros. Cette hausse est principalement liée à une augmentation de 4,7 millions d’euros des coûts de personnel, y compris les charges liées à la rémunération fondée sur des actions, ainsi que l’augmentation des honoraires de conseil et d’autres dépenses associées au développement commercial potentiel de lanifibranor, sous réserve de son approbation. Le résultat financier net (perte) s’est élevé à 0,9 million d’euros au premier semestre 2026, contre une perte de - 113,2 millions d’euros au cours de la même période en 2025. Le résultat financier du premier semestre 2026 reflète principalement (i) un impact positif de 16,2 millions d’euros, sans incidence sur la trésorerie, résultant de la comptabilisation à la juste valeur selon les normes IFRS des instruments financiers conclus dans le cadre de la restructuration des bons de souscription d’actions émis au profit de la Banque européenne d’investissement (“BEI”), des BSA Prêteurs attribués au profit des fonds et comptes gérés par BlackRock et Claret Capital Partners (ensemble les “Prêteurs”), ainsi que de l’option de conversion incorporée à la première tranche de 35,0 millions d’euros d’obligations senior garanties convertibles émises dans le cadre de l’opération de financement de juin 2026 conclu avec les Prêteurs pour un montant pouvant atteindre 130,0 millions d’euros (l’“Opération de Financement”), (ii) 4,8 millions d’euros de produits provenant des équivalents de trésorerie et de gains de change nets ; et (iii)
- 20,0 millions d’euros de charges d’intérêts et charges financières associées, dont 11,2 millions d’euros résultant du remboursement du prêt de la BEI et 7,4 millions d’euros de charges d’intérêts liées aux certificats de redevances émis en 2023 et 2024. La perte nette de la Société s’est élevée à - 69,5 millions d’euros au 30 juin 2026, contre - 175,9 millions d’euros au 30 juin 2025. pg. 2
COMMUNIQUÉ DE PRESSE
Au 30 juin 2026, la Société disposait de 166,1 millions d’euros de trésorerie et équivalents de trésorerie et de 67,8 millions d’euros de dépôts à court terme¹, contre respectivement 99,3 millions d’euros de trésorerie et équivalents de trésorerie et 131,6 millions d’euros de dépôts à court terme au 31 décembre 2025. Les flux nets de trésorerie consommés par les activités opérationnelles se sont élevés à - 45,4 millions d’euros au premier semestre 2026, contre - 53,7 millions d’euros au premier semestre 2025. La diminution des flux nets de trésorerie reflète principalement l’évolution favorable du besoin en fonds de roulement, qui a partiellement compensé l’augmentation des charges opérationnelles liées à l’avancement de l’étude clinique de Phase 3 NATiV3 et à la préparation des activités de précommercialisation. Les flux nets de trésorerie générés par les opérations d’investissement se sont élevés à 63,8 millions d’euros au premier semestre 2026, contre une consommation nette de - 24,8 millions d’euros au premier semestre 2025. Cette évolution s’explique principalement par les variations des dépôts à court terme de la Société, notamment dans le cadre de l’opération de refinancement global réalisée en juin 2026 3. Les flux de trésorerie générés par les activités de financement s’est élevée à 47,7 millions d’euros au premier semestre 2026, contre 104,8 millions d’euros au premier semestre 2025. Les flux nets de trésorerie générés par les activités de financement au cours du premier semestre 2026 reflètent l’opération de refinancement global annoncée le 2 juin 2026, comprenant l’offre aux Etats-Unis de 27.272.727 nouvelles American Depositary Shares (l’”Offre Equity”) pour un montant de 103 millions d'euros ainsi que les Tranches A et B de l’Opération de Financement, pour un montant de 75,0 millions d’euros, ces deux montants étant exprimés en produits bruts. Ce flux de trésorerie positif a été partiellement compensé par le remboursement anticipé intégral des prêts existants conclus avec la BEI, pour un montant total de 62,2 millions d'euros, ainsi que par le rachat de l’intégralité des bons de souscription d’actions émis au profit de la BEI dans le cadre de la première tranche des prêts BEI et de 700 000 des bons de souscription d’actions émis au profit de la BEI dans le cadre de la seconde tranche des prêts BEI, pour un prix total de rachat de 50 millions d'euros 4. Les flux nets de trésorerie générés par les activités de financement au cours du premier semestre 2025 provenaient du produit brut de 115,6 millions d'euros (soit un produit net de 108,0 millions d'euros) reçu dans le cadre du Financement Structuré de 2024 5. Compte tenu de la trésorerie et des équivalents de trésorerie dont dispose actuellement la Société, ainsi que du produit net de l’Offre Equity réalisée, de la finalisation des Opérations BEI et de l'émission des Tranches A et B dans le cadre de l’Opération de Financement 6, la Société prévoit de pouvoir financer ses activités conformément à ses prévisions actuelles jusqu'à la fin du deuxième trimestre 2027. A la date du présent communiqué, la trésorerie et les équivalents de trésorerie actuels de la Société ne sont pas suffisants pour couvrir ses besoins opérationnels actuellement prévus au cours des 12 prochains mois. Si la Tranche C de l’Opération de Financement3 est émise pour un produit potentiel pouvant atteindre 55,0 millions d'euros et les bons de souscription d'actions de la Tranche 3 précédemment émis dans le cadre du Financement Structuré5, représentant un produit potentiel pouvant atteindre 116,0 millions
3 Cf communiqué de presse du 2 juin 2026 4
Cf communiqué de presse du 2 juin 2026 et du 12 juin 2026 Cf communiqué de presse du 13 octobre 2024 6 Cf communiqué de presse du 2 juin 2026 (en particulier la description des engagements financiers regardant l'Opération de Financement) 5
pg. 3
COMMUNIQUÉ DE PRESSE
d'euros, sont intégralement exercés, la Société estime être en mesure de financer ses activités, conformément à son plan actuel, jusqu'au début du premier trimestre 2028 7. Au cours du premier semestre 2026, la Société a enregistré un effet de change positif sur la trésorerie et les équivalents de trésorerie de 0,7 million d’euros, contre un effet négatif de - 0,7 million d’euros au premier semestre 2025, principalement en raison de l’évolution du taux de change EUR/USD.
Actualités de la Société • • • •
•
•
Le 2 septembre 2026, Inventiva a annoncé que le dernier patient avait effectué sa dernière visite à 72 semaines dans le cadre de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor dans le traitement de patients atteints de MASH avec une fibrose modérée à avancée8. NATiV3 a inclus 1 009 patients adultes atteints de MASH non cirrhotique confirmée par biopsie et présentant une fibrose F2/F3, ainsi que 410 patients supplémentaires inclus dans une cohorte exploratoire. Inventiva prévoit de publier les résultats principaux (« topline ») de l’étude clinique de Phase 3 NATiV3 au quatrième trimestre 2026. Sous réserve de résultats favorables de l’étude NATiV3, la Société prévoit de soumettre une demande d’autorisation réglementaire au premier semestre 2027 et se prépare à un éventuel lancement du lanifibranor aux États-Unis en 2028, sous réserve de son approbation par la Food and Drug Administration (“FDA”) américaine. Depuis le début de l’année 2026, Inventiva a renforcé son équipe dirigeante avec la nomination d’ Axel-Sven Malkomes en qualité de Directeur financier (« Chief Financial Officer »), Susan Coles en qualité de Directrice juridique (« Chief Legal Officer »), Pamela Herbster en qualité de Directrice des ressources humaines (« Chief People Officer »)9et Chris Benecchi en qualité de Directeur des opérations (« Chief Operating Officer ») 10. Le Dr Barbara Krebs-Pohl, Ph.D., le Dr Anne Prener, M.D., Ph.D., et Mme Camilla Soenderby ont été nommés membres indépendants du Conseil d’administration de la Société, avec effet au 30 juin 2026, apportant l’expertise supplémentaire, la dimension internationale et les compétences stratégiques nécessaires pour accompagner la Société dans sa prochaine phase de développement et son potentiel développement commercial 11.
Webcast des résultats financiers du premier semestre La direction d’Inventiva tiendra une conférence téléphonique en anglais, suivie d’une séance de questions-réponses, le lundi 28 septembre 2026, à 8h00 (heure de New York, 14h00 (heure de Paris),
7 Ces estimations sont fondées sur le plan d’affaires actuel de la Société et supposent l’émission réussie de la Tranche C de l’Opération
de Financement, ainsi que l’exercice de l’intégralité des bons à souscription d’actions de la Tranche 3 précédemment émis par la Société dans le cadre du Financement Structuré, pour un produit potentiel pouvant atteindre 116,0 millions d’euros, et excluent tout paiement potentiel d’étapes clés dû à la Société ou payable par celle-ci, ainsi que toute dépense supplémentaire liée au candidat-médicament ou résultant de toute opération potentielle de prise de licence ou d’acquisition de candidats-médicaments ou de technologies supplémentaires, ou de tout développement de produit associé que la Société pourrait entreprendre. La Société pourrait avoir fondé ces estimations sur des hypothèses qui s’avéreraient inexactes et la Société pourrait être amenée à utiliser ses ressources plus rapidement que prévu. Ces estimations pourraient être réduites en cas d’augmentation des dépenses liées aux programmes de développement audelà des attentes de la Société, ou si les programmes de développement progressent plus rapidement que prévu. 8 Cf communiqué de presse du 2 septembre 2026 9
Cf communiqué de presse du 22 avril 2026
10
Cf communiqué de presse du 31 aout 2026
11
Cf communiqué de presse du 30 juin 2026 pg. 4
COMMUNIQUÉ DE PRESSE
afin de discuter des résultats financiers du premier semestre 2026. Les personnes souhaitant participer à la conférence téléphonique par téléphone et poser des questions doivent s’inscrire à l’avance ici. Après leur inscription, les participants recevront les informations de connexion par email. La retransmission en direct du webcast sera accessible dans la section Evènements du site internet d’Inventiva. Une rediffusion de la conférence téléphonique sera disponible après l’évènement sur le site internet de la Société.
Prochaine conférence scientifique American Association for the Study of Liver Diseases (AASLD), Denver, Colorado, du 5 au 9 novembre 2026.
Prochaine publication de résultats financiers Chiffre d’affaires et trésorerie et équivalents de trésorerie du troisième trimestre 2026 le lundi 23 novembre 2026 (avant l’ouverture des marchés européens et américains).
À propos du lanifibranor Le lanifibranor, principal candidat-médicament d’Inventiva, est une petite molécule administrée par voie orale qui vise à induire des effets antifibrotiques, anti-inflammatoires ainsi que des effets bénéfiques sur les fonctions vasculaires et métaboliques de l’organisme, en activant les trois isoformes des récepteurs activés par les proliférateurs de peroxysomes (« PPAR »), des protéines appartenant à la famille des récepteurs nucléaires qui régulent l’expression des gènes. Le lanifibranor est un agoniste des PPAR conçu pour cibler simultanément les trois isoformes PPAR avec une puissance modérée, grâce à une activation équilibrée de PPARα et PPARδ et à une activation partielle de PPARγ. Alors que d’autres agonistes des PPAR ciblent une ou deux isoformes, le lanifibranor est actuellement le seul agoniste pan PPAR en développement clinique pour le traitement de la MASH. Inventiva estime que le profil de liaison modéré et équilibré du lanifibranor aux trois isoformes PPAR contribue au profil de tolérance favorable observé à ce jour dans les études cliniques et précliniques. La FDA a accordé au lanifibranor les désignations « Breakthrough Therapy » et « Fast Track » pour le traitement de la MASH. Le lanifibranor est un médicament expérimental qui n’a été approuvé par aucune autorité réglementaire. Sa sécurité et son efficacité n’ont pas été établies.
À propos d'Inventiva Inventiva est une société biopharmaceutique au stade clinique spécialisée dans la recherche et développement d’une petite molécule administrée par voie orale pour le traitement de patients atteints de la MASH. La Société évalue actuellement le lanifibranor dans le cadre de l’étude clinique pivot de phase 3 pour le traitement de patients adultes atteints de la MASH, une maladie hépatique chronique courante et progressive. Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole : IVA, ISIN : FR0013233012) et sur le Nasdaq Global Market aux États-Unis (symbole : IVA). https://www.inventivapharma.com
H1 2026 Financial Report
September 28, 2026
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “estimate,” “may,” “will,” “could,” “should,” “designed,” “hope,” “target,” “potential,” “opportunity,” “possible,” “aim,” and “continue” or similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical fact, included in this presentation are forward-looking statements. These statements include, but are not limited to, statements concerning the potential therapeutic benefit of lanifibranor, the expected availability and timing of results from NATiV3, the timing of potential regulatory submissions, approvals and commercialization of lanifibranor, the potential market opportunity for lanifibranor, Inventiva’s cash resources and expenses and ability to obtain additional financial resources, including assumptions and conditions relating thereto, and Inventiva's future activities, expectations, plans, growth and prospects. Although Inventiva’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that such forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Inventiva, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, contingencies and uncertainties include, among other things, uncertainties inherent in research and development, clinical data and analysis and decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any product candidates, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; Inventiva’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; Inventiva’s ability to achieve milestones; Inventiva’s ability to obtain adequate financing to fund its operations and continue as a going concern, including Inventiva’s ability to enter into potential transactions on the expected timing or at all, Inventiva’s ability to comply with and satisfy the terms and conditions of its financing documents and whether, when and to what extent the securities issued in connection with Inventiva’s financing documents and other dilutive instruments, including the Tranche 3 warrants, may be exercised; Inventiva’s ability to execute on its strategy, including with respect to commercialization, marketing and manufacturing; potential negative impacts on Inventiva from changes in laws and regulations, unfavorable conditions in its industry, geopolitical events, and ongoing conflicts, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers; and the other risks and uncertainties described in Inventiva’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on April 8, 2026 and Inventiva’s Half-Year Report for the fiscal period ended June 30, 2026, filed on Form 6-K on September 28, 2026, including those described under the caption "Risk Factors", and in future filings with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Inventiva disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that Inventiva becomes aware of, except as required by law. This presentation discusses lanifibranor, a product candidate that is under clinical study and that has not yet been approved for marketing by the U.S. Food and Drug Administration or other regulatory agencies. No representation is made as to the safety or effectiveness of this product candidate for the therapeutic use for which such product candidate is being studied. This presentation does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
2
Inventiva Participants
ANDREW OBENSHAIN
JASON CAMPAGNA, MD, PhD
AXEL-SVEN MALKOMES
CHRIS BENECCHI
Chief Executive Officer
Chief Medical Officer & President of R&D
Chief Financial Officer
Chief Operating Officer
3
Agenda
- Corporate Overview
- Lanifibranor Clinical Program Update
- H1 2026 Highlights
- Q&A
4
Why Lanifibranor? Why Now? 01
DIFFERENTIATION
02
ADVANCING TO VALIDATION
03
MARKET OPPORTUNITY
Two Drivers of MASH
Phase 3 Builds on Phase 2b
MASH - A Validated Market
Designed to act on intra- and extra-hepatic drivers in a single, once-daily oral therapy, lanifibranor showed improvements across all histological endpoints in Phase 2b.
Same doses, histological endpoints used in Phase 2b, in F2/F3 patients. Powered at 90% on assumptions assuming higher placebo response and lower efficacy.
Potential to be well positioned as a differentiated option with the goal to address the multiple drivers of disease across patients with moderate to advanced fibrosis as well as high risk of progression.
18%
FIBROSIS IMPROVEMENT
26%
MASH RESOLUTION
24%
BOTH ENDPOINTS ACHIEVED
Q4 2026
NATiV3 TOPLINE 1,009 PATIENTS 72-WEEK
$15 Billion
EXPECTED MARKET SIZE BY 20351; THE FIRST APPROVED ORAL APPROACHED $1B IN ITS FIRST FULL YEAR
One molecule with differentiated potential. And a company built to deliver it.
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. NATIVE Phase 2b, NEJM 2021. NATiV3 design per company disclosures. Market: public company reporting and sell-side consensus. 1) DataM Intelligence November 2025
5
MASH: One Disease, Two Drivers 01
EXTRA-HEPATIC DRIVERS
02
INTRA-HEPATIC DRIVERS
Atherogenic Dyslipidemia
Hepatic Steatosis
Metabolic · ApoB Triglycerides Free Fatty Acid Flux
Metabolic · Hepatocyte
Insulin Resistance
Inflammation
Metabolic · Muscle And Systemic
Adipose Dysfunction Metabolic · Adipocyte
Inflammatory · Hepatic Macrophage
Fibrogenesis
Fibrotic · Hepatic Stellate Cell
An opportunity for a next-generation treatment to target more than just the liver. 6
Designed to Target Intra- and Extra-hepatic Drivers, Lanifibranor Showed Improvements Across Key MASH Endpoints in Phase 2b 01
EXTRA-HEPATIC DRIVERS Adipose Dysfunction
Direct
Adipocyte
PPARγ
Insulin Resistance
Direct
Muscle and Systemic
Atherogenic Dyslipidemia Cardiovbascular System
02
PAN-PPAR (Lanifibranor: Phase 2b – 6 Months)
PPARγ/δ
Hepatocyte
Inflammation Hepatic Macrophage
Fibrogenesis Hepatic Stellate Cell
26%
MASH RESOLUTION without worsening of fibrosis
24%
COMPOSITE ENDPOINT MASH resolution and fibrosis ≥1 stage
Direct PPARα
INTRA-HEPATIC DRIVERS Hepatic Steatosis
18%
FIBROSIS IMPROVEMENT ≥1 stage without worsening of MASH
Direct PPARα/δ
Direct PPARδ/γ
Direct PPARγ
Phase 3, NATiV3, evaluates the same doses, 800 mg and 1,200 mg, over 72-week with 1,009 patients, and powered at 90%. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. Lanifibranor: NATIVE Phase 2b (N=247, 6 mo), high-dose arm, effect size = active − placebo. Sources: NATIVE NEJM 2021. For discussion; not investment advice.
7
A Growing Market with Remaining High Unmet Need
~18M
AMERICANS WITH MASH1
~1.9M
Diagnosed MASH Population2
910K
Diagnosed F2 / F3 MASH Population2
~374K
F2 / F3 & Under Treater Care2
$15B
EXPECTED F2/F3 MASH MARKET BY 20353
+20-25%
GROWTH IN DIAGNOSED & F2–F3 POOLS VS 2024
MASH market evolving toward broader diagnosis and treatment – creating a potential opportunity for lanifibranor’s differentiated multi-pathway profile if approved.
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established.
- Estes. 2018. Hepatology; 2) Analysis conducted by Forian using CHRONOS ©2025 Forian Inc. and its licensors. All Rights Reserved; 3) DataM Intelligence November 2025
8
Lanifibranor’s Potential Profile Across Key MASH Patient Segments MASH is closely linked to cardiometabolic risk factors1 associated with disease progression F STAGES
CARDIOMETABOLIC RISK ASSOCIATED WITH DISEASE PROGRESSION
F2
F3
Non-T2D
~26%
~15%
T2D
~27%
~32%
Contested2
Potential for Differentiation2
Lanifibranor has the potential to offer a differentiated treatment option for patients with MASH and advanced fibrosis and in those at increased risk of disease progression driven by cardiometabolic risk factors.
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. This representation is an illustrative patient segmentation based on T2D status and fibrosis stage, informed by results from the NATIVE Phase 2b clinical trial. T2D is used as an illustrative cardiometabolic risk factor associated with disease progression. For discussion; not investment advice. 1) Cardiometabolic risk factors included in the MASLD definition are impaired glycemic control/diabetes, hypertension, low HDLC, hypertriglyceridemia, and obesity. 2) Positioning is forward-looking and based on our Phase 2b results and subject to clinical, regulatory and commercial outcomes.
9
Three Priorities to Potentially Unlock a Meaningful Impact for Patients
01
02
03
Q4 2026
H1 2027
2028
Potential NDA filing
Potential launch
EXPECTED TOPLINE READOUT
1,009 Patients
REGULATORY READINESS
COMMERCIAL READINESS
72-week
Last visit, last patient completed
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. 10
Rational Pan-PPAR Design Informed by Decades of Biology PPARs enable coordinated modulation of the metabolic, inflammatory, and fibrotic pathways at the core of MASH Potential Novel Chemical Entity Not a fibrate, not a thiazolidinedione (TZD).
Differentiated Co-activator Fingerprint Selective transcriptional fingerprint, enabling metabolic, anti-inflammatory, and antifibrotic activity.
A new chemical entity (not a fibrate, not a TZD) with FDA breakthrough therapy & fast track designation BALANCED RECEPTOR ACTIVATION PROFILE
SELECTIVE CO-FACTOR RECRUITMENT PROFILE
150
Balanced & Low Potency Across All Three Isoforms Engineered to mirror the potency range of pioglitazone and minimize the high γ-potency of rosiglitazone (~ 20x higher).
125
% Activation
Balanced PPAR Isoforms Engagement No single receptor dominance; delivers coordinated metabolic, inflammatory, and antifibrotic activity.
hPPAR
100
hPPAR hPPAR
75
Rosiglitazone Lanifibranor
50 25 0 -10
-8
-6
-4
Lanifibranor (M)
Lanifibranor: Low-potency, balanced PPAR-α/δ/γ activation designed to avoid receptor dominance. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. 11
NATIVE Phase 2b: Composite Endpoint Across Moderate to Advanced Fibrosis and Patients with T2D Resolution of MASH and improvement of fibrosis All patients (N=247)
7%
14% effect size Placebo
21%
24% effect size
31%
Phase 3 primary endpoint
p<0.001
p=0.017
Resolution of MASH and improvement of fibrosis F2/F3 patients only (N=188)
7%
24%
26% effect size
33%
3%
w/ diabetes subgroup
Lanifibranor 1,200 mg
17% effect size
F1 patients excluded
Resolution of MASH and improvement of fibrosis Patients with T2D (N=103)
Lanifibranor 800 mg
21% effect size
24%
26% effect size
29%
Composite response was numerically higher vs. all-patients population: F2/F3 (+3%) T2D (+2%)
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. NEJM – Table S4 Results for the key secondary histological endpoints on Full Analysis Set.
12
Phase 2b Safety and Tolerability Profile Investigator-reported most-frequent adverse events1 Placebo (N = 81)
800 mg (N = 83)
1,200 mg (N = 83)
Diarrhea
1 (1%)
8 (10%)
10 (12%)
Fatigue§
8 (10%)
3 (4%)
11 (13%)
Nausea
3 (4%)
8 (10%)
7 (8%)
Abdominal Painỻ
4 (5%)
4 (5%)
5 (6%)
Dizziness
3 (4%)
2 (2%)
6 (7%)
Constipation
6 (7%)
3 (4%)
5 (6%)
Increase In Aminotransferase Levelᶲ
1 (1%)
5 (6%)
3 (4%)
Headache
4 (5%)
4 (5%)
7 (8%)
Weight Gain
8 (10%)
7 (8%)
2 (2.5%)
5 (6%)
7* (8%)
1 (1%)
6 (7%)
Peripheral Edema** Anemia
iron deficiency anemia and decrease hemoglobin level
AE PROFILE CONSISTENT WITH RECEPTOR BIOLOGY
α
No rhabdomyolysis (acute, dose-related; clean preclinically and clinically). MACE at background rate
δ
No preclinical carcinogenicity and no myalgia or myopathy
γ
Weight gain, edema, dilutional Hgb decline, attenuated versus full agonists
full agonist for reference
Caveat: the clinical program runs 6 months, enough to detect acute signals but not long-latency ones (pioglitazone's bladder-cancer signal took years to emerge). Where preclinical and appropriately-timed clinical data both apply, the conclusion holds.
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. 1Adverse events are the ones reported by investigators and include those that occured in more than 5% of patients in either lanifibranor group. § Fatigue included asthenia. ỻ Abdominal pain included
upper and lower abdominal pain. ** Peripheral edema (bilateral ankle edema): usually mild, in most cases no treatment was required, a few patients received diuretics. 4 cases were considered study drug related by the investigator (2 at 800 and 1,200 mg each). One case of severe intensity, which resolved by stopping treatment (lanifibranor 1,200 mg) for 12 days, without reoccurrence when the study treatment was resumed. All were female patients. ᶲ Increase in aminotransferase level included increased in ALT, AST, or abnormal liver function test result.
13
Phase 2b Safety Profile: Findings Consistent with PPAR Pharmacology EARLY
LATER
Fluid Retention
Insulin Sensitization & Adipose Remodeling
PPARγ / ENaC · plasma volume ↑ · reversible
Adiponectin ↑
01
02
03
UNDERSTOOD
MODEST
MANAGEABLE
On-target, biphasic biology
+2.4 to +2.7 kg at Week 24
Weight gain is the on-target, biphasic effect of PPARγ: early fluid retention (ENaC, reversible) associated with peripheral edema and hemoglobin reduction, then adipose remodeling. Expected pharmacology.
vs −0.2 placebo; most within ±5% — within the TZD range. HOMA-IR, lipids & adiponectin improve.
Distal, ENaC-mediated fluid responds to natriuretics In LEGEND, adding an SGLT2i (empagliflozin) mitigated the γ-class signal — weight +0.1%, anemia 0% — with metabolic efficacy preserved.
On-target PPARγ activation: manageable fluid retention and insulin-sensitizing adipose remodeling. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. NATIVE Phase 2b (Week 24, Safety set); LEGEND Phase 2 (lanifibranor + empagliflozin, data on file). ±5% = clinically-meaningful weight threshold. For discussion; not investment advice.
14
NATiV3 Design Anchored in NATIVE Outcomes
Primary Endpoint
Dose, population, and endpoints aligned with NATIVE MAIN COHORT
72-WEEK OF TREATMENT
N=1,009
Noncirrhotic MASH and F2-F3 fibrosis
Placebo: once daily
End Of Treatment Biopsy
Key Secondary Endpoints
ACTIVE TREATMENT EXTENSION TRIAL
GLP-1 Inclusion
48-WEEK
EXPLORATORY COHORT 72-WEEK OF TREATMENT
N=410
Screen-failed patients from the main cohort: F1-F4 fibrosis
Composite end point of patients having both MASH resolution and 1 stage of fibrosis improvement
MASH resolution and no worsening of fibrosis, fibrosis improvement, and no worsening of MASH
Lanifibranor: 1,200 mg once daily Lanifibranor: 800 mg once daily
Lanifibranor: 1,200 mg once daily Lanifibranor: 800 mg once daily Placebo: once daily
NATiV3 CLINICAL TRIAL
EoT
Lanifibranor: 1,200 mg once daily Lanifibranor: 800 mg once daily
All patients who complete the main or the exploratory cohort are eligible for the Phase 3 active treatment extension trial
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. EoT, end of treatment; GLP-1, glucagon-like peptide-1; GLP-1-RA, glucagon-like peptide-1 receptor agonist; MASH, metabolic dysfunction-associated steatohepatitis.
Patients under a stable dose of GLP-1-RA for at least 3 months prior to screening or initiation after randomization into the study
Statistical Powering • • •
90% considered for sample size calculations Stratification by fibrosis stage and diabetic status NATiV3 fully recruited
Expected Topline Readout Q4 2026 Last Patient Last Visit completed 15
NATiV3 Population Consistent With NATIVE Higher diabetes prevalence and more advanced fibrosis NATiV3 (N=1,009)
DEMOGRAPHICS & METABOLIC PROFILE 59%
75%
58% 41%
Female
LIVER DISEASE PROFILE
Male
41%
33%
97
93
(± 23.6)
(± 18.8)
Weight (kg) mean ± SD
35%
F2
BMI Class Obese (≥30)
42%
9.8
10
(± 10.2)
(± 12.7)
6.5% T2D
5
(± 2.7)
(± 2.7)
329
37
ALT
AST median (U/L)
mean ±SD: NATiV3 = 59 ± 36 NATIVE = 62 ± 39
mean ±SD: NATiV3 = 47 ± 26 NATIVE = 47 ± 32
10%
3%
sGLT2i
327 9.6
10
6%
40
median (U/L)
F3
median: NATiV3 = 95kg NATIVE = 92kg
55%
51
50
4.6
CO-MEDICATIONS
67%
65%
42%
NATIVE (N=247)
1.3
9
9.7 14%
1.2
0%
HOMA-IR
HbA1c
Adiponectin (µg/mL)
LSM
CAP
Fib-4
ELF
mean ± SD
mean ± SD
mean ± SD
median (kPa)
median (dB/m)
median score
median score
median: NATiV3 = 6.2% NATIVE = 5.9%
median: NATiV3 = 4.0 NATIVE = 4.5
mean ±SD: NATiV3 = 11.1 ± 4.9 NATIVE = 10.09 ± 5.02
mean ±SD: NATiV3 = 324 ± 48 NATIVE = 327.7 ± 43.2
mean ±SD: NATiV3 = 1.49 ± 0.75 NATIVE = 1.41 ± 0.87
mean ±SD: NATiV3 = 9.7 ± 0.9 NATIVE = 9.7 ± 1.0
GLP-1 RA
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. Baseline characteristics are based on a preliminary data cut of October 2025 and are subject to change.
16
Lanifibranor is Designed to Target Core Pathophysiology Underlying MASH and cACLD Potential for an oral to address highest unmet medical need PPAR-α/δ normalize mitochondrial function and lipid flux; reduce lipotoxic stress
PPARγ inactivates hepatic stellate cells; restores quiescence
Adipose–liver axis: ↑ adiponectin → antifibrotic, anti-inflammatory, endothelial benefits
Portal pressure biology: Preclinical models showed improved sinusoidal tone and vascular remodeling
Broad reduction of systemic inflammation across macrophage and vascular beds
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. cACLD: compensated Advanced Chronic Liver Disease
Aiming to Confirm Potential Clinical Benefit In Compensated Advanced Chronic Liver Disease Due To MASH Planned Regulatory Filing Intended filing for Accelerated Approval (FDA) and Conditional Approval (EMA), subject to positive Phase 3 histology results
Planned Confirmatory Trial In patients with cACLD due to MASH designed to confirm clinical benefits: • Prevention of progression of the underlying liver disease physiology • Prevention or reduction of associated clinical outcomes: risk of hepatic decompensation, liver transplant, death 17
Highlights of First Half of 2026 Financial Results Six Months Ended (in thousands of euros)
June 30, 2026
Revenues
June 30, 2025
20
4,454
1,286
1,156
Research and development expenses
(46,238)
(44,890)
Marketing – business development expenses
(2,589)
(746)
General and administrative expenses
(22,247)
(14,713)
Other operating income (expenses)
(619)
(8,202)
(70,388)
(62,940)
Net Financial Income
907
(113,224)
Share of net loss - Equity method
117
(220)
(104)
503
(69,467)
(175,882)
(0.25)
(1.62)
273,582,870
108,839,636
Other income
Net Operating Loss
Income tax Net Loss for the Period Basic/diluted loss per share (euros/share) Weighted average number of outstanding shares used for computing basic/diluted loss per share
€233.9M in combined cash, cash equivalents, and short-term deposits as of June 30, 2026. Cash runway until the end of Q2 2027 1. Extending to the start of Q1 20282 assuming full exercise of the Tranche 3 warrants issued in the Structured Financing of up to €116M and successful completion of Tranche C of the Debt Financing €55M.
- Based on the Company’s existing cash and cash equivalents and short-term deposits, together with the net proceeds from the completed Equity Offering, the completed EIB Transactions and the issuance of Tranches A and B under the Debt Financing Transaction. 2) Cf press release of July 30, 2026.
18
Potential Value-Creating Milestones, Starting Q4 2026
Q4 2026
NATiV3 Topline
H1 2027
2027
2028
Planned U.S. Regulatory Filing
Planned Outcome Study Initiation
E.U. submission to follow
cACLD outcomes trial initiation
Commercial launch into the F2/F3 core
POTENTIAL VALUE UNLOCKED
POTENTIAL VALUE UNLOCKED
POTENTIAL VALUE UNLOCKED
POTENTIAL VALUE UNLOCKED
Confirms efficacy at pivotal scale and enables regulatory filing, if positive
Opens the path to approval
May enable expansion of the addressable population
May expand treatment options for patients and convert to a revenue-generating asset
Phase 3 results in F2/F3 MASH
Potential U.S. Launch
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. Sources: Company guidance and disclosures, 2025-2026. All timelines are targets and are anticipated, not committed, subject to data, regulatory review and capital.
19
An Oral Investigational Medicine Designed to Target Both Drivers of MASH POTENTIAL DIFFERENTIATED ORAL THERAPY FOR MASH Designed to address the broad spectrum of disease.
EXTRA-HEPATIC DRIVERS
One Disease. Two Disease Drivers. One Oral Medicine.
INTRA-HEPATIC DRIVERS
Q4 2026
$15B
2028
The Pivotal Readout
Expected Market by 2035
Structured to Deliver
Pivotal trial powered on conservative assumptions—with filing, outcomes trial and launch preparations aligned behind topline readout.
First MASH launches validate the opportunity: ~18M Americans affected, fewer than 400K treated, and diagnosis growing 25% annually1.
Integrated clinical, regulatory and commercial expertise positions Inventiva for best-indisease potential launch.
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established.
- Estes. 2018. Hepatology; Analysis conducted by Forian using CHRONOS ©2025 Forian Inc. and its licensors. All Rights Reserved; DataM Intelligence November 2025
20
inventivapharma.com
Phase 2b NATIVE Trial Design
Main Inclusion Criteria
Once-daily oral dosing; two doses, 800 mg and 1,200 mg
Patients with biopsy-proven MASH confirmed to have Steatosis-ActivityFibrosis (SAF) scores of 1-3 for steatosis, 3-4 for activity, and <4 for fibrosis
NATIVE RESULTS Placebo (N=81)
Improvement of fibrosis by ≥1 stage without MASH worsening
(secondary end point; N=247) RR (95% CI)
MASH resolution without worsening of fibrosis RR (95% CI)
MASH resolution and improvement of fibrosis by ≥1 stage (composite secondary end point; N=247) RR (95% CI)
24%
19%
7%
Lani 800 mg (N=83)
Lani 1,200 mg (N=83)
24-WEEK TREATMENT
4-WEEK FOLLOW-UP
28%
42%
Double blind, randomized, placebo-controlled ITT (247 patients)
1.18 (0.68-1.86)
1.8 (1.16-2.51)
Placebo
800 mg vs placebo
1,200 mg vs placebo
33%
Screening Liver biopsy
lanifibranor, 800 mg once daily lanifibranor, 1,200 mg once daily
45%
1.75 (1.02-2.68)
2.41 (1.53-3.35)
800 mg vs placebo
1,200 mg vs placebo
21%
31%
2.71 (1.16-5.40)
4.25 (2.02-7.37)
800 mg vs placebo
1,200 mg vs placebo
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH, N Engl J Med 2021;385:1547-1558; Table S4 Results for the key secondary histological endpoints on Full Analysis Set
End of Treatment Liver biopsy
NUMBER OF PATIENTS
102 M
86 M
F2
F3
53 M F1
1:1:1 Randomization Stratification on Type 2 Diabetes 22
Phase 2b Histologic Improvements Accompanied by Broad Biomarker Evidence Across Metabolic, Inflammatory and Fibrotic Pathways OBSERVED INTRA-HEPATIC IMPROVEMENTS
OBSERVED EXTRA-HEPATIC IMPROVEMENTS
HEALTHY
Glucose Metabolism Markers Improved insulin sensitivity and glycemic control CIRRHOSIS
Liver Enzymes
STEATOSIS measured by CAP MRI-PDFF
ALT AST GGT
Cardiovascular Risk Markers Improved cardiovascular risk and lipids metabolism
Fasting Glucose
HDL-C
Fasting Insulin
Triglycerides levels
Hba1c
LDL-cholesterol level
Fasting HOMA Index
APO-B
Hepatic Insulin Resistance
APO-B/APO-A1
Endogenous Glucose Production
APO-C3 DBP
STEATOHEPATITIS Circulating biomarkers of inflammation fibrosis: Ferritin, hs-CRP, cT1 and apoptosis: CK18-M30
FIBROSIS circulating biomarkers of fibrosis: Pro-C3, TIMP-1/MMP-2, MACK-3
Improved markers of glucose metabolism in patients with prediabetes
Metabolic and Anti-fibrotic Mediator Adiponectin (4.5x)
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH, N Engl J Med 2021;385:1547-1558; Cooreman MP et al. Nature Communications 2024;15:3962; LEGEND results presented March 2024; IIS-study led by Dr. Cusi presented June 2023.
23
Preclinical Data for Lanifibranor Showed Potential to Impact Portal Pressure INTRAHEPATIC RESISTANCE −29% p=0.02 0.75
Vehicle
Lanifibranor
ASCITES (RATS AFFECTED) −76% p=0.02
18
67
0.53
12.3
% Area
mmHg
11.2
mmHg·min/mL
13.1
FIBROSIS −32% p=0.02
%
PORTAL PRESSURE −14.5% p=0.003
16
Vehicle
Lanifibranor
Vehicle
Lanifibranor
Vehicle
Lanifibranor
Cirrhotic model — TAA, 12 wks induction + 2 wks lanifibranor 100 mg/kg (confirmed in CBDL).
METABOLIC MODEL (MCD)
NONCIRRHOTIC MODEL (PPVL)
Pan-PPAR Required
The Inflow Side
5.6 → 3.7 mmHg
10.9 → 6.7 mmHg
Portal venous pressure normalized: 5.6 → 3.7 mmHg (MCD+vehicle vs MCD+lani; CD control 3.5), p<0.0001. Also normalized transhepatic pressure gradient and vascular reactivity (methoxamine hyper-, ACh hypo-reactivity).
Portal pressure 10.9 → 6.7 mmHg (30 mg/kg), p<0.01 — driven by ↓ superior mesenteric artery flow (1.75 → 1.21 mL/min). Plus ↓ mesenteric vascular wall thickness (37 → 29 µm) and ↓ CD34.
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. Preclinical — not predictive of clinical outcome. Cirrhotic/TAA & CBDL: Boyer-Diaz Z et al. J Hepatol 2021;74(5):1188-1199. MCD/MASLD: Rautou PE et al. J Hep Reports 2025;7(6):101366; Chotkoe S et al. EASL 2023 (poster WED-466-YI). PPVL: Heldens A et al. Biomed Pharmacother 2025;183:117826. Values approximate group means read from source figures.
24
Lanifibranor Improved Vascular Remodeling on Phase 2b Biopsies
LANIFIBRANOR IMPROVES PERIPORTAL CD342
9.8 5.3
F0
6.2
F1
6.9
F2
Liver fibrosis stage (CRN-F) · KW p<0.0001
F3
• CD34 higher in MASH vs no-MASH (p<0.05) • Scales with fibrosis (p<0.0001) and inflammation (p=0.027) severity (n=208 MASH)
Patients with improved periportal CD34 score (%)
CD34⁺ vessels / µm²·10⁵
CAPILLARIZATION IS A DISEASE MARKER1
23.2% 18.5% 7.5%
Placebo (n=53)
800 mg (n=54)
1,200 mg (n=56)
• Significant improvement in periportal CD34 score mesured at 24 weeks; dose-trend in lobular score
Dose-dependent · CA p=0.025
Lanifibranor showed a potential impact on vascular remodeling
Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. Not predictive of clinical outcomes; cACLD indication under evaluation.
- Illustrative rendering of published data. Values approximate; see source figures. CD34 staining on NATIVE Phase 2b biopsies. CRN-F, Clinical Research Network Fibrosis stage; KW, Kruskal-Wallis; CA, Cochran-Armitage trend test. 2) Rautou PE et al. J Hep Reports 2025 Feb 22;7(6):101366 (CD34 in NATIVE Phase 2b). Exploratory analyses; lobular score showed a dose-trend (CA p=0.151).
25
Selected Financial Highlights as of July 9, 2026
SHARE CAPITAL1
~236M Ordinary shares outstanding (non-diluted)
ROYALTY CERTIFICATES
~433.6M Estimated fully diluted shares after topline data (assumes full exercise of T3 warrants (~77M)2)
Two Sets
Commence upon potential product sales
CERTIFICATE 1: 2% capped at ~ €92M, 15-year term following their issuance3
CERTIFICATE 2: 3%, 14-year term following their issuance4
- Cf press release of July 9, 2026; 2) Cf 20-F filed on April 8, 2026; 3) Cf press release of August 23, 2023; 4) Cf press release of July 18, 2024
26
INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 2,362,802.02 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255
Table of contents
- Interim Financial Report ............................................................................. 6 1.1.
General overview of activities ................................................................................................. 6
1.2.
Significant events in the first half of 2026 .............................................................................. 7
1.3.
Risk factors ............................................................................................................................ 13
1.4.
Earnings analysis for the six months ended June 30, 2026 ................................................... 18
1.5.
Analysis of financial situation ............................................................................................... 25
- Cash flow and equity .................................................................................. 28 2.1.
Cash and cash equivalents ..................................................................................................... 28
2.2.
Cash flow analysis ................................................................................................................. 31
2.3.
Anticipated sources of funds ................................................................................................. 34
- Unaudited interim condensed consolidated financial statements .......... 36 3.1.
Statutory Auditors’ Review Report on the Half-yearly Financial Information ..................... 36
3.2.
Interim Condensed Consolidated financial statement ........................................................... 38
- Other information ....................................................................................... 96 Table of delegations .............................................................................................................................. 96
2
Definitions In this first-half report (the “Interim Financial Report”), and unless otherwise specified, the terms Inventiva or the Company are taken to mean the company Inventiva S.A. with its registered office at 50, rue de Dijon, 21121 Daix, France, and which is listed with the Dijon Trade and Companies Register under number 537 530 255 and its subsidiary, 100% owned, Inventiva Inc. with its registered office at 10-34 44th Dr, Long Island City, 11101 New York, USA, created in January 2021. A glossary defining certain terms used in the Interim Financial Report can be found in the 2025 Company’s Annual Report on Form 20‑F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on April 8, 2026. Forward-looking information This Interim Financial Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than present and historical facts and conditions contained in this document, including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this document, the words “anticipate,” “seek,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “is designed to,” “may,” “might,” “plan,” “will,” “would,” “potential,” “predict,” “objective,” “should,” “target,” “hopefully,” “may,” or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about: • • • • • •
•
• • • • •
our ability to service our debt obligations; our plans to research, develop and commercialize our current and future product candidates; the timing, design, duration, recruitment, costs, screening, enrollment and randomization of our planned and ongoing clinical trials; clinical trial data releases and publications and the information and insights that may be gathered from our planned and ongoing clinical trials; the timing of any planned investigational new drug application, and comparable foreign submissions; expectations with respect to the benefits of our existing license agreements and future collaborations, including our license agreements with Chia Tai Tianqing Pharmaceutical Group, Co., LTD., (“CTTQ”), and with Hepalys Pharma, Inc. (“Hepalys”) on the clinical development, regulatory approvals and, if approved, commercialization of lanifibranor, and the achievement of milestones thereunder and the timing thereof; our ability to successfully cooperate with existing licensees or enter into new collaborations, and to fulfill our obligations under any agreements entered into in connection with such collaborations; the clinical utility, potential benefits and market acceptance of lanifibranor; potential milestone payments and royalties we may receive under our agreement with Biossil Inc. with respect to the development of odiparcil; our commercialization, marketing and manufacturing capabilities and strategy; our ability to identify additional products or product candidates with significant commercial potential; our expectations related to the sufficiency of our capital resources and our ability to continue as a going concern, including our expectations with respect to raising additional funds, executing any potential transactions and achievement of milestones and operating targets; 3
•
•
•
• • • • •
• •
•
our ability to satisfy in part or full the conditions precedent to close the third tranche of the structured equity financing of up to €348.0 million announced on October 14, 2024 (the “Structured Financing”) through the exercise of the T3 Warrants (as defined below), and the timing thereof; the potential exercise by the investors of our warrants and pre-funded warrants, including the securities issued or to be issued in connection with the Structured Financing and the Lenders’ Warrants (as defined below); the expected use of proceeds from financing transactions, including capital increases, royalty certificates, warrants and debt financing, and our ability to fulfill our obligations under any agreements entered into in connection with such transactions, including our ability to consummate further tranches under the Subscription Agreement; our ability to attract, retain and motivate key personnel and to manage executive succession and organizational changes; developments and projections relating to our competitors and our industry; the impact of government laws and regulations; the effects of epidemics or pandemics on our business, operations and development timelines and plans; our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for lanifibranor and our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others; our estimates regarding future revenue, expenses, capital requirements and need for additional financing; unfavorable conditions in our industry, the global economy or global supply chain, including financial and credit market fluctuations, tariffs and other trade barriers, international trade relations, political turmoil, natural catastrophes, warfare (such as, conflicts involving Russia and Ukraine, the conflict in the Middle East and the related risk of a larger conflict) and ongoing conflicts, and terrorist attacks; and other risks and uncertainties, including those listed in this document under the caption “Risk Factors” and those listed in our Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”).
We encourage you to read and carefully consider all of the risk factors disclosed in “Item 3.D—Risk Factors” of our Annual Report, for a more complete understanding of the risks and uncertainties material to our business, including important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this document will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. These forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this document and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
4
Market and competitive position This Interim Financial Report also contains information about the Company’s activities and the markets on which it operates. This information comes from studies or surveys carried out internally or externally. Other information contained in this Interim Financial Report is available to the general public. The Company considers that all of this information is reliable, but it has not been verified by an independent expert. The Company cannot guarantee that a third party using different methods to gather, analyze or calculate market data would obtain the same results. Rounding of figures Certain figures (including data expressed in thousands or millions of euros or dollars) and the percentages presented in this Interim Financial Report have been rounded up or down. Accordingly, totals given may vary slightly from those obtained by adding the exact (unrounded) values of those same figures. Abbreviations Certain figures are given in thousands or millions of euros and are indicated as € thousand or € million respectively in this Interim Financial Report.
5
Interim Financial Report
1.1. General overview of activities Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (together, “Inventiva” or the “Company”). Inventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva’s American Depositary Shares (“ADSs”), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020. Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”). Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently evaluating its product candidate lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase III clinical trial for the treatment of adult patients with MASH, a common and progressive liver disease (“NATiV3”). In 2020, the Company announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with MASH and announced that the U.S. Food and Drug Administration (“FDA”) had granted the Company the status of Breakthrough Therapy and Fast Track designation for the development of lanifibranor for the treatment of MASH. The Company initiated NATiV3 in the second half of 2021. In March 2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH and Type 2 Diabetes (“LEGEND”). In April 2025, Inventiva announced the completion of patient enrollment in NATiV3 with the randomization of the last patient in the main cohort. The publication of the topline results of NATiV3 is targeted for the fourth quarter of 2026. If the results are positive and subject to regulatory approval, the Company targets the potential new drug application (“NDA”) submission for lanifibranor in the first half of 2027, with a view to potential commercialization in 2028.
6
1.2. Significant events in the first half of 2026 1.2.1.
Governance
Appointments to Leadership Team in Preparation for Phase III lanifibranor Data Readout On April 22, 2026, we announced the strengthening of our leadership team with the appointment of Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments are intended to support our organizational buildout ahead of the expected top-line data readout from NATiV3, and the potential subsequent regulatory filings and commercialization activities. In connection with these appointments, Jean Volatier, previously Chief Financial Officer, transitioned to the role of EVP Finance & Corporate Social Responsibility. Appointment of three independent members to our Board of Directors At the general meeting of June 30, 2026, our shareholders appointed Dr. Barbara Krebs-Pohl, Dr. Anne Prener and Ms. Camilla Soenderby as independent members of our Board of Directors, effective June 30, 2026. These appointments strengthen the Board with significant expertise in biotechnology, clinical development, commercialization and corporate governance, supporting our continued development of lanifibranor. Ms. Annick Schwebig resigned from the Board of Directors prior to the general meeting. 1.2.2.
Combined transaction
Comprehensive refinancing transaction announced on June 2, 2026 In June 2026, we announced and executed a comprehensive refinancing transaction to fund the continued development and potential commercialization of lanifibranor. The transaction comprised three components: (i) (ii) (iii)
An Equity Offering; Transactions with the European Investment Bank (“EIB”) (the “EIB Transactions”); and A Debt Financing Transaction,
the “Combined Transaction”. Each of these components is described in further detail below. The accounting treatment of the transactions is described in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report.
7
(i)
Equity Offering
On June 2, 2026, we announced an offering of 27,272,727 ADSs, each representing one ordinary share, at a public offering price of $4.40 (€3.7781) 1 per ADS (the “Equity Offering”). The settlement occurred on June 5, 2026. 4F
The Equity Offering generated aggregate gross proceeds of $120.0 million (€103.0 million) 2. After deducting underwriting discounts and commissions and offering expenses payable by us of $9.1 million (€7.8 million), the net proceeds from the Equity Offering amounted to $110.9 million (€95.3 million). 5F
The Equity Offering resulted in an increase in share capital and share premium for the corresponding net proceeds amount as of June 30, 2026, with the transaction fees deducted from the premiums. (ii)
EIB Transactions
On June 1, 2026 (the “EIB Transactions Execution Date”), we entered into a master agreement with the EIB (the “EIB Master Agreement”) providing for: a) Repayment of an existing EUR 50 million EIB loan outstanding under the Finance Contract dated May 16, 2022 (the “Finance Contract”): on June 12, 2026 (the “EIB Completion Date”), we prepaid in full the outstanding principal and accrued interest under the Finance Contract, for an aggregate amount of €62.2 million. Pursuant to the EIB Master Agreement, the EIB waived the early prepayment fees that would otherwise have been due under the Finance Contract. As of December 31, 2025, both tranches of the EIB loan (“EIB Tranche A” and “EIB Tranche B”) qualified as financial liabilities, measured at amortized cost under IFRS 9 and the corresponding amounts recognized amounted to:
- EIB Tranche A principal (including capitalized interest): €27.9 million, and
- EIB Tranche B principal (including capitalized interest): €17.4 million. As of EIB Transactions Execution Date, the corresponding amounts recognized were:
EIB Tranche A principal (including capitalized interest): €27.9 million, EIB Tranche A accrued interests: €2.9 million, EIB Tranche B principal (including capitalized interest): €23.1 million, EIB Tranche B accrued interests: €2.8 million, EIB loans catch-up adjustment: €5.0 million, and €0.5 million resulting from the unwinding of the discount until the EIB Completion Date.
The accounting treatment of the repayment of the EIB loan is presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report.
b) Repurchase and cancellation of Legacy EIB Warrants: on June 12, 2026, we repurchased and cancelled all of the warrants we had issued to EIB in connection with EIB Tranche A under the Finance Contract (the “EIB Tranche A Warrants”) and 700,000 of the warrants we had issued to EIB in connection with EIB Tranche B under the Finance Contract (the “EIB Tranche B Warrants” and, together with the EIB Tranche A Warrants, the “Legacy EIB Warrants”),
1 2
The exchange rate on the pricing date (June 1, 2026) was 1.1646 dollar for one euro. The exchange rate on the settlement date (June 5, 2026) was 1.1640 dollar for one euro. 8
corresponding to approximately 22.7 million EIB underlying shares, for an aggregate repurchase price of €50.0 million. As of December 31, 2025, the EIB Tranche A Warrants and EIB Tranche B Warrants were classified as a derivative liability measured at fair value through profit or loss, for an aggregate carrying amount of €119.4 million, of which €74.0 million were related to the repurchased and cancelled Legacy EIB Warrants. As of June 30, 2026, the fair value of the repurchased and cancelled warrants amounted to €66.3 million for EIB Tranche A Warrants and to €13.7 million for EIB Tranche B Warrants (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report). The fair value variation recognized in financial income during the six-month period ended June 30, 2026 amounted to €68.5 million (see Note 5.4 – Financial income and expense to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report). This gain primarily resulted from the EIB Master Agreement, resulting in the repurchase and cancellation of the Legacy EIB Warrants for the repurchase price of €50.0 million. The accounting treatment of the repurchase of the Legacy EIB Warrants is presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report.
c) Restructuring of the remaining EIB Tranche B Warrants (the “Remaining EIB Warrants”): following approval by our shareholders at the general meeting of June 30, 2026, we cancelled the Remaining EIB Warrants (representing 2,444,654 warrants, corresponding to approximately 15.7 million underlying shares) and issued 15,677,573 new warrants to EIB (the “New EIB Warrants”) on July 9, 2026. Each New EIB Warrant entitles EIB to subscribe one ordinary share and the New EIB Warrants do not bear the anti-dilution mechanism applicable to the Legacy EIB Warrants, each entitling EIB to subscribe to one ordinary share per New EIB Warrant. The New EIB Warrants were issued at a unit price of €0.01, which was paid by EIB by way of set-off against an arrangement fee of €0.01 per warrant payable by us to EIB under the EIB Master Agreement, resulting in no net cash proceeds from such issuance, subject to approval of the June 30, 2026 general meeting of our shareholders. The exercise price of the New EIB Warrants is set at €0.01 per New EIB Warrant. On July 9, 2026, pursuant to the EIB Master Agreement and following the authorization granted by our shareholders' meeting held on June 30, 2026, our Chief Executive Officer approved the issuance of 15,677,573 New EIB Warrants to the EIB and the execution of a subscription agreement with the EIB governing such issuance. Upon subscription of the New EIB Warrants, the EIB irrevocably surrendered for cancellation all Remaining EIB Warrants. The fair value variation recognized in financial expenses during the six-month period ended June 30, 2026 amounted to €40.7 million (see Note 5.4 – Financial income and expense to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report). As a result of the restructuring completed during the period, no derivative liability related to the Legacy EIB Warrants remained as of June 30, 2026 (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report). The restructuring of the Legacy EIB Warrants results in the accounting treatment presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report. 9
(iii)
Debt Financing Transaction
On June 2, 2026, we entered into a subscription agreement with funds and accounts managed by BlackRock and Claret Capital Partners (the “Lenders”) providing for the issuance of new senior secured debt instruments for an aggregate committed principal amount of up to €130.0 million, plus an additional uncommitted tranche of up to €20.0 million subject to mutual consent following FDA approval of the NDA for lanifibranor (the “Subscription Agreement”) (together, the “Debt Financing Transaction”). The Debt Financing Transaction comprises: • • •
• •
Lenders’ Tranche A (as defined below) – €35.0 million of senior secured convertible bonds (Obligations Convertibles en Actions), drawn down on June 12, 2026; Lenders’ Tranche B (as defined below) – €40.0 million of senior secured non-convertible amortized bonds, drawn down on June 12, 2026; Lenders’ Tranche C – up to €55.0 million of senior secured non-convertible amortized bonds (uncommitted, drawable at the option of the Company until February 15, 2027 subject to conditions precedent); Additional Lenders’ Tranche – up to €20.0 million of additional debt instruments (uncommitted, subject to mutual consent following FDA approval of the NDA for lanifibranor); and Lenders’ Warrants – warrants to subscribe for ordinary shares with an aggregate notional value of up to €9.5 million (€6.75 million in respect of Lenders’ Tranches A and B and €2.75 million in respect of Lenders’ Tranche C.
The Subscription Agreement includes certain restrictive covenants, subject to customary exceptions, including, among other things, restrictions on the incurrence of indebtedness, the grant of security interests and guarantees, dividends and other distributions, asset disposals, mergers and restructurings, acquisitions and joint ventures. The Subscription Agreement also includes financial covenants requiring us to maintain at least €30.0 million in specified secured accounts. The obligations under the debt financing are secured by first-ranking security over specified collateral, including certain intellectual property rights, bank accounts and receivables. A portion of the proceeds were used to refinance the EIB loans (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report) and the remainder is intended to fund our activities and research and development programs (see Note 3.4 – Going concern to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report). The closing of the first tranche consisting of senior secured bonds (the “Convertible Bonds”), convertible into new ordinary shares (“Lenders’ Tranche A”) and the second tranche consisting of senior secured amortized bonds (“Lenders’ Tranche B”) was conditional upon the full repayment of the EIB loans and the completion of an equity financing of at least €90.0 million, which was satisfied upon the closing of the Equity Offering on June 5, 2026. On June 12, 2026, we drew down the first two tranches of the Debt Financing Transaction for an aggregate principal amount of €75.0 million (net proceeds of €69.6 million):
Lenders’ Tranche A for €35.0 million, with annual fixed interest of 9.90%, with an interest-only period until December 31, 2028, followed by sixteen monthly instalments of principal and interest, until final maturity on April 1, 2030. The Convertible Bonds have a par value of one euro each and a conversion price equal to a premium of 40%, applied on the lower of (i) the 30day VWAP of the ordinary shares on Euronext Paris immediately prior to April 30, 2026 (being €4.6681), (ii) the 30-day VWAP of the ordinary shares on Euronext Paris immediately prior to
10
the issuance date of the Convertible Bonds, or (iii) the euro-equivalent offering price per ordinary share, represented by each ADS sold in the Equity Offering, being €3.7781. The conversion price is subject to a minimum equal to the 30-day VWAP immediately prior to the issuance date and the minimum price per our current authorizations. Pursuant to the conversion price formula described above, the conversion price was set on June12, 2026 at €5.2893 per ordinary share, corresponding to a conversion ratio of 0.18907 ordinary shares per Convertible Bond of €1 par value. The conversion ratio is subject to customary anti-dilution adjustments and may be adjusted pursuant to an equity-linked pricing reset mechanism.
Lenders’ Tranche B for €40.0 million, with annual fixed interest of 9.90%, supplemented by payment-in-kind interest of 2.10% capitalized annually, with an initial interest-only period ending on March 31, 2027 (extendable at our election to December 31, 2027 subject to (i) meeting the NATiV3 primary endpoint and (ii) the confirmation of the exercise of the third tranche warrants (the “T3 Warrants”) issued under the structured financing of up to €348.0 million announced on October 14, 2024 (the “Structured Financing”) or prior completion of an equity fundraising for at least €100 million following release of results of NATiV3, with both (i) and (ii) being met no later than February 15, 2027, and thereafter to December 31, 2028 subject to FDA approval of the NDA for lanifibranor), by no later than 15 business days prior to December 31, 2027), with final maturity on April 1, 2030.
The drawdown of the Lenders’ Tranches A and B results in the accounting treatment presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026, included elsewhere in this report. In addition, an uncommitted tranche (“Lenders’ Tranche C”) of up to €55.0 million, with annual fixed interest of 8.90%, supplemented by payment-in-kind interest of 2.10% capitalized annually, remains available for drawdown no later than February 15, 2027, subject to certain conditions precedent: (a) the prior and full issuance of Lenders’ Tranches A and B, (b) compliance with a maximum debt-to-market capitalization ratio of 10% based on a 30-day VWAP (which market capitalization includes the ordinary shares and the pre-funded warrants issued in the Structured Financing), (c) the achievement of the primary composite endpoint of the ongoing NATiV3 trial and (d) the confirmation of the exercise of the T3 Warrants issued by us on May 7, 2025 of at least €100 million (the “T3 Warrants Exercise”) or prior completion of an equity fundraising for at least €100 million. Finally, the Debt Financing Transaction comprises an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following FDA approval of the NDA for lanifibranor. As of the date of authorization of these financial statements, the conditions (b), (c) and (d), for drawdown have not been met and therefore there is no financial effect. In connection with the Subscription Agreement, on June 12, 2026, we issued warrants (bons de souscription d’actions) to the Lenders (the “Lenders’ Warrants”): • •
1,624,196 Lenders' Warrants in respect of Lenders’ Tranches A and B, exercisable upon issuance, representing an aggregate notional value of €6.75 million; and 661,709 Lenders' Warrants in respect of Lenders’ Tranche C, exercisable only upon any future drawdown of Lenders’ Tranche C, representing an aggregate notional value of €2.75 million.
The issuance of Lenders’ Warrants results in the accounting treatment presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report. Each Lenders' Warrant entitles the holder to subscribe to one of our ordinary shares. The exercise price was set at €4.1559 per ordinary share, corresponding to a 10% premium applied to the lowest of (i) the 11
30-day VWAP of the ordinary shares on Euronext Paris immediately prior to April 30, 2026 (€4.6681), (ii) the 30-day VWAP immediately prior to the initial closing of Lenders’ Tranches A and B, and (iii) the euro-equivalent offering price per ordinary share represented by each ADS sold in the Equity Offering (€3.7781). The exercise ratio is subject to customary anti-dilution adjustments and may also be adjusted pursuant to an equity-linked pricing reset mechanism in certain circumstances specified in the Subscription Agreement. The Lenders' Warrants will expire on the earlier of (i) the tenth anniversary of their issuance date and (ii) the closing of a tender offer under sections 14(d) and 14(e) of the U.S. Securities Exchange Act of 1934. 1.2.3.
Recent events and prospects
In accordance with IAS 10 Events after the Reporting Period, we have assessed transactions and events occurring between June 30, 2026, and the date the interim condensed consolidated financial statements were authorized for issue by the Board of Directors on September 25, 2026. Completion of the EIB warrant restructuring On July 9, 2026, we completed the restructuring of warrants held by the EIB through the issuance of 15,677,573 New EIB Warrants and the surrender and cancellation of all Remaining EIB Warrants. See Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report. Appointment of Chris Benecchi as Chief Operating Officer On August 31, 2026, we announced the appointment of Chris Benecchi as Chief Operating Officer. Mr. Benecchi brings over 30 years of biopharmaceutical industry experience, including leadership roles in commercial operations, launch readiness and corporate strategy. He will be responsible for leading our operational readiness as we approach the expected topline results from NATiV3 in the fourth quarter of 2026 and prepare for potential commercialization, subject to regulatory approvals. This appointment supports our strategy to strengthen our organizational, operational and commercial capabilities ahead of the anticipated next stages of development. Completion of last patient last visit in the NATiV3 trial On September 2, 2026, we announced that the last patient had completed the final 72-week visit in the NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Following completion of the treatment period, we expect to report topline results in the fourth quarter of 2026.
12
1.3. Risk factors The Company’s business faces significant risks. You should carefully consider all of the information set forth in this document and in the Company’s other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors which the Company faces and which are faced by the Company’s industry described in 2025 Universal Registration Document, and in Part I, “Item 3.D— Risk Factors” of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025. Except as updated below, the Company believes that there have been no material changes to such risk factors since the filing of those documents. The risk factors below update and supplement the corresponding risk factors contained in those documents and retain the same numbering used in the 2025 Universal Registration Document for ease of reference. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. 2.1.5.1 Risks related to securing and finalizing financing and risks related to uncertain additional financing The Company estimates that it has raised the funds necessary to finance its activity until the end of the second quarter of 2027, subject to changes in its business plan and operational needs. However, the Company will require additional funds, particularly if NATiV3 is successful, to prepare the marketing authorization application and to manufacture and commercialize lanifibranor, as applicable. The T3 Warrants of the structured financing announced by the Company on October 14, 2024, in the amount of €116 million, will potentially be available if any key primary endpoint or key secondary endpoint of the NATiV3 study is met no later than June 15, 2027. Furthermore, as part of the combined transaction announced on June 2, 2026, the Company could also benefit from the drawdown of Tranche C for an amount of up to €55 million, subject to compliance with the conditions set forth in the applicable financing documentation. However, there is no guarantee that Tranche C under the Debt Financing Transaction will actually be available or drawn down, nor that the Tranche 3 warrants will be exercised, in whole or in part, nor that the USD ten (10) million payment (gross proceeds) owed on publication of Positive Topline Data under the CTTQ License Agreement3, will become due. Consequently, a significant portion of the financial resources that could extend the Company’s cash flow horizon depends on uncertain future events, some of which depend in particular on the results of the NATiV3 study. Completion of these various assumptions could therefore enable the Company to finance its business through the beginning of the first quarter of 2028. The T3 Warrants funding would occur at the earliest after the publication of Positive Topline Data and remains optional at the discretion of the T3 Warrants holders (who have a period of forty-five (45) calendar days to exercise the T3 Warrants as from the publication by the Company of the baseline data announcing that any key primary endpoint or key secondary endpoint of the NATiV3 study is met). If no other financing is secured by the time the T3 Warrants are potentially available, the Company may, even if all conditions precedent are satisfied, face additional funding requirement from the end of the second quarter of 2027 until such T3 Warrants are potentially exercised, should the holders elect not to exercise them immediately. To meet its financing needs, the Company could therefore rely on a 3
Refer to the accounting principles and CTTQ License Agreement and amendment described in the Notes 3.12 – Revenue and Note 19.1 – Revenues to the annual consolidated financial statements for the year ended on December 31, 2025 13
combination of equity or equity-linked offerings, debt financing, strategic partnerships, licensing agreements, or other transactions. However, taking on additional debt could result in higher financial expenses and could also require the Company to comply with certain additional covenants, such as restrictions on the Company’s ability to incur additional debt or to carry out certain transactions. Similarly, the execution of additional financing agreements could be accompanied by covenants limiting the Company’s ability to acquire or grant intellectual property rights, particularly if it is required to provide additional collateral and accept other operational restrictions that could have a negative impact on the Company’s ability to continue its business operations. It should be noted that additional financing, particularly in the form of equity instruments, could result in significant dilution. Furthermore, financing in the form of debt would weaken the Company’s financial condition. The need for, and pursuit of, additional financing could also divert the Company’s management from its day-to-day business, which could adversely affect the future development and commercialization, if any, of its drug candidate. As part of the refinancing executed in June 2026, the Company prepaid the entire amount of the financing previously arranged with the EIB. Consequently, the refinancing risk associated with the repayment maturities scheduled for December 2026 and January 2027 under the previous EIB financing no longer exists in this form. Nevertheless, the Company remains subject to the obligations arising from its currently outstanding financing arrangements under the Debt Financing Transaction. Its ability to meet these obligations depends, in particular, on its future liquidity levels, the success of the NATiV3 study, and its ability to access additional financing on acceptable terms, in a timely manner or at all. If the Company is unable to secure such additional financing and/or refinancing on acceptable terms or in a timely manner - particularly given the generally unfavorable environment for financing companies in the biotechnology sector - its business, organization, results, and development could be adversely affected; it could be, in particular, forced to delay or suspend its activities, the development or commercialization of any approved product, or be unable to expand its operations or capitalize on its business opportunities as intended. The Company may also have to reimplement a plan to reduce and manage its fixed costs or enter into new collaboration agreements that could be less favorable to it than those it might have obtained under different circumstances, which could adversely affect its growth prospects or business operations, as discussed in the risk factor related to liquidity in paragraph 2.1.5.3 below.
2.1.5.2 Risks related to the commitments and conditions attached to the financing agreement with BlackRock and Claret On June 2, 2026, the Company entered into a structured financing arrangement with funds and accounts managed by BlackRock and Claret Capital providing for a total gross financing amount of up to €130 million in the form of committed tranches, to which an additional uncommitted tranche of €20 million may be added, subject to the parties’ agreement. This financing included, in particular, (i) an issuance of €35 million in convertible bonds (Tranche A) and (ii) an issuance of €40 million in amortizable bonds (Tranche B), both of which have been drawn in June 2026, as well as (iii) an additional tranche of amortizable bonds of up to €55 million (Tranche C), the availability of which remains subject to the satisfaction of specific conditions. The financing documentation sets forth a series of representations, warranties, covenants, and restrictions that govern the Company’s business operations. These commitments include, in particular restrictions on additional debt, the granting of security interests (notably certain intellectual property rights related to lanifibranor in certain jurisdictions, as well as security interests granted over bank 14
accounts), certain restructuring, merger, or asset disposal transactions, as well as the maintenance of security interests granted to lenders and compliance with other obligations set forth in the financing documentation. The financing documentation also includes financial covenants requiring the Company to maintain at least €30.0 million of cash and cash equivalents in specified secured accounts and, commencing September 30, 2026, to hold in bank accounts located in Luxembourg an amount equal to the lesser of (i) €75.0 million, as reduced by any repayments or prepayments of principal made under the financing documentation, and (ii) two-thirds of the Company's total consolidated cash and cash equivalents at the relevant time. The financing documentation contains customary events of default. In addition, failure to achieve the primary composite endpoint in NATiV3, or the occurrence of any adverse regulatory outcomes, would constitute an event of default, subject to specified cure mechanics. Furthermore, Tranches A and B may be subject to mandatory prepayment if the aggregate principal amount thereof exceeds 10% of post NATiV 3 results market capitalization. In addition, access to a significant portion of the financing remains contingent upon the achievement of certain clinical and financial milestones. In particular, Tranche C, representing up to €55 million in additional financing, is available only subject to, among other conditions, (i) compliance with a debt-tomarket-capitalization ratio of 10%, (ii) the publication of positive results from the Phase III NATiV3 clinical trial, and (iii) the exercise, for at least €100 million of the T3 Warrants or prior completion of an equity fundraising for at least €100 million. Failure to comply with the covenants set forth in the financing documentation, failure to satisfy the conditions for drawing future tranches, or the occurrence of an unresolved default or termination event could lead the lenders to suspend the availability of undrawn tranches, demand early repayment of all or part of the amounts due, enforce the security interests they hold, or exercise other remedies provided for in the financing documentation. The Company might then be forced to seek alternative sources of financing, which may not be available or may only be accessible on less favorable terms. The occurrence of any of these events could have a material adverse effect on the Company’s cash flow, financial condition, operations, the clinical development of its programs, its prospects, and, ultimately, its ability to continue as a going concern.
2.1.5.3 Liquidity Risk: the Company estimates that it can finance its operations until the end of the second quarter of 2027 As of June 30, 2026, the Company’s cash and cash equivalents totaled €166.1 million, and its short-term deposits totaled €67.8 million. As of the date of this document, taking into account the net proceeds from the financing transaction announced on June 2, 2026 (excluding the conditional Tranche C), the Company estimates that its cash, cash equivalents, and short-term deposits will enable it to finance its operations, in accordance with its current plan, through the end of the second quarter of 20274. The Company considers that its current cash, cash equivalents, and short-term deposits remain insufficient to cover all of its currently projected operating needs over the next 12 months.
4
Short-term deposits are classified under “other current assets” in the consolidated statement of financial position in accordance with IFRS. 15
These events and conditions indicate that there is significant uncertainty regarding the Company’s ability to continue as a going concern and, consequently, it may not be able to realize its assets and settle its liabilities in the normal course of business. Assuming that the T3 Warrants issued as part of the structured financing announced by the Company on October 14, 2024, are exercised in full for gross proceeds of up to €116.0 million, and assuming full completion of Tranche C of the financing transaction announced on June 2, 2026, representing potential gross proceeds of up to €55.0 million, the Company believes it will be able to finance its operations, in accordance with its current plan, until the beginning of the first quarter of 2028. These estimates, which are based on the Company’s current business plan, take into account the net proceeds from the financing transaction announced on June 2, 2026, as well as the availability of T3 Warrants, and exclude any potential milestone payments to be made or received by the Company, as well as any additional expenses related to the candidate product or resulting from the licensing or acquisition of additional candidate products or technologies, or from any associated development the Company may pursue. It is possible that the Company has based these estimates on incorrect assumptions or that it may modify its business plan in the future and ultimately use its resources more quickly than anticipated. These estimates could be revised downward in the event of an increase in expenses related to development programs that exceeds the Company’s estimates, or if the Company’s development program progresses more rapidly than anticipated. Furthermore, there is no guarantee that Tranche C of the financing transaction announced on June 2, 2026, representing an amount of up to €55.0 million, will be drawn down by the Company, nor that the T3 Warrants, will be exercised, nor to what extent they will be exercised, if at all. The Company will need to raise additional funds to achieve its long-term objectives for the development and potential commercialization of lanifibranor, in accordance with its current plan, through other potential public offerings or private placements, ADS sales under its ATM program, or potential strategic transactions such as commercial development partnerships, and/or licensing agreements. The Company cannot guarantee that it will be able to obtain the necessary financing or complete the proposed transactions, nor that it will be able to do so on terms deemed acceptable, or even that it will succeed at all, which could have a material adverse effect on its prospects, business, and financial condition. Although recently completed financing transactions have improved the Company’s financial position, the Company’s future access to additional capital will remain subject, in particular, to market conditions and investor interest. 2.1.5.4 Dilution Risk: The issuance of new shares and/or the allocation of new financial instruments conferring rights to the Company’s capital will result in dilution—potentially significant—for the Company’s shareholders The Company may need to raise capital through the issuance of new shares or financial instruments conferring rights to the Company’s capital to finance all or part of its corresponding needs. This would result in potential further dilution for shareholders. Furthermore, as part of its policy to incentivize its executives, directors, and employees and to attract and retain qualified personnel, as well as under its financing agreement with the EIB, the Company has issued and allocated stock subscription warrants (“BSA”), founder’s share subscription warrants (“BSPCE”), and bonus shares (“AGA”)5, which could result in potentially significant additional dilution for the Company’s current and future shareholders.
5
Presented in Section 6.2.5 – Summary of Dilutive Instruments Held by Executives, Directors, and Employees in the Company’s 2025 Universal Registration Document 16
Furthermore, as part of the agreements entered into with the EIB on June 1st, 2026, intended, among other things, to fully refinance the loan granted by the EIB and to streamline the Company’s capital structure, the Company issued 15,677,573 new warrants to the EIB on July 9, 2026 in exchange for the Company’s cancellation of all warrants previously issued to the EIB. Each new warrant entitles the holder to subscribe for one ordinary share of the Company. These new warrants, subject to a 90-day lock-up period ending on August 30, 2026, are exercisable until January 4, 2036. The exercise of all or part of these new warrants is likely to result in further dilution for existing shareholders. Full exercise of these new warrants would result in the issuance of 15,677,573 new shares, representing approximately 6.64% of the number of shares currently outstanding. As of August 31, 2026, the exercise of all dilutive instruments granted but not yet exercised, held by executives, directors, and employees, representing 29,816,382 shares, would result in a dilution of approximately 11.8% based on a share capital of €2,362,802.02. Furthermore, the exercise of (i) all dilutive instruments held by executives, directors, and employees, (ii) the new warrants issued to the EIB, (iii) the pre-financed warrants issued in October 2024, December 2024, and May 2025 (for a total of 61,747,112 pre-financed warrants outstanding as of the date hereof, which, if exercised, would represent an issuance of 61,747,112 additional shares), , would result in a dilution of 31.6% based on the Company’s current share capital (€2,362,802.02 euros) (to which the aforementioned instruments conferring rights to the capital would be added and excluding shares resulting from the exercise of the T3 Warrants6). The Company also implemented a new At-the-Market (ATM) program in October 2025, which allows it to issue and sell common stock in the form of American Depositary Shares (ADS) to unsolicited investors who have expressed interest, for a total gross amount of up to $100 million. If the Company issues ADSs under its ATM program, this could dilute shareholders, reduce the price of ordinary shares or ADSs, or hinder the Company’s ability to raise capital in the future. Any share issuances that may result from the exercise of these dilutive instruments could be made at significant discounts in accordance with the terms set forth in the resolutions passed at the general meetings that approved the terms and conditions for the granting of the dilutive instruments. In the event that the funds raised by the Company prove insufficient to enable it to successfully implement its development plan, the Company may, in the future, issue or allocate shares or new financial instruments conferring rights to the Company’s capital, excluding, however, any issuance of warrants free of charge, or on subscription terms unrelated to the market value of the warrants, to the benefit of the directors in accordance with applicable legal provisions and as disclosed by the AMF in a press release dated June 5, 20187. This would result in additional, potentially significant, dilution for the Company’s shareholders.
6
As of the date of this document, the T3 Warrants would represent, if fully exercised (subject to completion of specific conditions), 77,333,319 additional ordinary shares 7 Allocation of Stock Options to Directors: The AMF Draws Issuers’ Attention, June 5, 2018 17
1.4. Earnings analysis for the six months ended June 30, 2026 1.4.1.
Revenue and other income
For the six months ended June 30, 2026, and June 30, 2025 Six months ended Operating income
June 30, 2025
In thousands of euros Revenue Total revenue CIR research tax credit Subsidies Other Other income Total revenue and other income
June 30, 2026
4,454 4,454 1,125 32 1,156 5,610
20 20 839 5 442 1,286 1,305
We recorded minimal revenues during the first six months of 2026, compared to €4.5 million revenues during the first six months of 2025. The revenues recognized in the first half of 2025 were mainly attributable to the CTTQ License Agreement. Other income increased by €0.1 million, or 11%, compared to the six months ended June 30, 2025. This increase was primarily driven by a €0.4 million increase in other income mainly related to a €0.2 million rise due to ADS management fees retrocession, partially offset by a €0.3 million decrease in the French research tax credit (Crédit d'Impôt Recherche, “CIR”), resulting from a lower proportion of eligible research and development expenses.
1.4.2.
Operating expenses
For the six months ended June 30, 2026, and June 30, 2025 Six months ended Operating expenses In thousands of euros Research and development expenses Marketing – Business development expenses General and administrative expenses Total operating expenses
June 30, 2025
June 30, 2026
(44,890)
(46,238)
(746)
(2,589)
(14,713) (60,349)
(22,247) (71,074)
The increase in operating expenses of €10.7 million, or 18%, compared to the six months ended June 30, 2025, is driven by an increase in general and administrative expenses described in paragraph 1.4.2.3 General and administrative expenses, an increase in research and development expenses described in paragraph 1.4.2.1 Research and development expenses, and an increase in marketing and business development expenses described in paragraph 1.4.2.2 Marketing - Business development expenses.
18
1.4.2.1 Research and development expenses Research and development expenses for the six months ended June 30, 2026 and June 30, 2025, break down as follows: Six months ended Research and development expenses
June 30, 2025
In thousands of euros Studies Personnel costs Depreciation, amortization and provisions IT systems Energy and liquids Patents Maintenance Disposables Fees Other Total research and development expenses
(34,487) (6,811) (1,580) (414) (402) (343) (177) (210) (141) (327) (44,890)
June 30, 2026 (32,610) (10,396) (1,216) (569) (114) (470) (51) (31) (173) (609) (46,238)
The €1.3 million increase in research and development expenses, or 3%, compared to the six months ended June 30, 2025, was primarily driven by a €3.6 million rise in personnel costs, of which €2.3 million were related to share-based compensation plans (see Note 4.8 Shareholders’ equity to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report), reflecting the strengthening of our research and development organization to support the advancement of the lanifibranor development program. This increase was partially offset by lower depreciation, amortization and provisions expenses and lower study costs. Our research and development activities during the period remained focused on our single product candidate, lanifibranor, including the ongoing NATiV3 trial, and the finalization of Phase I and Phase II studies. Costs relating to lanifibranor in the six months ended June 30, 2026, can be broken down into two main categories: (i) clinical costs, mainly relating to the ongoing NATiV3 trial, the finalization of LEGEND and the Phase I BioEquivalence/Food Effect study; and (ii) development activities, mainly including pharmaceutical development and manufacturing, non-clinical and preclinical activities, regulatory support, medical affairs and external consulting support. Costs linked to our clinical trial activities included the following developments over the six months ended June 30, 2026: NATiV3 Phase III trial in MASH We continued to conduct our NATiV3 trial, with patients remaining on treatment during the period. Activities mainly included regulatory submissions following protocol amendment No. 8, data cleaning and reconciliation work, and the completion of enrollment of the extension cohort in China in February 19
- Other study expenses included Fibroscan equipment rental, biopsy slide readings, PK analyses, CEC and DMC fees, histology-related collaboration and patient retention initiatives. LEGEND Phase IIa trial The LEGEND trial remained in its finalization stage during the period, with activities mainly related to Trial Master File preparation. Phase I studies Phase I expenses mainly related to the BioEquivalence/Food Effect study, including healthy volunteer follow-up, CRO supervision. The period also included reversals of provisions relating to completed studies. Phase II studies Expenses relating to our closed Phase II studies mainly reflected reversals of provisions and foreign exchange variations on remaining provisions. Development activities With respect to other development activities, costs mainly related to pharmaceutical development and manufacturing activities in preparation for potential commercialization, including API and drug product manufacturing, packaging and distribution activities for NATiV3, CMC consulting support, non-clinical development activities, biomarker and pharmacokinetic analyses, preclinical studies, regulatory submissions and interactions in the United States and Europe, as well as external expert support across clinical, regulatory, quality assurance, pharmacovigilance and development functions. Medical affairs activities also increased during the period.
1.4.2.2 Marketing and business development expenses Marketing and business development expenses break down as follows: For the six months ended June 30, 2026, and June 30, 2025 Six months ended Marketing – Business development In thousands of euros
June 30, 2025
June 30, 2026
Personnel costs
(73)
(955)
IT systems
(10)
(8)
(663)
(1,626)
(746)
(2,589)
Other Marketing - Business development expenses Total marketing and business development expenses
Marketing and business development expenses for the first six months of 2026 increased by €1.8 million, compared to the first six months of 2025, mainly due to the increase of €0.9 million of personnel costs of which €0.5 million is related to share-based compensation plans (see Note 4.8 Shareholders’ equity to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report) and the remaining €0.4 million to employer contributions; and an increase of €1.0 million in other expenses primarily related to the commercial development of lanifibranor.
20
1.4.2.3 General and administrative expenses General and administrative expenses are mainly composed of administrative staff costs, support costs (mainly consisting of security costs, taxes and various rentals), non-scientific IT costs and consulting fees. General and administrative expenses break down as follows: For the six months ended June 30, 2026, and June 30, 2025 Six months ended General and administrative expenses
June 30, 2025
In thousands of euros Personnel costs Depreciation, amortization and provisions Insurance IT systems Fees Support costs (including taxes) Other general and administrative expenses Total general and administrative expenses
June 30, 2026
(8,300) (124) (792) (55) (3,247) (330) (1,866)
(12,970) (190) (871) (39) (5,219) (437) (2,522)
(14,713)
(22,247)
General and administrative expenses for the first six months of 2026 increased by €7.5 million compared to the first six months of 2025, mainly due to a €4.7 million increase in personnel costs of which €2.3 million is notably related to share-based compensation expenses (see Note 4.8 – Shareholders’ equity to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report) and the remaining €1.6 million to employer contributions; as well as an increase of €2.0 million in consulting fees and an increase of €0.7 million in other expenses associated with the commercial development of lanifibranor.
21
1.4.3.
Other operating income and expenses
Other operating income and expenses break down as follows: For the six months ended June 30, 2026, and June 30, 2025
Six months ended Other operating income and expenses
June 30, 2025
In thousands of euros Other operating income Other operating expenses Other operating income and expenses
June 30, 2026
381 (8,583)
151 (770)
(8,202)
(619)
For the first six months of 2026, other operating expenses amounted to €0.6 million, which mainly comprises: •
•
An additional provision of €0.6 million recorded related to unpaid amounts owing under an existing contract. (see Note 4.10 – Provisions to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report), and restructuring expenses which amounted to €0.1 million.
(See Note 5.3 – Other operating income and expenses to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report). For the first six months of 2025, other operating income amounted to €0.4 million, related to the use of the inventory provision of €0.4 million. For the first six months of 2025, other operating expenses amounted to €8.6 million, due to restructuring expenses related to the partial implementation of the Strategic Pipeline Prioritization Plan, which comprises: •
• •
severance and other employee costs, as well as consulting fees associated with our restructuring activities for €3.1 million recorded in short-term provisions (see Note 4.10 Provisions of the unaudited interim condensed consolidated financial statements as of June 30, 2026), restructuring expenses which amounted to €4.2 million, and non-cash expenditures related to acceleration of vesting of Bonus share awards of €1.3 million (see Note 4.8 Shareholders’ Equity of the unaudited interim condensed consolidated financial statements as of June 30, 2026).
22
1.4.4.
Financial income and expenses
Financial income and expenses break down as follows: For the six months ended June 30, 2026, and June 30, 2025
(in thousands of euros) Income from cash equivalents Foreign exchange gains Gains on derecognition of Legacy EIB Warrants Gains on fair value of Convertible option (Convertible Bonds) Total financial income Interest cost Catch-up impact of the EIB debt remeasurement Foreign exchange losses
Six months ended June 30, June 30, 2025 2026 1 246 2 215 1 181 3 230 68 454 1 012 2 427 74 910 (9 716) (14 460) (5 517) (3 266) (669)
Losses on fair value variation remeasurement of Legacy EIB Warrants
(102 640)
(8 569)
Loss on derecognition of remaining EIB warrant settlement obligation
(40 744)
Losses on fair value variation of Lenders’ Warrants Loss on initial measurement at fair value of the Lenders' Tranche B cash collateral deposit Other financial expenses Total financial expenses Net financial income (loss)
(3 475)
(555)
(30) (115 651) (113 224)
(15) (74 004) 907
The net financial gain for the first six months of 2026 was €0.9 million, compared to a net loss of €113.2 million in the same period of 2025. This decrease is primarily attributable to the variation in fair value of the financial instruments. For the first six months of 2026, financial expenses mainly include:
Interest costs in which: o €5.7 million correspond to the interest related to the Finance Contract (€2.9 million related to the EIB Tranche A and €2.8 million related to the EIB Tranche B); o €7.4 million correspond to the interest related to the royalty certificate liabilities (€1.9 million related to the 2023 Royalty Certificates and €5.5 million related to the 2024 Royalty Certificates); o €1.3 million correspond to the interest related to the Debt Financing Transaction (€0.6 million related to the Lenders’ Tranche A and €0.6 million related to the Lenders’ Tranche B); o €0.1 million related to the residual interest related to the PGE and PPR loans. €5.5 million, in which €5.0 million correspond to the catch-up adjustment to reflect the revised cash flows resulting from the repayment of the EIB loan, and €0.5 million resulting from the unwinding of the discount until the EIB Completion Date; €8.6 million of loss in fair value reassessment of the Legacy EIB Warrants as of EIB Transactions Execution Date, €40.7 million of which: o €50.2 million from the recognition of the fair value of the New EIB Warrants forward contract (see Note 4.8 – Shareholders’ equity to the unaudited interim condensed 23
consolidated financial statements as of June 30, 2026 included elsewhere in this report); partially offset by o (€9.5) million from the extinguishment of the derivative financial liability following the General Meeting’s decision to issue the New EIB Warrants (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities). €3.5 million of change in fair value of the Lenders’ Warrants (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report); €0.6 million of recognition at fair value of the Lenders’ Tranche B cash collateral deposit (see Note 4.5 – Other non-current assets to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report) ; and €0.7 million of foreign exchange losses.
For the first six months of 2026, financial income mainly includes:
€68.5 million change in fair value related to the Legacy EIB Warrants, of which: o €30.0 million from the repurchase and cancellation of Legacy EIB Warrants, and o €38.5 million from the restructuring of the Remaining EIB Warrants. €1.0 million change in fair value related to the conversion option embedded in the Lenders’ Tranche A (see Note 4.9 – Debt, derivatives and royalty certificates liabilities. to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report); €2.2 million interest income related to deposit account; and €3.2 million of foreign exchange gains.
1.4.5.
Income tax
In accordance with IAS 34, the income tax recognized in the financial statements for each interim period is adjusted based on a best estimate calculated by applying the expected weighted average tax rate for the entire year. Current taxes As the imputation of tax benefits on tax losses of Inventiva, at short or mid-term, were considered unlikely due to our growth phase and regarding the nil projected tax rate as of December 31, 2025, no current taxes were recorded as of June 30, 2026, for Inventiva. Deferred taxes Inventiva has recorded tax losses for the first six months of 2026. As recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to our activity, no deferred tax assets were recognized on this basis for the six months ended June 30, 2026.
1.4.6.
Net loss for the period
We recorded a net loss of €69.5 million in the first six months of 2026 compared to a net loss of €175.9 million in the first six months of 2025, which was a decrease in net loss of €106.4 million between both periods.
24
1.5. Analysis of financial situation 1.5.1.
Current assets
Current assets
December 31, 2025
In thousands of euros
June 30, 2026
Trade receivables Tax receivables Other current assets
2,016 2,281 140,861
3,734 3,083 73,021
Cash and cash equivalents
99,312
166,127
Total current assets
244,469
245,966
Current assets increased by €1.5 million (1%) compared to December 31, 2025. This was mainly attributable to the €66.8 million (67%) increase in cash and cash equivalents related to our investing and financing activities (See section 2 Cash flow and equity), and the €67.8 million decrease in other current assets is mainly related to the closing of short-term deposits at Société Générale for $71.8 million (€63.1 million) and Crédit Agricole for $56.5 million (€49.6 million), partially offset by the opening of a new short-term deposit account at Société Générale for $39.5 million (€34.7 million) and a new short-term deposit account at Crédit Agricole for $16.4 million (€14.4 million). As of June 30, 2026, tax receivables are mainly composed of CIR receivable in the amount of €2.3 million corresponding to the 2025 CIR, as well as a €0.8 million provision related to the 2026 CIR.
1.5.2.
Non-current assets
Non-current assets consist of:
Property, plant, and equipment, mainly comprising assets acquired on our incorporation and the right of use from Fibroscans leasing; Investments accounted for using the equity method; Other non-current assets mainly comprising term accounts with progressive interest rate; and Intangible assets, mainly comprising the compound and software library.
Non-current assets In thousands of euros Intangible assets Property, plant and equipment Deferred tax assets Investments accounted for using the equity method Other non-current assets Total non-current assets
December 31, 2025 182 2,979 191 527 1,162 5,042
June 30, 2026 310 2,360 197 528 1,849 5,244
Non-current assets increased by €0.2 million (4%) compared to December 31, 2025 mainly due to a €0.7 million increase in other non-current assets related to non-current term deposits, reflecting an advance payment under Tranche B of the Financing Agreement that is recoverable upon final repayment. This
25
increase was partially offset by a €0.6 million decrease in property, plant and equipment, primarily attributable to asset disposals following the discontinuation of certain research activities.
1.5.3.
Shareholders’ equity
Shareholders’ equity
December 31, 2025
In thousands of euros
June 30, 2026
Share capital Premiums related to share capital Reserves Foreign currency translation reserve
1,932 528,230 (205,182) 636
2,363 643,924 (518,278) 460
Net loss for the period
(354,138)
(69,467)
Total shareholders’ equity
(28,522)
59,002
Shareholders’ equity increased by €87.5 million compared to December 31, 2025, primarily reflecting the capital increases completed during the period, including the Equity Offering, partially offset by the net loss of the period (€69.5 million). Changes in shareholders’ equity during the first six months of 2026 are described in further detail in Note 4.8 - Shareholders’ equity to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report, and in Section 2 Cash flow and equity of this document.
1.5.4.
Non-current liabilities
Non-current liabilities
December 31, 2025
In thousands of euros
June 30, 2026
Long-term debt Royalty certificates liabilities Derivative instruments Provisions for retirement benefit obligations Long-term contract liabilities Other non-current liabilities
27,551 51,645 119,385 755 126 1,193
53,345 59,079 13,051 680 126 1,339
Total non-current liabilities
200,655
127,620
As of June 30, 2026, non-current liabilities decreased by €73.0 million (36%) compared to December 31, 2025, mainly due to the €106.3 million decrease in derivative financial liabilities following the EIB Transactions. This decrease was partially offset by a €25.8 million increase in long-term debt, mainly related to the full prepayment of the EIB debt and the recognition of new long-term debt under the Debt Financing Transaction with BlackRock and Claret Capital Partners, as well as by a €7.4 million increase in royalty certificates liabilities.
26
1.5.5. Current liabilities Current liabilities
December 31, 2025
In thousands of euros
June 30, 2026
Short-term debt
32,309
13,314
Trade payables
26,017
34,532
Provisions - short-term portion
1,071
980
Other current liabilities
17,981
15,761
Total current liabilities
77,378
64,588
Current liabilities decreased by €12.8 million (17%) for the six months ended June 30, 2026, compared to December 31, 2025. This change is mainly driven by a €19.0 million decrease in short-term debt, mainly related to the settlement of the pre-funded warrants issued under the Structured Financing. This decrease is partially offset by an increase of €8.5 million in trade payables.
27
Cash flow and equity
This section discusses our shareholders’ equity, cash position for the six months ended June 30, 2026, and the fiscal year ended December 31, 2025, and our sources of funding for the six months ended June 30, 2026, and the six months ended June 30, 2025.
2.1. Cash and cash equivalents Net cash and cash equivalents In thousands of euros Other cash equivalents Cash at bank and at hand Cash and cash equivalents
December 31, 2025 82,628 16,684 99,312
June 30, 2026 132,293 33,835 166,127
Since our inception, we have financed our growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. We continue to pursue our research and development activities for lanifibranor. As of June 30, 2026, cash and cash equivalents amounted to €166.1 million compared to €99.3 million as of December 31, 2025, reflecting an increase of €66.8 million (67%). (see Section 2.2 – Cash flow analysis). Cash held by us is generally invested in short-term deposit accounts that are readily convertible into known amounts of cash. Cash is used to finance our activities, in particular our research and development costs and operating activities related to our lanifibranor development program. There are no restrictions on the use of our cash and cash equivalents resources.
2.1.1.
Equity financing
As of June 30, 2026, our share capital was set at €2,362,802.02 divided into 236,280,202 shares with a nominal value of €0.01 each, compared to a share capital of €1,932,369.78 divided into 193,236,978 shares with a nominal value of €0.01 each, as of December 31, 2025. The 430,432 euros share capital increase in the first six months of 2026 is attributable to the exercise of Warrants, including 2,059,386 shares issued following the exercise of T1 Warrants, 11,111,111 shares issued following the exercise of T2 Warrants, two separate issuances of 1,300,000 shares each following the exercise of T1 Warrants on February 11 and April 23, 2026, as well as 27,272,727 shares issued in connection with the Equity Offering. (See Note 4.8 - Shareholders’ equity to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report).
28
2.1.2. In thousands of euros
PGE SG 2020 PGE BPI France 2020 PGE CA 2020 PPR CA 2022 PPR SG 2022 PGE BPI France 2022 EIB Tranche A 2022 EIB Tranche B 2024 BlackRock - Claret Tranche A BlackRock - Claret Tranche B Bank overdraft Total Bank Borrowings EIB Warrants Tranche A EIB Warrants Tranche B Convertible option Lenders’ Warrants Derivatives Accrued interest payable on loans 2023 Royalty Certificates 2024 Royalty Certificates Royalty certificates liabilities Lease liabilities Total Debt
Financing from bank loans and market securities
Debt carried on the balance sheet at Jan. 1, 2026
Derecognition of Remaining EIB Warrant settlement obligation
Effect of movements in exchange rates
Debt carried on the balance sheet on June 30, 2026
Additions
Capitalized Interests
Cost of debt
Interests paid
Repayments
Fair Value Variation
Gain on derecognition
422
8
(8)
(422)
604
5
(5)
(604)
230 1,780 1,780
2 42
(2) (42)
(230)
1,780 1,780
1,113
18
(18)
(223)
890
27,900
4,880
(7,781)
(25,000)
17,393
5,687
6,344
(4,424)
(25,000)
21,894
325
(183)
22,035
37,121
312
(209)
37,224
13
(13)
51,233
59,002
5,687
11,935
(12,671)
(51,478)
63,710
61,004
(40,624)
5,252
(25,632)
58,381
(9,376)
3,317
(42,822)
(9,500)
119,385
10,588 3,784 14,371
(50,000)
(1,012) (309) 7,249
(68,454)
(9,500)
9,576 3,475 13,051
5,855
(5,687)
456
624
13,055
1,937
14,992
38,590
5,497
44,087
51,645
7,433
59,079
2,771
671
48
(1,167)
2
2,325
230,890
74,044
19,873
(12,671)
(102,645)
7,249
(68,454)
(9,500)
2
138,789
(1)
(1) The General Meeting’s decision to issue the new warrants resulted in the extinguishment of the 9.5m€ liability, the
recognition of the new warrants in equity for 50.2m€, and the recognition of a finance expense of 40.7m€ (see Note 1.4.4. – Financial income and expenses).
As of June 30, 2026, cost of debt mainly includes interest cost on bank borrowings and royalty certificates recognized using the effective interest rate method and the catch-up impact of the EIB debt remeasurement to reflect the revised cash flows resulting from the repayment of the EIB loan (see Note 1.4.4. – Financial income and expenses). As part of the Debt Financing Transaction, the carrying amount of the financing provided by BlackRock and Claret Capital Partners amounted to €59.3 million as of June 30, 2026, comprising €22.0 million relating to Lenders’ Tranche A and €37.2 million relating to Lenders’ Tranche B. These amounts reflect their initial recognition at fair value and subsequent measurement at amortized cost. In addition, the embedded conversion option in Lenders’ Tranche A was recognized as a derivative liability at the fair value of €10.6 million and remeasured at the fair value of €9.6 million as at June 30, 2026. (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report).
29
Our loans and debt maturity profile as of June 30, 2026, is as follows:
Less than one year
Between 1 and 3 years
Between 3 and 5 years
More than five years
Debt carried on the balance sheet on June 30, 2026
10,716 624 1,974 13,314
34,070 13,051 351 5,860 53,332
18,924 15,257 34,182
37,961 37,961
63,710 13,051 624 2,325 59,079 138,789
June 30, 2026
In thousands of euros
Bank borrowings Derivatives Accrued interests payable on loans
Lease liabilities Royalty certificates liabilities Total Debt
2.1.3.
Financing from Research Tax Credits
Due to our status as a European small and medium-sized enterprise (“SME”), we receive payment for research tax credits granted in the previous period. Consequently, cash proceeds from research tax credits in a given period correspond to the amount of credits calculated on eligible expenditure for the previous period. Research tax credits during the six months ended June 30, 2026 and June 30, 2025 were as follows:
Financing from research tax credits
June 30, 2025
In thousands of euros
June 30, 2026
Income statement impact of research tax credits
1,125
839
Cash flow impact of research tax credits
4,915
The €0.8 million CIR income for the first six months of 2026 is related to the R&D Tax Credit of Inventiva S.A.
30
2.2. Cash flow analysis The following table sets forth our cash flows for the first six months of 2026 and 2025:
Cash flow
June 30, 2025
In thousands of euros
June 30, 2026
Net cash used in operating activities
(53,725)
(45,438)
Net cash provided by (used in) investing activities
(24,799)
63,819
Net cash provided by financing activities
104,780
47,699
Net increase (decrease) in cash and cash equivalents
26,257
66,079
In the first six months of 2026 and 2025, our main financing needs related to our operating activities, including our working capital requirements. Net cash used in operating activities in the first six months of 2026 and 2025 amounted to €45.4 million and €53.7 million, respectively. The net cash used was mainly the result of our planned operating activities related to our lanifibranor development program. For the first six months of 2026 and 2025, net cash provided by (used in) investing activities amounted to €63.8 million and (€24.8) million, respectively. The net cash impact is related to the closing of shortterm deposits. Net cash provided by financing activities in the first six months of 2026 and 2025 amounted to €47.7 million and €104.8 million, respectively. The breakdown of these variations is available in the sections below.
31
2.2.1.
Cash flow linked to operating activities June 30, 2025
In thousands of euros Net loss for the period
June 30, 2026
(175,882)
(69,467)
Depreciation, amortization and provisions
4,109
1,554
Net book value of tangible and intangible assets sold Deferred and current taxes Tax credits Cost of net debt Share-based compensation expenses
14 (571) (1,125) 9,598 8,009
186 (124) (839) 19,874 11,753
Share of net loss (profit) of associates and joint ventures accounted for using the equity method
220
172
Unrealized foreign exchange losses/(gains)
908
(819)
Fair value variation through profit and loss Other
102,640
(16,130) (626)
Cash flows used in operations before tax and changes in working capital
(52,080)
(54,467)
Increase (decrease) in operating and other receivables (Increase) decrease in operating and other payables Tax credit received Other
(14,491) 8,438 4,915 (507)
(299) 6,292 3,036
Tax and changes in operating working capital
(1,645)
9,029
Net cash used in operating activities
(53,725)
(45,438)
Elimination of non-cash or non-operating income and expenses
Net cash used in operating activities amounted to €45.4 million and €53.7 million for the six months ended June 30, 2026, and 2025, respectively. The net cash used was mainly the result of our planned operating activities related to our lanifibranor development program.
32
2.2.2.
Cash flow linked to investing activities
Cash flow provided by investing activities over the periods presented was as follows:
June 30, 2025
June 30, 2026
(57)
(168)
(Increase)/decrease in current term accounts
(24,742)
63,987
Net cash provided by (used in) investing activities
(24,799)
63,819
In thousands of euros Purchases of property, plant and equipment and intangible assets
Net cash provided by investing activities amounted to €63.8 million for the six months ended June 30, 2026, compared to net cash used in investing activities of €24.8 million for the six months ended June 30, 2025, primarily due to the variation of the short-term deposits between both periods.
2.2.3.
Cash flow linked to financing activities
Cash flow used in financing activities over the periods presented was as follows: June 30, 2025
In thousands of euros
June 30, 2026
Capital increase
57,370
103,197
Transaction costs related to capital increase
(7,519) 58,206 (1,791) (1,317)
(8,205) (303) (50,000) 68,338 (51,491) (1,167)
(168)
(12,671)
104,780
47,699
Issue of warrants Repurchase of prefunded Warrants Subscription of borrowings Repayment of debt Repayment of lease liabilities Interest paid Net cash provided by (used in) financing activities
During the first six months of 2026, net cash provided by financing activities amounted to €47.7 million as described below, compared to €104.8 million during the first six months of 2025 primarily due to the receipt of proceeds from the second tranche of the Structured Financing in May 2025 and representing aggregate gross proceeds of €115.6 million (net proceeds of €108.0 million). As of June 30, 2026, financing activities cash inflows comprised:
- €103.0 million of gross proceeds raised through the Equity Offering, which, after €7.8 million of transaction fees, generated net proceeds of €95.3 million.
- €0.2 million received from the exercise of T1 and T2 Warrants issued under the Structured Financing, 33
These financing cash inflows were partly offset by:
- €50.0 million related to the repurchase of the Legacy EIB Warrants;
- €50.0 million repayment of the EIB loan under the Finance Contract;
- €1.5 million repayment of the state-guaranteed loans (Prêts Garantis par l’Etat, “PGE”) and Bpifrance (“BPI”) loans;
- €12.7 million of interest paid, mainly related to the existing EIB loan contracted under the Finance Contract; and
- €0.4 million of transaction costs incurred related to the previous Public Offering (American Depositary Shares). (See Note 4.8 - Shareholders' equity and Note 4.9 - Debt, derivatives and Royalty Certificates liabilities to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report)
2.3. Anticipated sources of funds From inception, we have financed our growth through successive capital increases, debt including royalty certificates, collaboration and license agreements and payment of French CIR receivables. We continue to pursue our research and development activities for lanifibranor. We have incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates we were developing and the product candidate we continue to develop, which necessitates a research and development phase spanning several years. We do not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, our financing needs will continue to grow as clinical trials of lanifibranor progress. As of June 30, 2026, we have €166.1 million of cash and cash equivalents, consisting of cash and shortterm deposit accounts that are liquid and easily convertible within three months without penalty or risk of change in value (refer to Note 4.7 – Cash and Cash equivalents to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report) and €67.8 million of short-term deposits convertible in a period exceeding three months, of which €30.0 million are required to be maintained in such form to comply with the minimum cash covenant under the Debt Financing Transaction. (refer to Note 4.6 – Trade receivables, tax receivables and other current assets to the unaudited interim condensed consolidated financial statements as of June 30, 2026 included elsewhere in this report). At the date of authorization of issuance of these unaudited interim condensed consolidated financial statements, based on our existing cash and cash equivalents and short-term deposits, excluding the amount held to comply with the minimum cash covenant, we estimate that we would be able to finance our operations as currently planned until the end of the second quarter of 2027. Accordingly, our current cash and cash equivalents will not be sufficient to cover our operating needs for at least the next 12 months. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on our ability to continue as a going concern and, therefore, we may be unable to realize our assets and discharge our liabilities in the normal course of business. If the T3 Warrants issued in our Structured Financing are exercised in full for gross proceeds of up to c. €116.0 million and Tranche C of the Debt Financing Transaction is issued for gross proceeds of up to €55.0 million, we estimate that such potential additional proceeds would enable us to finance our activities until the beginning of the first quarter of 2028. 34
These estimates are based on our current business plan, take into account the net proceeds from the Combined Transaction announced on June 2, 2026, as well as the availability of T3 Warrants issued in our Structured Financing and exclude any potential amounts payable to or by us and any additional expenditures related to the product candidate or resulting from any potential in licensing or acquisition of additional product candidates or technologies, or any associated product development we may pursue. We may have based these estimates on assumptions that are incorrect, we may amend our business plan in the future and may have to use our resources sooner than anticipated. These estimates may be shortened in the event of an increase in expenditure relating to the development program beyond our expectations, or if anticipated timing of the development program changes. There can be no assurance whether, and to what extent, the T3 Warrants will be exercised and the Tranche C will be issued, if at all. We will need to raise additional funds to support our activities and research and development programs, as currently planned, through: •
potential issuances of ADSs under our existing ATM program;
•
potential other public or private offerings; and
• potential strategic transactions such as business development partnerships and/or other business development arrangements. We cannot guarantee that we will be able to obtain the necessary financing or execute any transaction, through any of the aforementioned measures or by other means, to meet our needs or to obtain funds on acceptable terms and conditions, on a timely basis, or at all. If we are unable to obtain funding in a timely manner, we may be required to significantly curtail, delay or discontinue one or more of our research or development program or the commercialization of any approved product or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which would impair our prospects and operations. While recent financing events have improved our financial position, access to additional capital in the future remains subject to market conditions and investor interest. If we are unable to continue as a going concern, we may have to liquidate assets and may receive less than the value at which those assets are carried on our financial statements. We may also determine to cease operations or file for bankruptcy protection. In any of these circumstances, it is likely that investors will lose all or part of their investment. If there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide funding to us on commercially reasonable terms, if at all. The unaudited interim condensed consolidated financial statements as of and for the period ended June 30, 2026, have been prepared on a going concern basis assuming we will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if we were not able to continue as a going concern.
35
- Unaudited interim financial statements
condensed
consolidated
3.1. Statutory Auditors’ Review Report on the Half-yearly Financial Information This is a free translation into English of the statutory auditors’ review report on the half-yearly financial information issued in French and is provided solely for the convenience of English-speaking users. This report includes information relating to the specific verification of information given in the Group’s half-yearly management report. This report should be read in conjunction with, and construed in accordance with, French law and professional standards applicable in France.
Statutory Auditors’ Review Report on the interim Financial Information
For the period from January 1, 2026 to June 30, 2026
To the Shareholders, In compliance with the assignment entrusted to us by your Shareholders’ meetings and in accordance with the requirements of article L. 451-1-2 III of the French Monetary and Financial Code ("Code monétaire et financier"), we hereby report to you on:
•
the review of the accompanying interim condensed consolidated financial statements of Inventiva S.A., for the period from January 1, 2026 to June 30, 2026,
•
the verification of the information presented in the half-yearly management report.
These interim condensed half-yearly consolidated financial statements are the responsibility of the Board of Directors. Our role is to express a conclusion on these financial statements based on our review. Conclusion on the financial statements We conducted our review in accordance with professional standards applicable in France. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 - standard of the IFRSs as adopted by the European Union applicable to interim financial information. Without qualifying our conclusion, we draw your attention to the matter set out in note 3.4 to the interim condensed consolidated financial statements regarding the material uncertainty regarding events or circumstances that may cast doubt on the entity's ability to continue as a going concern.
36
Specific verification We have also verified the information presented in the half-yearly management report on the interim condensed consolidated financial statements subject to our review. We have no matters to report as to its fair presentation and consistency with the condensed half-yearly consolidated financial statements.
Paris La Défense, September 28, 2026
Paris, September 28, 2026
KPMG SA
LCA Audit
[sc_sign1.signature/]
[sc_sign2.signature/]
Philippe Grandclerc
Lison Dahan Chouraki
Partner
Partner
37
3.2. Interim Condensed Consolidated financial statement Unaudited interim condensed consolidated statement of financial position (in thousands of euros) December 31, 2025
June 30, 2026
Non-current assets
Notes
Intangible assets
4.1
182
310
Property, plant and equipment
4.2
2,979
2,360
Deferred tax assets
4.3
191
197
Investments accounted for using the equity method
4.4
527
528
Other non-current assets
4.5
1,162
1,849
5,042
5,244
2,016
3,734
Total non-current assets Current assets Trade receivables and others
4.6
Tax receivables
4.6
2,281
3,083
Other current assets
4.6
140,861
73,021
Cash and cash equivalents
4.7
99,312
166,127
Total current assets
244,469
245,966
Total assets
249,511
251,210
1,932
2,363
Premiums related to share capital
528,230
643,924
Reserves
(205,182)
(518,278)
Shareholders’ equity
4.8
Share capital
Translation reserve
636
460
Net loss for the period
(354,138)
(69,467)
Total Shareholders’ equity
(28,522)
59,002
Long-term debt
4.9
27,551
53,345
Long-term debt – derivatives
4.9
119,385
13,051
Royalty certificates liabilities
4.9
51,645
59,079
Provisions for retirement benefit obligations
4.11
755
680
Long-term contract liabilities
4.13
126
126
Other non-current liabilities
4.12
1,193
1,339
200,655
127,620
32,309
13,314
Total non-current liabilities Short-term debt
4.9
Short-term provisions
4.10
1,071
980
Trade payables Other current liabilities
4.13
26,017
34,532
4.12
17,981
15,761
Total current liabilities
77,378
64,588
Total liabilities
278,033
192,208
Total liabilities and shareholders' equity
249,511
251,210
The accompanying notes form an integral part of these financial statements
38
Unaudited interim condensed consolidated statement of income (loss) (in thousands of euros)
Six months ended
Notes
June 30, 2025
June 30, 2026
Revenues
5.1
4,454
20
Other income
5.1
1,156
1,286
5,610
1,305
Total revenues and other income Research and development costs
5.2
(44,890)
(46,238)
Marketing – Business development expenses
5.2
(746)
(2,589)
General and administrative expenses
5.2
(14,713)
(22,247)
Other operating income (expenses)
5.3
(8,202)
(619)
(62,940)
(70,388)
Operating profit (loss) Financial income
5.4
2,427
74,910
Financial expenses
5.4
(115,651)
(74,004)
(113,224)
907
5.5
(220)
117
5.6
503
(104)
(175,882)
(69,467)
(1.62)
(0.25)
108,839,636
273,582,870
Financial income (loss) Share of net loss (Equity method) and dilution gain (1) Income tax Net loss for the period Basic/diluted loss per share (euros/share) Weighted average number of shares outstanding used to calculate basic/diluted loss per share (1)
5.7
Including €0.3 million of dilution gain on investment in associate as of June 30, 2026.
The accompanying notes form an integral part of these financial statements
39
Unaudited interim condensed consolidated statement of comprehensive income (loss) (in thousands of euros)
Six months ended June 30, 2025 Net loss for the period Items that will be reclassified subsequently to profit or loss Currency translation differences - equity method Currency translation differences Items that will not be reclassified subsequently to profit or loss Remeasurement of defined benefit plans Total other comprehensive loss Total comprehensive loss
June 30, 2026
(175,882) (260)
(69,467) (175)
(183) (77)
(116) (59)
93
73
93
73
(167) (176,049)
(102) (69,570)
The accompanying notes form an integral part of these financial statements
40
Unaudited interim condensed consolidated statement of changes in shareholders’ equity (in thousands of euros)
Share capital Notes At December 31, 2025 Net loss for the period Remeasurement of defined benefit plans Currency translation differences Total comprehensive loss Appropriation of 2025 net income (loss) Issue of ordinary shares(1) Transaction costs Issue of warrants Vesting of bonus shares Share-based payment compensation expenses Treasury shares Other June 30, 2026
Premiums related to share capital
Net profit (loss)
Translation Reserves
Reserves (Accumulated losses)
Shareholders’ equity
528,230
(354,138) (69,467)
636
(205,182)
(28,522) (69,467)
73
73
(175)
(175) (69,570)
Number of shares
Amount
193,236,978
1,932
(2)
(69,467)
(175)
73
4.8
354,138
(354,138)
4.8 4.8 4.9 4.8
43,043,224
430
123,899 (8,205)
(21,132) 49,933
103,197 (8,205) 49,933
4.8
11,753
11,753
4.8
236,280,202
2,363
643,924
(69,467)
460
299 116 (518,278)
299 116 59,002
(1)
Share capital variation include a €272 thousand increase from the Equity Offering completed on June 5, 2026, corresponding to the issuance of 27,272,727 ordinary shares, and a €157 thousand increase in share capital resulting from the exercise of T1 and T2 warrants issued under the Structured Financing (see Note 4.8 – Shareholders’ equity).
(2)
Premiums related to share capital include €102.8 million of share premium resulting from the Equity Offering and €21.1 million resulting from the exercise of T1 and T2 warrants issued under the Structured Financing and (€7.8) million of transaction costs related to the Equity Offering and (€0.4) million relating to transaction costs recognized on January 1, 2026 in connection with the November 2025 public offering (see Note 4.8 – Shareholders’ equity). Share capital Notes
At December 31, 2024 Net loss for the period Remeasurement of defined benefit plans Currency translation differences Total comprehensive loss Appropriation of 2024 net income (loss) Issue of ordinary shares(1) Transaction costs Issue of prefunded warrants(2) Share-based payment compensation expenses Treasury shares Other June 30, 2025
95,662,391
957
Premiums related to share capital 249,160
(184,212)
600
(173,151)
(106,647)
(175,882)
(175,882)
93
93
(260)
(260) (176,049)
Number of shares
Amount
Net profit (loss)
Translation Reserves
Shareholders’ equity
Reserves
(175,882)
(260)
93
4.8
184,212
(184,212)
4.8 4.8 4.9
43,488,883
435
135,115 (7,519)
138,130
135,550 (7,519) 138,130
4.8
8,009
8,009
4.8
85 (467)
85 (467)
139,151,274
1,392
376,755
(175,882)
340
(211,513)
(8,909)
(1)
Corresponding mainly to the share capital increase consisting of the issuance of 42,488,883 new ordinary shares (see Note 4.8 Shareholders’ equity to the annual consolidated financial statements for the year ended on December 31, 2025)
(2)
Corresponding to the issuance of 43,437,036 pre-funded warrants (see Note 4.9 – Financial Debt – Short term Derivatives to the annual consolidated financial statements for the year ended on December 31, 2025)
The accompanying notes form an integral part of these financial statements
41
Unaudited interim condensed consolidated statement of cash flows (in thousands of euros) Notes Net loss for the period
June 30, 2025
June 30, 2026
(175,882)
(69,467)
4,109
1,554
Elimination of non-cash or non-operating income and expenses Depreciation, amortization and provisions
5.2
Net book value of tangible and intangible assets disposed Deferred and current taxes
14
186
(571)
(124)
Tax credits
5.1
(1,125)
(839)
Cost of debt
5.4
9,598
19,874
Share-based compensation expense
5.2
8,009
11,753
Share of net loss (profit) of associates and joint ventures accounted for using the equity method
5.5
220
172
908
(819)
5.3
102,640
(16,130)
(626)
Cash flows used in operations before tax and changes in working capital
(52,080)
(54,467)
Decrease / (increase) in operating and other receivables
(14,491)
(299)
Increase / (decrease) in operating and other payables
8,438
6,292
Tax credit received
4,915
(507)
3,036
Exchange (gains) / losses Fair value variation through profit and loss Other(1)
(2)
Other
Tax and changes in operating working capital
(1,645)
9,029
Net cash used in operating activities
(53,725)
(45,438)
Purchases of property, plant and equipment and intangible assets
(57)
(168)
Disposals of property, plant and equipment and intangible assets
(24,742)
63,987
(24,799)
63,819
Cash flows provided by (used in) investing activities
Decrease / (Increase) in short-term deposit accounts
4.6
Net cash flows provided by (used in) investing activities Cash flows provided by (used in) financing activities Capital increase
4.8
57,370
103,197
Transaction costs related to capital increase
4.8
(7,519)
(8,205)
Issue of warrants
4.9
58,206
(303)
(50,000)
Repurchase of prefunded Warrants Subscription of borrowings(3) Repayment of debt
4.9
68,338
4.9
(1,791)
(51,491)
Repayment of lease liabilities
4.9
(1,317)
(1,167)
(168)
(12,671)
Net cash flows provided by (used in) financing activities
104,780
47,699
Net increase (decrease) in cash and cash equivalents
26,257
66,079
96,564 (744)
99,312
Exchange gains / (losses) Net cash and cash equivalents at the end of period
122,076
166,127
Interest paid
Cash and cash equivalents at beginning of period
(1) (2) (3)
4.7
Including €0.3 million of gain on lease modification and €0.3 million of dilution gain on investment in associate as of June 30, 2026 Including variation of prepaid expenses in the amount of €0.5 million as of June 30, 2025 and €2.8 million as of June 30, 2026 Net of the amount of €1.3 million advance payment related to the Lenders’ Tranche B under the Debt Financing agreement as of June 30, 2026 (see Note 4.5 – Other non-current assets).
The accompanying notes form an integral part of these financial statements 42
736
Notes to the unaudited interim condensed consolidated financial statements Table of contents Note 1. Company information ............................................................................................................... 44 1.1 Company information.............................................................................................................. 44 1.2 Significant events in the first six months of 2026 ................................................................... 45 Note 2. Basis of preparation and statement of compliance ................................................................... 50 2.1 Statement of compliance ......................................................................................................... 50 2.2 Scope and method of consolidation ......................................................................................... 51 2.3 Foreign currency translation .................................................................................................... 52 Note 3. Accounting principles ............................................................................................................... 53 3.1 Use of estimates and judgment ................................................................................................ 53 3.2 Fair value measurement ........................................................................................................... 54 3.3 Specific disclosure requirements for unaudited interim financial statements ......................... 54 3.4 Going concern ......................................................................................................................... 55 Note 4. Notes to the unaudited interim condensed consolidated statement of financial position ......... 57 4.1 Intangible assets ...................................................................................................................... 57 4.2 Property, plant and equipment ................................................................................................. 57 4.3 Deferred tax assets................................................................................................................... 57 4.4 Investments accounted for using the equity method ............................................................... 58 4.5 Other non-current assets .......................................................................................................... 59 4.6 Trade receivables, tax receivables and other current assets .................................................... 60 4.7 Cash and cash equivalents balance from the statement of cash flows ..................................... 61 4.8 Shareholders’ equity ................................................................................................................ 62 4.9 Debt, Derivatives and Royalty Certificates liabilities ............................................................. 70 4.10 Provisions .............................................................................................................................. 79 4.11 Provisions for retirement benefit obligations ........................................................................ 80 4.12 Other current and non-current liabilities ............................................................................... 81 4.13 Trade payables ....................................................................................................................... 82 4.14 Financial assets and liabilities ............................................................................................... 83 Note 5. Notes to the interim condensed consolidated statement of income (loss) ................................ 85 5.1 Revenues and other income ..................................................................................................... 85 5.2 Operating expenses.................................................................................................................. 86 5.3 Other operating income and expenses ..................................................................................... 88 5.4 Financial income and expenses ............................................................................................... 89 5.5 Share of net profit – Equity method ........................................................................................ 90 5.6 Income tax ............................................................................................................................... 91 5.7 Basic and diluted loss per share............................................................................................... 91 Note 6. Other financial information ...................................................................................................... 92 6.1 Commitments related to operational activities ........................................................................ 92 6.2 Related-party transactions ....................................................................................................... 93 6.3 Financial risk management ...................................................................................................... 94 6.4 Events after the reporting date ................................................................................................. 95
43
Note 1. Company information
1.1 Company information Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (together, “Inventiva” or the “Company”). Inventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva’s American Depositary Shares (“ADSs”), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020. Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”). Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently evaluating its product candidate lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase III clinical trial for the treatment of adult patients with MASH, a common and progressive liver disease. In 2020, the Company announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with MASH and announced that the U.S. Food and Drug Administration (“FDA”) had granted the Company the status of Breakthrough Therapy and Fast Track designation for the development of lanifibranor for the treatment of MASH. The Company initiated the pivotal Phase III trial of lanifibranor in MASH (“NATiV3”) in the second half of 2021. In March 2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH and Type 2 Diabetes (“T2D”) (“LEGEND”). In April 2025, Inventiva announced the completion of patient enrollment in its NATiV3 trial with the randomization of the last patient in the main cohort. The publication of the topline results of the NATiV3 trial is targeted for the fourth quarter of 2026. If the results are positive and subject to regulatory approval, the Company targets the potential New Drug Application (“NDA”) submission for lanifibranor in the first half of 2027, with a view to potential commercialization in 2028.
44
1.2
Significant events in the first six months of 2026
1.2.1 Governance Appointments to Leadership Team in Preparation for Phase 3 lanifibranor Data Readout On April 22, 2026, the Company announced the strengthening of its leadership team with the appointment of Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments are intended to support the Company's organizational build-out ahead of the expected top-line data readout from NATiV3, and the potential subsequent regulatory filings and commercialization activities. In connection with these appointments, Jean Volatier, previously Chief Financial Officer, transitioned to the role of EVP Finance & Corporate Social Responsibility. Appointment of three independent members to the Board of Directors At the general meeting of June 30, 2026, the Company’s shareholders appointed Dr. Barbara KrebsPohl, Dr. Anne Prener and Ms. Camilla Soenderby as independent members of its Board of Directors, effective June 30, 2026. These appointments strengthen the Board with significant expertise in biotechnology, clinical development, commercialization and corporate governance, supporting the Company’s continued development of lanifibranor. Ms. Annick Schwebig resigned from the Board of Directors prior to the general meeting. 1.2.2 Combined transaction Comprehensive refinancing transaction announced on June 2, 2026 In June 2026, the Company announced and executed a comprehensive refinancing transaction to fund the continued development and potential commercialization of lanifibranor. The transaction comprised three components: (i) (ii) (iii)
An Equity Offering; Transactions with the European Investment Bank (“EIB”) (the “EIB Transactions”); and Debt Financing Transaction,
the “Combined Transaction”. Each of these components is described in further detail below. The accounting treatment of the transactions is described in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities.
45
(i)
Equity Offering
On June 2, 2026, the Company announced an offering of 27,272,727 ADSs, each representing one ordinary share, at a public offering price of $4.40 (€3.7781) 8 per ADS (the “Equity Offering”). The settlement occurred on June 5, 2026. 4F
The Equity Offering generated aggregate gross proceeds of $120.0 million (€103.0 million) 9. After deducting underwriting discounts and commissions and offering expenses payable by the Company of $9.1 million (€7.8 million), the net proceeds from the Equity Offering amounted to $110.9 million (€95.3 million). 5F
The Equity Offering resulted in an increase in share capital and share premium for the corresponding net proceeds amount as of June 30, 2026, with the transaction fees deducted from the premiums.
(ii)
EIB Transactions
On June 1, 2026 (the “EIB Transactions Execution Date”), the Company entered into a master agreement with the EIB (the “EIB Master Agreement”) providing for: (a) Repayment of an existing EUR 50 million EIB loan outstanding under the Finance Contract dated May 16, 2022 (the “Finance Contract”): on June 12, 2026 (the “EIB Completion Date”), the Company prepaid in full the outstanding principal and accrued interest under the Finance Contract, for an aggregate amount of €62.2 million. Pursuant to the EIB Master Agreement, the EIB waived the early prepayment fees that would otherwise have been due under the Finance Contract. As of December 31, 2025, both tranches of the EIB loan (“EIB Tranche A” and “EIB Tranche B”) qualified as financial liabilities, measured at amortized cost under IFRS 9 and the corresponding amounts recognized amounted to:
- EIB Tranche A principal (including capitalized interest): €27.9 million, and
- EIB Tranche B principal (including capitalized interest): €17.4 million. As of EIB Transactions Execution Date, the corresponding amounts recognized were:
EIB Tranche A principal (including capitalized interest): €27.9 million, EIB Tranche A accrued interests: €2.9 million, EIB Tranche B principal (including capitalized interest): €23.1 million, EIB Tranche B accrued interests: €2.8 million, EIB loans catch-up adjustment: €5.0 million, and €0.5 million resulting from the unwinding of the discount until the EIB Completion Date.
The accounting treatment of the repayment of the EIB loan is presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities.
(b) Repurchase and cancellation of Legacy EIB Warrants: on June 12, 2026, the Company repurchased and cancelled all of the warrants it had issued to EIB in connection with EIB Tranche A under the Finance Contract (the “EIB Tranche A Warrants”) and 700,000 of the warrants it had issued to EIB in connection with EIB Tranche B under the Finance Contract (the 8 9
The exchange rate on the pricing date (June 1, 2026) was 1.1646 dollar for one euro. The exchange rate on the settlement date (June 5, 2026) was 1.1640 dollar for one euro. 46
“EIB Tranche B Warrants” and, together with the EIB Tranche A Warrants, the “Legacy EIB Warrants”), corresponding to approximately 22.7 million EIB underlying shares, for an aggregate repurchase price of €50.0 million. As of December 31, 2025, the EIB Tranche A Warrants and EIB Tranche B Warrants were classified as a derivative liability measured at fair value through profit or loss, for an aggregate carrying amount of €119.4 million, of which €74.0 million were related to the repurchased and cancelled Legacy EIB Warrants. As of June 30, 2026, the fair value of the repurchased and cancelled warrants amounted to €66.3 million for EIB Tranche A Warrants and to €13.7 million for EIB Tranche B Warrants (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities). The fair value variation recognized in financial income during the six-months period ended June 30, 2026 amounted to €68.5 million (see Note 5.4 – Financial income and expense). This gain primarily resulted from the EIB Master Agreement, resulting in the repurchase and cancellation of the Legacy EIB Warrants for the repurchase price of €50.0 million. The accounting treatment of the repurchase of the Legacy EIB Warrants is presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities.
(c) Restructuring of the remaining EIB Tranche B Warrants (the ‘Remaining EIB Warrants’): following approval by the Company’s shareholders at the general meeting of June 30, 2026, the Company cancelled the Remaining EIB Warrants (representing 2,444,654 warrants, corresponding to approximately 15.7 million underlying shares) and issued 15,677,573 new warrants to EIB (the ‘New EIB Warrants’) on July 9, 2026. Each New EIB Warrant entitles EIB to subscribe one ordinary share and the New EIB Warrants do not bear the anti-dilution mechanism applicable to the Legacy EIB Warrants, each entitling EIB to subscribe to one ordinary share per New EIB Warrant. The New EIB Warrants were issued at a unit price of €0.01, which was paid by EIB by way of setoff against an arrangement fee of €0.01 per warrant payable by the Company to EIB under the EIB Master Agreement, resulting in no net cash proceeds from such issuance, subject to approval of the June 30, 2026 general meeting of the Company’s shareholders. The exercise price of the New EIB Warrants is set at €0.01 per New EIB Warrant. On July 9, 2026, pursuant to the EIB Master Agreement and following the authorization granted by the Company's shareholders' meeting held on June 30, 2026, the Chief Executive Officer of the Company approved the issuance of 15,677,573 New EIB Warrants to the EIB and the execution of a subscription agreement with the EIB governing such issuance. Upon subscription of the New EIB Warrants, the EIB irrevocably surrendered for cancellation all Remaining EIB Warrants. The fair value variation recognized in financial expenses during the six-month period ended June 30, 2026 amounted to €40.7 million (see Note 5.4 – Financial income and expense). As a result of the restructuring completed during the period, no derivative liability related to the Legacy EIB Warrants remained as of June 30, 2026 (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities). The restructuring of the Legacy EIB Warrants results in the accounting treatment presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities and Note 4.8 – Shareholders’ equity.
(iii)
Debt Financing Transaction
On June 2, 2026, the Company entered into a subscription agreement with funds and accounts managed by BlackRock and Claret Capital Partners (the “Lenders”) providing for the issuance of new senior 47
secured debt instruments for an aggregate committed principal amount of up to €130.0 million, plus an additional uncommitted tranche of up to €20.0 million subject to mutual consent following FDA approval of the NDA for lanifibranor (the “Subscription Agreement”) (together, the “Debt Financing Transaction”). The Debt Financing Transaction comprises: • • •
• •
Lenders’ Tranche A (as defined below) – €35.0 million of senior secured convertible bonds (Obligations Convertibles en Actions), drawn down on June 12, 2026; Lenders’ Tranche B (as defined below) – €40.0 million of senior secured non-convertible amortized bonds, drawn down on June 12, 2026; Lenders’ Tranche C – up to €55.0 million of senior secured non-convertible amortized bonds (uncommitted, drawable at the option of the Company until February 15, 2027 subject to conditions precedent); Additional Lenders’ Tranche – up to €20.0 million of additional debt instruments (uncommitted, subject to mutual consent following FDA approval of the NDA for lanifibranor); and Lenders’ Warrants – warrants to subscribe for ordinary shares with an aggregate notional value of up to €9.5 million (€6.75 million in respect of Lenders’ Tranches A and B and €2.75 million in respect of Lenders’ Tranche C.
A portion of the proceeds were used to refinance the EIB loans (see Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities) and the remainder is intended to fund the Company's activities and research and development programs (see Note 3.4 – Going concern). The Subscription Agreement includes certain restrictive covenants, subject to customary exceptions, including, among other things, restrictions on the incurrence of indebtedness, the grant of security interests and guarantees, dividends and other distributions, asset disposals, mergers and restructurings, acquisitions and joint ventures. The Subscription Agreement also includes financial covenants requiring us to maintain at least €30.0 million in specified secured accounts. The obligations under the debt financing are secured by first-ranking security over specified collateral, including certain intellectual property rights, bank accounts and receivables. The closing of the first tranche consisting of senior secured bonds (the “Convertible Bonds”), convertible into new ordinary shares (“Lenders’ Tranche A”) and the second tranche consisting of senior secured amortized bonds (“Lenders’ Tranche B”) was conditional upon the full repayment of the EIB loans and the completion of an equity financing of at least €90.0 million, which was satisfied upon the closing of the Equity Offering on June 5, 2026. On June 12, 2026, the Company drew down the first two tranches of the Debt Financing Transaction for an aggregate principal amount of €75.0 million (net proceeds of €69.6 million):
Lenders’ Tranche A for €35.0 million, with annual fixed interest of 9.90%, with an interest-only period until December 31, 2028, followed by sixteen monthly instalments of principal and interest, until final maturity on April 1, 2030. The Convertible Bonds have a par value of one euro each and a conversion price equal to a premium of 40%, applied on the lower of (i) the 30day VWAP of the Ordinary Shares on Euronext Paris immediately prior to April 30, 2026 (being €4.6681), (ii) the 30-day VWAP of the ordinary shares on Euronext Paris immediately prior to the issuance date of the Convertible Bonds, or (iii) the euro-equivalent offering price per ordinary share, represented by each ADS sold in the Equity Offering, being €3.7781. The conversion price is subject to a minimum equal to the 30-day VWAP immediately prior to the issuance date and the minimum price per the Company's current authorizations. Pursuant to the conversion price formula described above, the conversion price was set on June12, 2026 at €5.2893 per ordinary share, corresponding to a conversion ratio of 0.18907
48
ordinary shares per Convertible Bond of €1 par value. The conversion ratio is subject to customary anti-dilution adjustments and may be adjusted pursuant to an equity-linked pricing reset mechanism.
Lenders’ Tranche B for €40.0 million, with annual fixed interest of 9.90%, supplemented by payment-in-kind interest of 2.10% capitalized annually, with an initial interest-only period ending on March 31, 2027 (extendable at the Company's election to December 31, 2027 subject to (i) meeting the NATiV3 primary endpoint and (ii) the confirmation of the exercise of the third tranche warrants (the “T3 Warrants”) issued under the structured financing of up to €348.0 million announced on October 14, 2024 (the “Structured Financing”) or prior completion of an equity fundraising for at least €100 million following release of results of NATiV3, with both (i) and (ii) being met no later than February 15, 2027, and thereafter to December 31, 2028 subject to FDA approval of the NDA for lanifibranor), by no later than 15 business days prior to December 31, 2027), with final maturity on April 1, 2030.
The drawdown of the Lenders’ Tranches A and B results in the accounting treatment presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities. In addition, an uncommitted tranche (“Lenders’ Tranche C”) of up to €55.0 million, with annual fixed interest of 8.90%, supplemented by payment-in-kind interest of 2.10% capitalized annually, remains available for drawdown no later than February 15, 2027, subject to certain conditions precedent: (a) the prior and full issuance of Lenders’ Tranches A and B, (b) compliance with a maximum debt-to-market capitalization ratio of 10% based on a 30-day VWAP (which market capitalization includes the ordinary shares and the pre-funded warrants issued in the Structured Financing), (c) the achievement of the primary composite endpoint of the ongoing NATiV3 trial and (d) the confirmation of the exercise of the T3 Warrants issued by the Company on May 7, 2025 of at least €100 million (the “T3 Warrants Exercise”) or prior completion of an equity fundraising of at least €100 million. Finally, the Debt Financing Transaction comprises an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following FDA approval of the NDA for lanifibranor. As of the date of authorization of these financial statements, the conditions (b), (c) and (d), for drawdown have not been met and therefore there is no financial effect. In connection with the Subscription Agreement, on June 12, 2026, the Company issued warrants (bons de souscription d’actions) to the Lenders (the “Lenders’ Warrants”): • •
1,624,196 Lenders' Warrants in respect of Lenders’ Tranches A and B, exercisable upon issuance, representing an aggregate notional value of €6.75 million; and 661,709 Lenders' Warrants in respect of Lenders’ Tranche C, exercisable only upon any future drawdown of Lenders’ Tranche C, representing an aggregate notional value of €2.75 million.
The issuance of Lenders’ Warrants results in the accounting treatment presented in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities. Each Lenders' Warrant entitles the holder to subscribe to one ordinary share of the Company. The exercise price was set at €4.1559 per ordinary share, corresponding to a 10% premium applied to the lowest of (i) the 30-day VWAP of the ordinary shares on Euronext Paris immediately prior to April 30, 2026 (€4.6681), (ii) the 30-day VWAP immediately prior to the initial closing of Lenders’ Tranches A and B, and (iii) the euro-equivalent offering price per ordinary share represented by each ADS sold in the Equity Offering (€3.7781). The exercise ratio is subject to customary anti-dilution adjustments and may also be adjusted pursuant to an equity-linked pricing reset mechanism in certain circumstances specified in the Subscription Agreement.
49
The Lenders' Warrants will expire on the earlier of (i) the tenth anniversary of their issuance date and (ii) the closing of a tender offer under sections 14(d) and 14(e) of the U.S. Securities Exchange Act of 1934.
Note 2. Basis of preparation and statement of compliance 2.1 Statement of compliance These unaudited interim condensed consolidated financial statements were prepared in compliance with International Accounting Standard IAS 34 — Interim Financial Reporting, which provides for the presentation of selected explanatory notes. The accompanying notes do not contain all the disclosures required for annual financial statements and should therefore be read in conjunction with the Company’s financial statements prepared in accordance with IFRS® Accounting Standards, as of and for the year ended December 31, 2025. These unaudited interim condensed consolidated financial statements as of June 30, 2026, were approved by the Board of Directors of the Company on September 25, 2026. IFRS® Accounting Standards basis adopted The accounting policies applied by the Company in the preparation of the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2026, are identical to those used in the annual financial statements prepared in accordance with IFRS® Accounting Standards as of and for the year ended December 31, 2025 with the exception of specific provisions for the preparation of unaudited interim condensed consolidated financial statements. Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2026 The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2026, in the European Union primarily concern: • • •
Amendments to IFRS 9 and IFRS 7 – Classification and Measurement of Financial Instruments – as of January 1, 2026 Amendments to IFRS 9 and IFRS 7 – Contracts Referencing Nature-dependent Electricity – as of January 1, 2026 Annual Improvements to IFRS Accounting Standards, as of January 1, 2026 – Amendments to: o IFRS 1 First-time Adoption of International Financial Reporting Standards; o IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7; o IFRS 9 Financial Instruments; o IFRS 10 Consolidated Financial Statements; and o IAS 7 Statement of Cash flows
Those amendments had no material impact on the Company’s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2026. Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory
50
The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable are: • • • • •
Amendments to IAS 21 – The Effects of Changes in Foreign Exchange Rates – as of January 1, 2027 Amendments to IAS 28 – Fair Value Measurement for Investments in Associates and Joints Ventures – as of January 1, 2027 New standard – IFRS 18 – Presentation and Disclosure in Financial Statements – as of January 1, 2027 New standard – IFRS 19 – Subsidiaries without Public Accountability: Disclosures – as of January 1, 2027 New standard - IFRS 20 Regulatory Assets and Regulatory Liabilities – as of January 1, 2029
The Company is continuing to assess the potential impacts of adopting IFRS 18. At this stage, it does not expect the application of this new standard to have a significant impact on its financial statements. The Company is currently assessing the applicability and impact of the other new standards, interpretations and amendments.
2.2 Scope and method of consolidation •
Accounting policy
In accordance with IFRS 10 Consolidated Financial Statements, an entity (subsidiary) is consolidated when it is controlled by the company (the parent). Subsidiaries are all entities over which the Company has control. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date the control ceases. All intercompany transactions, balances, and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries are consistent with the policies adopted by the parent. •
Consolidated entities
As of June 30, 2026, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized.
INVENTIVA Inc.
•
Date of incorporation
Percent of Ownership Interest
Accounting Method
01/05/2021
100%
Fully Consolidated
Interests in associates and joint ventures
The Company owns 13.68% of the ownership and voting rights of Hepalys, which is incorporated and has its principal place of business in Japan. In accordance with IAS 28 Investments in Associates and
51
Joint Ventures, Hepalys is an associate of the Company and is accounted for using the equity method (see Note 4.4 – Investments accounted for using the equity method). 2.3 Foreign currency translation •
Functional and presentation currency
The Company’s consolidated financial statements are presented in euros, which is also the functional currency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S. dollar. All amounts presented in these notes to the consolidated financial statements are denominated in euros unless otherwise stated. •
Translation of financial statements into presentation currency
The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into euros, the presentation currency, as follows: •
Assets and liabilities for each balance sheet presented are translated at the closing rate on the date of that balance sheet,
•
Income and expenses for each statement of (income) loss and statement of comprehensive (income) loss are translated at average exchange rates (which is an approximate value of the exchange rate on the transaction date in the absence of significant fluctuations. Income and expenses are translated at the transaction dates if the exchange rates fluctuate significantly), and
•
All resulting exchange differences are recognized in other comprehensive income.
Exchange rate (USD per EUR)
June 30, 2025
December 31, 2025
June 30, 2026
Average exchange rate for the period
1.0927
1.1300
1.1667
Exchange rate at the end of period
1.1720
1.1750
1.1394
52
Note 3. Accounting principles 3.1 Use of estimates and judgment The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made. There have been no significant changes in the material judgments and main estimates used by management when applying the Company’s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2025. However, during the six-month period ended June 30, 2026, the Company completed a number of significant financing transactions, including the EIB Transactions and the Debt Financing Transaction, resulting in the issuance of new derivative instruments and equity instruments, as described in Note 1.2 - Significant events in the first six months of 2026. Derivatives The fair value measurement of the Legacy EIB Warrants was based on a Longstaff-Schwartz option valuation model. The valuation of the New EIB Warrants and the Lenders' Warrants was based on a Black & Scholes approach including assumptions regarding the Company's share price, expected volatility, expected term, risk-free interest rates and other market parameters. In addition, the fair value measurement of the conversion option embedded in Convertible Bonds required management to estimate the value of the conversion feature separately from the host debt instrument. These valuations involve significant judgment and estimation uncertainty. The accounting for these transactions required management to exercise judgment, in particular in assessing the classification of certain financial instruments under IAS 32 and IFRS 9, the identification and valuation of derivatives, and issued instruments. These estimates and judgments are described in Note 4.9 – Debt, Derivatives and Royalty Certificates liabilities. The conflict in Ukraine and the conflicts in the Middle East have not led to any material changes in the estimates or judgements made by management in the preparation of the Company’s consolidated financial statements.
53
3.2 Fair value measurement In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs: •
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
•
Level 2: Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
•
Level 3: Unobservable inputs for the asset or liability.
The table below presents the financial liabilities of the Company measured at fair value on June 30, 2026:
At June 30, 2026 (in thousands of euros) Financial liabilities at fair value through profit or loss Long-term financial debt - derivatives
Level 1
Total liabilities
Level 2
Level 3
13,051
13,051
The table below presents the financial liabilities of the Company measured at fair value at December 31, 2025:
At December 31, 2025 (in thousands of euros) Financial liabilities at fair value through profit or loss Long-term financial debt - derivatives Total liabilities
Level 1
Level 2
Level 3
119,385 119,385
3.3 Specific disclosure requirements for unaudited interim financial statements Seasonality of operations The Company’s operations are not subject to material seasonal fluctuations. Income tax Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year. The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes.
54
3.4 Going concern From inception, the Company has financed its growth through successive capital increases, debt including royalty certificates, collaboration and license agreements and payment of French Research tax credit (Crédit d’Impôt Recherche, “CIR”) receivables. The Company continues to pursue its research and development activities for its product lanifibranor. The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it was developing and the product candidate it continues to develop, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of lanifibranor progress. As of June 30, 2026, the Company has €166.1 million of cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within three months without penalty or risk of change in value (refer to Note 4.7 – Cash and Cash equivalents) and €67.8 million of short-term deposits convertible in a period exceeding three months, of which €30.0 million are required to be maintained in such form to comply with the minimum cash covenant under the Debt Financing Transaction. (refer to Note 4.6 – Trade receivables, tax receivables and other current assets). At the date of authorization of issuance of these unaudited interim condensed consolidated financial statements, based on the Company’s existing cash and cash equivalents and short-term deposits, excluding the amount held to comply with the minimum cash covenant, the Company estimates that it would be able to finance its operations as currently planned until the end of the second quarter of 2027. Accordingly, the Company’s current cash and cash equivalents will not be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. If the T3 Warrants issued in the Company’s Structured Financing are exercised in full for gross proceeds of up to c. €116.0 million and Tranche C of the Debt Financing Transaction is issued for gross proceeds of up to €55.0 million, the Company estimates that such potential additional proceeds would enable it to finance its activities until the beginning of the first quarter of 2028. These estimates are based on the Company’s current business plan, take into account the net proceeds from the Combined Transaction announced on June 2, 2026, as well as the availability of T3 Warrants issued in our Structured Financing, and exclude any potential amounts payable to or by the Company and any additional expenditures related to the product candidate or resulting from any potential in licensing or acquisition of additional product candidates or technologies, or any associated product development the Company may pursue. The Company may have based these estimates on assumptions that are incorrect, the Company may amend its business plan in the future and may have to use its resources sooner than anticipated. These estimates may be shortened in the event of an increase in expenditure relating to the development program beyond the Company's expectations, or if the anticipated timing of the development program changes. There can be no assurance whether, and to what extent, the T3 Warrants will be exercised and the Tranche C will be issued, if at all. The Company will need to raise additional funds to support its activities and research and development programs, as currently planned, through: •
potential issuances of ADSs under its existing ATM program; 55
•
potential other public or private offerings; and
• potential strategic transactions such as business development partnerships and/or other business development arrangements. The Company cannot guarantee that it will be able to obtain the necessary financing or execute any transaction, through any of the aforementioned measures or by other means, to meet its needs or to obtain funds on acceptable terms and conditions, on a timely basis, or at all. If the Company is unable to obtain funding in a timely manner, it may be required to significantly curtail, delay or discontinue one or more of its research or development program or the commercialization of any approved product or be unable to expand its operations or otherwise capitalize on its business opportunities, as desired, which would impair the Company’s prospects and operations. While recent financing events have improved the Company’s financial position, access to additional capital in the future remains subject to market conditions and investor interest. If the Company is unable to continue as a going concern, the Company may have to liquidate assets and may receive less than the value at which those assets are carried on the Company’s financial statements. The Company may also determine to cease operations or file for bankruptcy protection. In any of these circumstances, it is likely that investors will lose all or part of their investment. If there remains substantial doubt about the Company’s ability to continue as a going concern, investors or other financing sources may be unwilling to provide funding to the Company on commercially reasonable terms, if at all. The unaudited interim condensed consolidated financial statements as of and for the period ended June 30, 2026, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.
56
Note 4. Notes to the unaudited interim condensed consolidated statement of financial position 4.1 Intangible assets In thousands of euros Intangible assets, gross Amortization and impairment Intangible assets, net
December 31, 2025 4,094 (3,911) 182
June 30, 2026 4,230 (3,920) 310
4.2 Property, plant and equipment
In thousands of euros Property, plant and equipment, gross Depreciation and impairment Property, plant and equipment, net
December 31, 2025
June 30, 2026
19,939
17,952
(16,960)
(15,592)
2,979
2,360
As of June 30, 2026, the gross carrying amount decreased by €2.0 million, mainly related to (i) a €3.0 million decrease in connection with asset disposals, mainly related to the termination of certain research activities, partially offset by (ii) a €1.0 million increase as a result of the reassessment of the Fibroscans right-of-use asset following the amendment of the Echosens lease contract effective January 1, 2026. Depreciation and impairment decreased by €1.4 million, reflecting both the increase in depreciation expense associated with the reassessed IFRS 16 right-of-use asset and the derecognition of €2.8 million of accumulated depreciation on assets disposed of during the period. Accordingly, the net carrying amount decreased by €0.6 million.
4.3 Deferred tax assets Inventiva S.A. and Inventiva Inc. are taxed as two separate entities and cannot apply the tax consolidation. For each entity, the deferred tax assets and deferred tax liabilities are offset in the consolidated financial statements. Deferred tax assets are recognized only when an entity has sufficient evidence that it will have a sufficient taxable benefit available to use the unused tax losses in the foreseeable future. As recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to Inventiva S.A.’s activity, deferred tax assets were recognized on this basis on June 30, 2026 only for Inventiva Inc.
57
4.4 Investments accounted for using the equity method On September 26, 2023, the Company exercised an option to buy 30% (1,500,000 ordinary shares) of Hepalys at an aggregate exercise price of ¥300 (equal to €1.90). Following the receipt of the exercise notice, Hepalys’s Board of Directors authorized the transfer of the 1,500,000 ordinary shares from Catalys to the Company on October 11, 2023. The Company did not participate in Hepalys’ capital increases in 2023 and 2024, which resulted in a dilution of the Company’s ownership down to 15%. (See Note 7 – Investments accounted for using the equity method to the annual consolidated financial statements for the year ended on December 31, 2025) During the six-month period ended June 30, 2026, the Company's equity-accounted investee, Hepalys, completed two capital increases in which the Company did not participate. These capital increases resulted in a mechanical dilution of the Company's ownership interest in Hepalys, as follows: On January 14, 2026 and February 24, 2026, Hepalys completed two capital increases reserved to existing shareholders, of €1.7 million and €0.6 million, respectively. The Company's non-participation in this capital raise resulted in a dilution of its ownership interest from 14.64% to 13.92% as at January 14, 2026 and to 13.68% as at February 24, 2026. The Company analyzed its ownership of Hepalys and concluded that, as of June 30, 2026, it has a significant influence but not control or joint control of Hepalys, as concluded as of December 31, 2025. As the Company maintained significant influence over Hepalys despite the dilution, the investment continues to be accounted for using the equity method. The combined dilution effect resulted in a total dilution gain of €0.3 million, recognized in the consolidated statement of income (loss) for the six-month period ended June 30, 2026. As of June 30, 2026, the Company holds 13.68% of Hepalys' shares. The tables below provide the summarized statement of financial position of Hepalys. The disclosed information reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below also provide the reconciliation between the Hepalys statement of financial position and the carrying amount in the Company’s statement of financial position.
58
December 31, 2025 12,729 183 12,912
(in thousands of euros) Non-current assets Current assets Total assets
June 30, 2026 11,556 1,966 13,522
Shareholders’ equity Current liabilities Equity and liabilities
12,766 146 12,912
13,389 133 13,522
Opening net assets Loss for the period(1) Other comprehensive income Capital variations Closing net assets
18,368 (3,816) (1,786) 0 12,766
12,766 (1,642) (70) 2,335 13,389
15%
14%
1,869 (1,378) 37 527
1,832 (1,340) 37 528
Group's share in % Group's share Elimination of unrealized profit on downstream sales Goodwill Carrying amount (1)
Refer to Note 5.5 – Share of net profit - equity method
4.5 Other non-current assets December 31, 2025
(in thousands of euros) Long-term deposit accounts Advance payments – non-current Allowance for doubtful accounts Other non-current assets
115 1,047 1,162
June 30, 2026 836 1,047 (33) 1,849
As of June 30, 2026, Other non-current assets increased by €0.7 million compared to December 31, 2025, primarily related to the long-term deposit accounts amounting to €0.8 million as of June 30, 2026, compared to €0.1 million as of December 31, 2025. The increase relates to an cash collateral deposit made in connection with Lenders’ Tranche B of the Debt Financing Transaction, recognized initially at the fair value for €0.7 million. This amount is contractually recoverable upon final repayment of the related financing. The other advance payments remain stable at €1.0 million corresponding to the advance paid under the contract research organization (“CRO”) contract with Pharmaceutical Research Associates Group B.V. (“PRA”) (See Note 6.1 – Commitments related to operational activities).
59
4.6 Trade receivables, tax receivables and other current assets Trade receivables and others Trade receivables and others break down as follows (by maturity of issuance date):
(in thousands of euros) 3 months or less Trade receivables and others
December 31, 2025 2,016 2,016
June 30, 2026 3,734 3,734
The average payment period is 30 days. As of June 30, 2026, trade receivables and others increased by €1.7 million, mainly in connection with the reinvoicing to Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (‘CTTQ’) of part of the Company’s study costs.
Tax receivables and Other current assets (in thousands of euros) CIR and other research tax credits Other Tax receivables Prepaid expenses Short-term deposit accounts Current accrued income Liquidity agreement - Cash VAT receivables Other receivables Other current assets Other current assets and tax receivables
December 31, 2025 2,267 14 2,281 3,952 131,558 1,575 527 3,148 101 140,861 143,142
June 30, 2026 3,080 3 3,083 1,660 67,765 862 2,677 57 73,021 76,104
French Research Tax Credit (“CIR”) As of June 30, 2026, tax receivables are mainly composed of 2025 CIR receivable for €2.3 million and for the estimated 2026 CIR for €0.8 million. As of December 31, 2025, tax receivables amounted to €2.3 million, mainly relating to the 2025 CIR for an amount of €2.3 million. Prepaid expenses As of June 30, 2026, prepaid expenses, which decreased by €2.3 million, are mainly composed of trial costs related to NATiV3 and €0.4 million of transaction costs mainly related to the ATM program as of the first six months of 2026 (see Note 1.2 – Significant Events in the first six months of 2026).
60
As of December 31, 2025, prepaid expenses were mainly composed of trial costs related to NATiV3 in 2025 and €1.3 million in connection with the new ATM program as of December 31, 2025. Short-term deposit accounts These deposits have original maturities exceeding three months and therefore do not qualify as cash equivalents under IAS 7. As of June 30, 2026, short-term deposit accounts decreased by €63.8 million compared to December 31, 2025, mainly related to the closing of short-term deposits at Société Générale for $71.8 million (€63.1 million) and Crédit Agricole for $56.5 million (€49.6 million), partially offset by the opening of a new short-term deposit account at Société Générale for $39.5 million (€34.7 million) and a new short-term deposit account at Crédit Agricole for $16.4 million (€14.4 million). Included in short-term deposits is an amount of €30.0 million held in term deposits to satisfy the minimum cash covenant under the Debt Financing Transaction. These deposits are excluded from cash and cash equivalents because they are held primarily for covenant compliance purposes. As of December 31, 2025, the short-term deposit accounts amounted to €131.6 million, primarily composed of the short-term deposit accounts subscribed during the fourth quarter of the period with Crédit Agricole for €43.0 million and $14.6 million (€12.4 million), and with Société Générale for €53.0 million and $26.5 million (€22.5 million). Current accrued income As of June 30, 2026, current accrued income amounted to €0.9 million related to the re-invoicing of costs related to NATiV3. Liquidity agreement - Cash As of June 30, 2026, no cash was held under the liquidity agreement, compared to €0.5 million as of December 31, 2025. This decrease is related to the termination of the liquidity agreement with Kepler Cheuvreux during the first half of 2026. (see Note 4.8 – Shareholders’ equity)
4.7 Cash and cash equivalents balance from the statement of cash flows
December 31, 2025 (in thousands of euros) Other cash equivalents (1) Cash at bank and at hand Cash and cash equivalents (2) Cash and cash equivalents balance from the statement of cash flows (1) (2)
Other cash equivalents correspond to short-term bank deposits Balances presented in the statement of financial position
61
June 30, 2026
82,628 16,684 99,312
132,293 33,835 166,127
99,312
166,127
4.8 Shareholders’ equity In accordance with the decision of the Annual General Meeting of shareholders, the net loss of €354.1 million for the financial year ending December 31, 2025, has been appropriated to reserves (accumulated losses). No appropriation to statutory or other reserves has been made.
Share capital As of June 30, 2026, the share capital was set at 2,362,802.02 divided into 236,280,202 fully authorized, subscribed and paid-up shares with a nominal value of €0.01. Share capital variation in the first six months of 2026 is set forth in the table below: (In euros, except number of shares) Nature of the Date transactions Balance as of December 31, 2025 Transaction costs related to the Public offering January 1, 2026 (American Depositary Shares) of November 18, 2025 Structured Financing January 14, 2026 (Exercise of T1bis warrants) Structured Financing January 23, 2026 (Exercise of T2 warrants) Structured Financing February 11, 2026 (Exercise of T1 warrants) Structured Financing April 23, 2026 (Exercise of T1 warrants) June 5, 2026
Equity Offering
Balance as of June 30, 2026
1,932,370
Premiums related to share capital 528,230,262
Number of shares 193,236,978
(428,028)
20,594
2,759,577
2,059,386
0.01
111,111
14,888,889
11,111,111
0.01
13,000
1,742,000
1,300,000
0.01
13,000
1,742,000
1,300,000
0.01
272,727
94,989,798
27,272,727
0.01
2,362,802
643,924,498
236,280,202
0.01
Share capital
Nominal value
The increase of the first six months of 2026 on the share capital and premiums related to: • •
•
•
The recognition on January 1, 2026 of capital increase transaction costs amounting to €0.4 million, recorded as a decrease in share premium; the exercise on January 14, 2026 of warrants issued under tranche 1bis of the Structured Financing (the “T1bis BSAs”), which had been pre-funded, resulting in the issuance of 2,059,386 new ordinary shares for gross proceeds of €20,594. Given a nominal value of €0.01 per share, the increase in share capital amounted to €20,594, with a corresponding increase in share premium of €2.8 million, transferred from reserves; the exercise on January 23, 2026 of second tranche warrants issued under the Structured Financing (the “T2 BSAs”), which had been pre-funded, resulting in the issuance of 11,111,111 new ordinary shares for gross proceeds of €111,111. Given a nominal value of €0.01 per share, the increase in share capital amounted to €111,111, with a corresponding increase in share premium of €14.9 million, transferred from reserves; the exercise on February 11, 2026 of first tranche warrants issued under the Structured Financing (the “T1 BSAs”), which had been pre-funded, resulting in the issuance of 1,300,000 new ordinary shares for gross proceeds of €13,000. Given a nominal value of €0.01 per share, the increase in share capital amounted to €13,000, with a corresponding increase in share premium of €1.7 million, transferred from reserves;
62
0.01
•
•
The exercise on April 23, 2026 of T1 BSAs, which had been pre-funded, resulting in the issuance of 1,300,000 new ordinary shares. Given a nominal value of €0.01 per share, the increase in share capital amounted to €13,000, with a corresponding increase in share premium of €1.7 million, transferred from reserves; The capital increase completed on June 5, 2026 in connection with the Equity Offering, resulting in the issuance of 27,272,727 new ordinary shares. Given a nominal value of €0.01 per share, the increase in share capital amounted to €272,727 with a corresponding increase in share premium of €95.0 million, net of transaction costs. The transaction costs amounted to €7.8 million.
Liquidity agreement On January 19, 2018, the Company entered into a liquidity agreement with Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF. This agreement with Kepler Cheuvreux, as amended in 2019, automatically renews for 12-month periods unless terminated by either party. Under the terms of the agreement, the investment services provider (“ISP”) is authorized to buy and sell the Company’s treasury shares without interference from the Company to ensure the liquidity of the shares on the Euronext market. As of June 30, 2026, this agreement was terminated by Inventiva, thereby ending the collaboration with Kepler Cheuvreux.
BSA and BSPCE plans BSA and BSPCE plan characteristics As of June 30, 2026, one BSPCE plan and 9 BSA plans are outstanding. The BSPCE and BSA plans are described in the Note 12.3 – Share warrants plans of the annual consolidated financial statements for the year ended on December 31, 2025. On June 30, 2026, the Company granted 300,000 BSAs to members of the Board of Directors under the BSA 2026 warrant plan. The BSAs under this plan have a subscription price set at €0.68 and an exercise price of €3.28.
63
Movements in BSPCE share warrants and BSA share warrants (in number of shares issuable upon exercise)
Type BSPCE - Plan 2021 TOTAL BSPCE share warrrants BSA - Plan 2017 BSA - Plan 2018 BSA 2019 BSA 2019 bis BSA 2019 ter BSA 2021 BSA 2023 BSA 2023 - 2 BSA 2026 TOTAL BSA share warrants Total share warrants
Decision of issuance by the Board of Directors
Grant Date
04/16/2021
04/16/2021
05/29/2017 12/14/2018 06/28/2019 03/09/2020 03/09/2020 04/16/2021 05/25/2023 12/15/2023 06/30/2026
05/29/2017 12/14/2018 06/28/2019 03/09/2020 03/09/2020 04/16/2021 05/25/2023 12/15/2023 06/30/2026
Exercice price (in euros)
Outstanding at Jan 1, 2026
Issued
Exercised
Forfeited / Lapsed
Outstanding at June 30, 2026
Number of exercisable shares
11.74
430,000
430,000
430,000
430,000
430,000
430,000
130,000 116,000 10,000 10,000 36,000 14,333 10,000 20,000
300,000
130,000 116,000 10,000 10,000 36,000 14,333 10,000 20,000 300,000
130,000 116,000 10,000 10,000 36,000 14,333 300,000
346,333
300,000
646,333
616,333
776,333
300,000
1,076,333
1,046,333
6.67 6.07 2.20 3.68 3.68 11.74 2.51 3.91 3.28
At June 30, 2026, a total of 430,000 BSPCEs (representing, if exercised, 430,000 shares) and 646,333 BSAs (representing, if exercised, 646,333 shares) were outstanding, corresponding to a total of 1,076,333 shares if exercised, the maximum number of shares to be issued when all related conditions are met.
Free Shares (“AGA”) plans AGA plans As of June 30, 2026, 13 AGA plans are outstanding: AGA 2023-1, AGA 2024-1, AGA 2024-2, AGA 2024-3, AGA 2024-4, AGA 2025-1, AGA 2025-2, AGA 2025-4, AGA 2025-5, AGA 2026-1, AGA 2026-1bis, AGA 2026-2, AGA 2026-2bis. On March 27, 2026, the Board of Directors decided to grant: • 434,000 free shares, of which 134,000 to beneficiary employees and 300,000 to Susan Coles, Chief Legal Officer, under the new AGA 2026-1 plan; and •
38,000 free shares to beneficiary employees under the new AGA 2026-1-bis plan.
On May 1, 2026, the Board of Directors decided to grant: •
137,500 free shares to beneficiary employees under the new AGA 2026-2 plan; and
• 450,000 free shares to Axel-Sven Malkomes, Chief Financial Officer under the new AGA 20262-bis plan.
Movements in AGA (in number of shares issuable upon exercise)
64
AGA 2023-1
05/25/2023
05/25/2023
Stock price at grant date (in euros) 2.60
385,706
385,706
AGA 2024-1 (Tr1 - Tr2 - Tr3)
12/13/2024
01/06/2025
2.30
276,849
276,849
AGA 2024-2 (Tr1 - Tr2 - Tr3)
12/13/2024
01/06/2025
2.30
113,179
113,173
AGA 2024-3 (Tr1 - Tr2 - Tr3)
12/13/2024
01/06/2025
2.30
975,043
(29,749)
945,294
AGA 2024-4 (Tr1 - Tr2 - Tr3)
12/13/2024
01/17/2025
113,000
(23,183)
89,817
AGA 2025-1 (Tr1 - Tr2 - Tr3)
09/30/2025
09/30/2025
1,588,663
1,588,663
09/30/2025
09/30/2025
630,070
630,070 2,223,399
Type
Decision of issuance by the Board of Directors
Grant Date
Outstanding at Jan 1, 2026
Granted
Vested
Forfeited / Lapsed
Outstanding at June 30, 2026
09/26/2025
09/26/2025
2.30 3.67 4.92 3.61 4.76 4.95
2,298,000
(74,601)
AGA 2025-4
12/15/2025
12/15/2025
3.79
68,000
(5,000)
63,000
AGA 2025-5
12/15/2025
12/15/2025
3.79
500,000
500,000 429,000
AGA 2025-1 (Tr4) AGA 2025-2
AGA 2026-1
03/27/2026
03/27/2026
5.15
434,000
(5,000)
AGA 2026-1bis
03/27/2026
03/27/2026
5.15
38,000
38,000
AGA 2026-2
05/01/2026
05/01/2026
4.31
137,500
137,500
AGA 2026-2bis TOTAL free shares
05/01/2026
05/01/2026
4.31
6,948,504
450,000 1,059,500
(137,533)
450,000 7,870,471
On June 30, 2026, a total of 7,870,471 AGA were outstanding. During the first six months of 2026, 137,533 AGA were forfeited, mainly due to employee departures. For the first six months of 2026, share-based compensation expense with respect to AGA and BSA totaled €4.4 million, compared to €2.2 million for the corresponding period in 2025, mainly due to the new AGA plans between both periods. These expenses are recognized in personnel costs (see Note 5.2 – Operating expenses). The main features of the AGA plans granted during the six-month period of the year 2026 are detailed below:
65
AGA 2026-1 (Tr1 - Tr2 - Tr3)
AGA 2026-1bis (Tr1 - Tr2 - Tr3)
AGA 2026-2 (Tr1 - Tr2 - Tr3)
AGA 2026-2bis (Tr1 - Tr2 - Tr3)
Decision of issuance by the Board of Directors
03/27/2026
03/27/2026
05/01/2026
05/01/2026
Grant date
03/27/2026
03/27/2026
05/01/2026
05/01/2026
Beneficiary
Employees and Susan Coles (Chief Legal Officer)
Employees
Employees
Axel-Sven Malkomes (Chief Financial Officer)
3
3
3
3
Service condition
Yes
Yes
Yes
Yes
Performance condition
No
No
No
No
434,000
38,000
137,500
450,000
1
1
1
1
Share price
Share price
Share price
Share price
Fair value per AGA at grant date
5.15
5.15
4.31
4.31
Expected volatility
N/A
N/A
N/A
N/A
Average life (years)
N/A
N/A
N/A
N/A
Risk-free rate
N/A
N/A
N/A
N/A
Expected dividends
–
–
–
–
Stock price reference
N/A
N/A
N/A
N/A
Non-transferable discount
N/A
N/A
N/A
N/A
Holding period (year)
Number of AGA granted Number of shares per AGA Valuation method used
66
Stock Options (“SO”) plans As of June 30, 2026, seven stock options plans were outstanding: SO 2024-1, SO 2024-2, SO 2025-1, SO 2025-2, SO 2025-3, SO 2026-1 and SO 2026-2. On June 9, 2026, the Board of Directors decided to grant: • 1,067,000 stock options, of which 517,000 to beneficiary employees and 550,000 to Pamela Herbster, Chief People Officer, under the new SO 2026-1 plan; and On June 30, 2026, the Board of Directors decided to grant: • 3,000,000 stock options to Mark Pruzanski, Chairman of the Board of Directors, under the new SO 2026-2 plan.
Movements in stock-options
Grant Date
Fair value at grant date (in euros)
Outstanding at Jan 1, 2026
12/20/2024
01/23/2025
1.10
12,898,116
SO 2024-2
12/20/2024
01/23/2025
1.10
213,000
SO 2025-1
10/10/2025
10/10/2025
1.77
1,865,750
SO 2025-2
12/02/2025
12/04/2025
1.78
6,000,000
SO 2025-3
12/15/2025
01/26/2026
3.68
1,145,500
SO 2026-1
06/09/2026
06/09/2026
1.68
SO 2026-2
06/30/2026
07/07/2026
1.83
Type SO 2024-1
Decision of issuance by the Board of Directors
Issued
Exercised
Forfeited / Lapsed
Outstanding at June 30, 2026
12,898,116
22,122,366
213,000 1,858,250
6,000,000
1,145,500
1,067,000
1,067,000
3,000,000
TOTAL Stock options
(7,500)
4,067,000
3,000,000
(7,500)
26,181,866
On June 30, 2026, a total of 26,181,866 stock options were outstanding. The implied stock options fair values are estimated at €14.2 million for SO 2024-1, €0.2 million for SO 2024-2, €3.3 million for SO 2025-1, €10.7 million for SO 2025-2, €4.2 million for SO 2025-3, €1.8 million for SO 2026-1, and €5.5 million for SO 2026-2. For the first six months of 2026, share-based compensation expense with respect to stock options totaled €7.3 million. No expense was recognized in relation to the SO 2026-2 plan during the period, as the grant date of July 7, 2026, occurred after the reporting date of June 30, 2026. The main features of the SO plans granted during the six-month period of the year 2026 are detailed below:
67
SO 2025-3
SO 2026-1
SO 2026-2
Decision of issuance by the Board of Directors
12/15/2025
06/09/2026
06/30/2026
Grant date
01/26/2026
06/09/2026
07/07/2026
Beneficiary
Employees
Employees and Pamela Herbster, (Chief People Officer)
Mark Pruzanski (Chairman of the Board of Directors)
Vesting period (year)
3
3
1.5
Holding period (year)
1
1
1
Service condition
Yes
Yes
Yes
Performance condition
No
No
Yes
Number of SO granted
1,145,500
1,067,000
3,000,000
1
1
1
Black & Scholes
Black & Scholes
Black & Scholes
3.68
1.68
1.83
Expected volatility
57.3%
59.0%
58.7%
Average life (years) Risk-free rate Expected dividends
5 2.7% –
Stock price reference
3.63 €
5 3.1% – 3.26 € N/A
5 3.1% – 3.33 € N/A
Number of shares per SO Valuation method used Fair value per SO at grant date
Non-transferable discount
N/A
Forward contract relating to the New EIB Warrants The fair value of the forward contract relating to the New EIB Warrants was determined using the BlackScholes option pricing model based on the underlying warrants. The valuation reflects the contractual characteristics of the underlying warrants, including their exercise price, expected term, risk-free interest rate, expected volatility and the market price of the Company's ordinary shares at the valuation date. The New EIB Warrants underlying the forward contract have an exercise price of €0.01 per warrant and a contractual term ending on January 4, 2036. The hypothesis and results are detailed in the following table:
68
As of June 30, 2026 (Shareholders approval and valuation date)
New EIB Warrants Number of warrants outstanding
15,677,573
Number of shares per warrant
1.00
Stock price (€)
3.22
Maturity (years)
9.5
Volatility
58.6%
Strike price (€)
0.01
Risk free rate
3.7%
Expected dividends
—
Fair Value (k€)
50,400
Unit Fair value (€)
3.21
Based on the Company's analysis, the commitment to issue the New EIB Warrants met the fixed-forfixed criterion under IAS 32 and was therefore classified as an equity instrument. Accordingly, the derivative liability previously recognized in respect of the Remaining EIB Warrants was derecognized and replaced by the equity instrument.
PRESS RELEASE
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update • Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 • Cash runway guidance remains unchanged from July 30, 2026 2 • Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026 • Key highlights from the first half of 2026 and recent Company updates • Management to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.
Key Financial Results for the First Half of 2026 (in thousands of euros)
Six Months Ended June 30, 2026
Revenues
June 30, 2025 20
4,454
1,286
1,156
Research and development expenses
(46,238)
(44,890)
Marketing – business development expenses
(2,589)
(746)
General and administrative expenses
(22,247)
(14,713)
Other operating income (expenses)
(619)
(8,202)
(70,388)
(62,940)
Net Financial Income (Loss)
907
(113,224)
Share of net loss- Equity method and dilution gain
117
(220)
Other income
Net Operating Loss
1
Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available. 2 Cf press release of July 30, 2026. pg. 1
PRESS RELEASE
Income tax Net Loss for the Period Basic/diluted loss per share (euros/share) Weighted average number of outstanding shares used for computing basic/diluted loss per share
(104)
503
(69,467)
(175,882)
(0.25)
(1.62)
273,582,870
108,839,636
There were no revenues recorded for the first half of 2026, compared to €4.5 million generated for the same period in 2025. Revenue recognized in the first half of 2025 was attributable to the 2022 License Agreement with Chia Tai Tianging Pharmaceutical Group Co., Ltd. (as amended and assigned to Chia Tai Tianging (Guangzhou) Co., Ltd). Other income amounted to €1.3 million for the first half of 2026, stable as compared to €1.2 million for the first half of 2025. Other income mainly consisted of the French research tax credit (“Crédit d’Impôt Recherche”). R&D expenses for the first half of 2026 amounted to €46.2 million, mainly driven by the clinical development of lanifibranor in MASH, up 3.0% compared to the €44.9 million for the first half of 2025. This increase was in line with operational plan expectations and did not include any preclinical research expenses following the discontinuation of preclinical R&D activities implemented mid-2025. Marketing and business development expenses amounted to €2.6 million for the first half of 2026, compared to €0.7 million for the same period in 2025, primarily reflecting increased personnel costs and expenses related to preparations for the potential commercial development of lanifibranor, if approved. General and administrative expenses (G&A) amounted to €22.2 million in the first half of 2026, compared to €14.7 million in the first half of 2025, an increase of €7.5 million. The change was primarily related to €4.7 million of increase in personnel costs, including share-based compensation expenses, consulting fees and other expenses associated with potential commercial development of lanifibranor, if approved. Net financial income (loss) amounted to €0.9 million in the first half of 2026, compared to (€113.2) million for the same period in 2025. The financial result for the first half of 2026 mainly reflected (i) €16.2 million of non-cash impact from the IFRS fair value accounting of financial instruments entered into in connection with the restructuring of warrants issued to European Investment Bank (“EIB”), the Lenders' Warrants issued to funds and accounts managed by BlackRock and Claret Capital Partners (together, the “Lenders”) and the embedded convertible option in the first tranche of €35.0 million of senior secured convertible bonds issued under the June 2026 debt financing with the Lenders for up to €130.0 million (the “Debt Financing”), (ii) €4.8 million of income from cash equivalents and foreign exchange gains (net), and (iii) (€20.0) million of interest and related financial expenses, including (€11.2) million resulting from the repayment of the loan with the EIB and (€7.4) million of interest expense related to the royalty certificates issued in 2023 and 2024. The Company’s net loss stood at (€69.5) million as of June 30, 2026, compared to (€175.9) million as of June 30, 2025. As of June 30, 2026, the Company’s cash and cash equivalents amounted to €166.1 million and €67.8 million in short-term deposits1, compared to cash and cash equivalents of €99.3 million and €131.6 million in short-term deposits as of December 31, 2025. Net cash used in operating activities amounted to (€45.4) million for the first half of 2026, compared to (€53.7) million for the same period in 2025. The lower cash consumption mainly reflects the favorable working capital change partially offset by the increase in operating expenses relating to the continued advancement of the NATiV3 Phase 3 clinical trial and preparation of pre-commercial activities. pg. 2
PRESS RELEASE
Net cash generated from investing activities for the first half of 2026 amounted to €63.8 million, compared to (€24.8) million for the first half of 2025. The increase primarily reflects changes in the Company's short-term deposits, including in connection with the June 2026 comprehensive refinancing transaction 3. Net cash generated from financing activities for the first half of 2026 amounted to €47.7 million, compared to €104.8 million for the first half of 2025.The net cash generated from financing activities in the first half of 2026 reflects the comprehensive refinancing transaction announced on June 2, 2026, including the offering of 27,272,727 American Depositary Shares (the “Equity Offering”) for €103.0 million and the Tranches A and B of the Debt Financing of €75.0 million, both in gross proceeds. These cash inflows were partially offset by the repayment in full of the existing EIB loans for an aggregate amount of €62.2 million, and the repurchase of all of the warrants issued to EIB in connection with the first tranche of the EIB loans and 700,000 of the warrants issued to EIB in connection with the second tranche of the EIB loans for an aggregate repurchase price of €50.0 million 4. The net cash generated from financing activities in the first half of 2025 came from the gross proceeds of €115.6 million (net proceeds of €108.0) of the 2024 Structured Financing 5. Based on the Company’s existing cash and cash equivalents and short-term deposits, together with the net proceeds from the completed Equity Offering, the completed EIB Transactions and the issuance of Tranches A and B under the Debt Financing Transaction 6, the Company expects to be able to finance its operations as currently planned until the end of the second quarter of 2027. At the date of this press release, the Company's current cash and cash equivalents are not sufficient to cover operating needs as currently planned for the next twelve months. If Tranche C of the Debt Financing Transaction3 is issued for potential gross proceeds of up to €55.0 million and the Tranche 3 warrants previously issued by the Company in the Structured Financing5 for potential gross proceeds of up to €116.0 million are exercised in full, the Company expects to be able to finance its operations as currently planned until the start of the first quarter of 2028 7. Over the first half of 2026, the Company recorded a positive foreign exchange effect on cash and cash equivalents of €0.7 million, compared with a negative effect of (€0.7) million for the first half of 2025, primarily due to the changes in the EUR/USD exchange rate.
Corporate Updates •
On September 2, 2026, Inventiva announced that the last patient had completed their final 72week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate and advanced fibrosis 8.
3 Cf press release of June 2, 2026 4 Cf press releases of June 2, 2026, and June 12, 2026. 5 Cf press release of October 13, 2024. 6 Cf press release of June 2, 2026 (please refer to the description of the financial covenants pertaining to the Debt Financing). 7
These estimates are based on the Company’s current business plan and assume the successful issuance of Tranche C of the Debt Financing, and the exercise in full of the Tranche 3 warrants previously issued by the Company in the Structured Financing for potential proceeds of up to €116.0 million, and exclude any potential milestones payable to or by the Company and any additional expenditures related to the product candidate or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based these estimates on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. These estimates may be shortened in the event of an increase, in expenditure relating to the development programs beyond the Company's expectations, or if the development program progresses more quickly than expected. 8 Cf press release of September 2, 2026.
pg. 3
PRESS RELEASE
• • • • •
NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort. Inventiva expects to report topline results from the Phase 3 clinical trial NATiV3 in the fourth quarter of 2026. If the NATiV3 topline results are favorable, the Company anticipates regulatory submission in the first half of 2027 and is preparing for a potential U.S. launch of lanifibranor in 2028, subject to U.S. Food and Drug Administration (“FDA”) approval. Since the start of 2026, Inventiva strengthened its leadership team with the appointment of Axel-Sven Malkomes as Chief Financial Officer, Susan Coles, as Chief Legal Officer, Pamela Herbster as Chief People Officer 9 and Chris Benecchi, as Chief Operating Officer 10. Barbara Krebs-Pohl, Anne Prener, and Camilla Soenderby, were appointed as independent members of the Company’s Board of Directors, effective June 30, 2026, reflecting the additional expertise, international reach, and strategic acumen required to guide the Company through its next phase of development and potential commercialization 11.
First-Half Financial Results Webcast Inventiva’s management will hold a conference call in English, followed by a Q&A session, on Monday, September 28, 2026, at 8:00 AM (New York), 2:00 PM (Paris) to discuss first-half financial results for 2026. Participants wishing to join the conference call by phone and ask questions must register in advance here. Upon registration, participants will receive dial-in details by email. The live webcast may be accessed on the Events section of the Inventiva website. A replay of the conference call will be available after the event on the Company’s website.
Upcoming Scientific Conference Participation The American Association for the Study of Liver Diseases (AASLD), Denver, CO, November 5-9, 2026.
Next Financial Results Publication Revenues and cash and cash equivalents for the third quarter 2026 on Monday November 23, 2026 (before E.U. and U.S. market open).
About Lanifibranor Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of
9
Cf press release of April 22, 2026.
10 Cf press release of August 31, 2026. 11 Cf press release of July 8, 2026.
pg. 4
PRESS RELEASE
MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established.
About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com
Avis d’information relatif à la conclusion de conventions réglementées au titre de l’article L. 22-10-13 du code de commerce
Offres d’indemnisation signées entre la Société et ses administrateurs (Autorisation du conseil d’administration en date du 25 septembre 2026) Conventions individuelles conclues entre la Société et les administrateurs suivants :
- Barbara KREBS-POHL, membre du conseil d’administration lors de la signature de l’offre le 30 septembre 2026 ;
- Camilla SOENDERBY, membre du conseil d’administration lors de la signature de l’offre le 28 septembre 2026 ;
- Anne PRENER, membre du conseil d’administration lors de la signature de l’offre le 28 septembre 2026. Objet des offres : Mise en place au bénéfice des administrateurs, dans la mesure du possible compte tenu des lois et règlements applicables et sous réserve des limitations additionnelles prévues par les conventions, d’un mécanisme d’indemnisation par la Société dans l’hypothèse où la responsabilité civile des administrateurs serait mise en cause dans le cadre l’exercice de leurs fonctions. Conditions financières : La Société s’engage à prendre en charge les Pertes (Losses) supportées par un administrateur au titre d’une Réclamation Indemnisable (Indemnifiable Claim) et qui ne seraient pas couverte par l’Assurance RCMS en vigueur au sein de la Société, en ce compris, notamment, toutes franchises ou autres sommes retenues, ainsi que certaines Dépenses de procédures (Expenses), dans les limites permises par la loi. Motif justifiant de l’intérêt, pour la Société, à conclure les Offres : Les titres de la Société font l’objet d’une cotation en bourse, à la fois sur Euronext Paris (sous forme d’actions ordinaires) et sur le Nasdaq Global Market aux États-Unis (sous forme d’American Depositary Shares, ou ADS). La cotation des ADS de la Société sur le marché boursier américain, ainsi que les obligations déclaratives qui en découlent auprès de la Securities and Exchange Commission, exposent les administrateurs de la Société à des risques significatifs et spécifiques liés à l’exercice de leurs fonctions (plus importants que ceux auxquels les administrateurs seraient susceptibles d’être exposés dans le cadre du seul droit français). Compte tenu de ces risques accrus, les administrateurs de sociétés cotées aux États-Unis bénéficient généralement de dispositifs d’indemnisation et/ou d’assurance. La Société a ainsi considéré qu’en l’absence d’une telle protection, certaines personnes pourraient être réticentes à accepter un mandat d’administrateur au sein de la Société, ou pourraient décider d’y mettre fin. La Société a par ailleurs considéré qu’il était nécessaire que de telles personnes siègent à son conseil d’administration, dans l’optique d’atteindre ses objectifs sur les marchés financiers et commerciaux internationaux. En conséquence, et compte tenu du fait que la cotation des ADS sur le marché boursier américain constitue un facteur clé pour le développement futur de la Société, celle-ci a conclu qu’il était dans son intérêt de mettre en place, au bénéfice des administrateurs concernés, une couverture d’assurance ainsi que des dispositifs d’indemnisation et d’avance sur frais, dans toute la mesure permise par les lois et réglementations applicables. Rapport entre le prix des offres et le dernier bénéfice annuel de la Société : n/a (Pas de bénéfice annuel enregistré pour la Société)
INVENTIVA S.A.
WHISTLEBLOWER POLICY May 16, 2019
Purpose
General Policy Statement
This Whistleblower Policy (the "Policy") was created and adopted by Inventiva SA ("Inventiva" or the "Company"). The purpose of this Policy is to establish procedures for the receipt, retention and treatment of complaints regarding bribes, improper payments, or other corrupt or improper behavior in furtherance of the Company's Anti-Corruption Policy dated May 16, 2019. This Policy is therefore an extension of, and forms part of, Inventiva's Anti-Corruption Policy. This Policy applies to the Company and any subsidiaries, in compliance with local laws and regulations. The corporate values of Inventiva stress the need to operate with integrity, and Inventiva expects that all areas of its business be conducted in an honest and ethical way by all employees and third parties. Inventiva is committed to complying with all applicable anti-corruption laws and regulations, standards, controls and practices. Inventiva encourages its employees as well as third parties whom we work to help maintain the integrity of Inventiva by reporting any misconduct. To assist in these efforts, Inventiva personnel or third parties may submit a complaint regarding bribes, improper payments or corrupt behavior in accordance with this Policy. All such complaints should be made to Inventiva’s Compliance Officer. If a Compliance Officer has not yet been appointed, reports should be made to the General Counsel. For the purposes of this Policy, all references to the Compliance Officer shall be considered as references to the General Counsel if no Compliance Officer has been appointed by Inventiva. The following procedures are designed to facilitate submission by Inventiva employees or third parties of concerns or complaints regarding bribes, improper payments or corrupt behavior and to ensure the appropriate receipt, retention and treatment of such complaints and concerns.
Submission of Complaints
- Inventiva employees and third parties may report evidence of wrongdoing, complaints, or concerns regarding bribes, improper payments or corrupt behavior to the Compliance OQcer at any time. This report may be made by leaving a message using any one of two methods: Secure Hotline (00 1) 877-250-1724, or Secure Web Form https://www.whistleblowerservices.com/IVA
- These procedures are not mandatory and are in addition to the other possible reporting methods. Inventiva employees and third parties may also submit a complaint regarding suspected violations of anti-corruption rules to any other
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
member of Inventiva's Board or to any executive oQcer of Inventiva. Executive oQcers of Inventiva receiving such a complaint will refer the complaint to the Compliance OQcer. 03. Employees of Inventiva and third parties are encouraged to provide as many specific details as possible regarding the nature of the complaint, including names, dates, places, events that took place, and the reporting person's belief as to why the incident(s) may be misconduct. 04. Employees or third parties whose personal data is contained in the whistleblowing database are informed that they have a right to access and rectify their personal data in accordance with applicable law.
Handling of Complaints
General Principles
-
Upon receipt of a complaint, the Compliance OQcer will (i) determine whether the complaint actually pertains to bribes, improper payments or corrupt behavior, and (ii) when possible, acknowledge receipt of the complaint to the sender.
-
Complaints will be reviewed by the Compliance OQcer, or by such other persons as the Compliance OQcer deems appropriate under the Compliance OQcer's direction and oversight. Confidentiality will be maintained to the fullest extent possible in accordance with applicable regulations.
-
Prompt and appropriate corrective action will be taken when and as warranted in the judgment of the Compliance OQcer.
-
A written record of the complaint or disclosure and its disposition will be prepared by the Compliance OQcer and retained by outside legal counsel throughout the investigation into the complaint and any follow-on legal proceedings only.
-
In case of serious and imminent danger, in case of irreversible harm, or in the event that the Compliance OQcer and other responsible persons within Inventiva have not undertaken the appropriate steps to investigate the merits of the complaint in a reasonable time period, then persons making complaints may also address them directly to judicial or administrative authorities, other relevant professional orders or made public.
-
Confidentiality and non-disclosure: Inventiva will take appropriate measures to ensure the security and confidentiality of the reports and complaints as well as the personal information contained therein. Inventiva and its third party providers will not use the personal information other
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
than for the purposes of this whistleblower policy, and will destroy all personal information in accordance with Section 5.6 below. Only the following data may be processed: • • • • • • •
identity, position and details of the whistleblower; identity, position and details of the person named in the complaint; identity, position, details of other people involved in the whistleblowing procedure; facts reported; information collected during the investigation; the investigation report; and actions taken and follow-up.
- Non-Use or Good Faith of whistleblower rights Inventiva shall not take any disciplinary measures, harass, or discriminate against any employee of Inventiva or any third party who: • •
does not follow the procedures set forth in this Policy; or reports a complaint in good faith.
- Sanctions in the event of misuse of whistleblower rights: Inventiva may take legal action or impose disciplinary sanctions, including the dismissal or removal of Inventiva employees or termination of the business relationship with third parties, in the event of misuse of this whistleblower procedure.
- Right to Information: The Compliance Officer shall notify the person identified in a complaint as soon as information pertaining to such person is received in order to allow them to exercise their rights to object to the processing of personal data. Notification may be delayed if injunctive or protective measures (i.e. to prevent destruction of evidence) are taken. The person identified in the complaint will be informed of the existence and specific nature of the complaint, the persons involved in implementing the whistleblowing procedure, and how they may access and modify such information.
- Compliance with the right to access and modify personal information: Inventiva and the Compliance Officer will ensure that each person identified in the whistleblower procedure has the right to access their personal information and to request the modification or the deletion thereof should such information be inaccurate, incomplete, erroneousorout-of-date. The person named in the complaint cannot under any circumstances, obtain information concerning the identity of the whistleblower on the basis of this right of access.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
-
Retention of Personal Data: Information that does not pertain to the behavior under investigation will be destroyed or archived as soon as possible by the Compliance Officer. If the complaint is not followed by disciplinary or legal action, information relating thereto will be destroyed or archived by the Compliance Officer no later than two months after the complaint is closed. If disciplinary measures or legal actions are taken, the information relating to the complaint and investigation will be retained by the Compliance Officer until the close of such measures or actions. The archived information will be held for no longer than the duration of legal proceedings, and access to such information shall be restricted.
-
Transfer of personal data outside the European Union: In the event that the whistleblowing procedures are administered by independent third parties located outside of the European Union, data transfers outside the EU will be carried out in compliance with EU regulations. In the event such independent third party service provider is located in the United States, it must be done in accordance with EU regulations, including with respect to human resources information, and in accordance with the EU-US Privacy Shield.
-
Protection of personal data – Information Notice Employees or third parties using this Policy are informed that their personal data are collected as set forth in this Policy in accordance with the legal obligations of Inventiva. Personal data may be provided to the persons indicated in article 4.2 of this Policy, and retained for the durations indicated in article 5.6 of this Policy. In case of a transfer of personal data outside of the EU, employees or third parties will be informed on a case-by-case basis of the country of destination and of the means implemented to protect their data. In compliance with applicable data protection laws, employees or third parties have the right to access and correct their personal data, and under certain circumstances, to request the deletion of their personal data, or to object to or restrict the processing of their personal data. These rights may be exercised by writing to Inventiva’s Compliance Officer. Employees and third parties are informed that they may always submit a complaint to the competent data protection authority.
Complaint Review Procedure
- Inventiva shall inform all employees and third parties of the way they may submit a complaint or report bribes, improper payments or corrupt behavior as set forth in this Policy.
- Any complaint or disclosure of bribes, improper payments or corrupt behavior made to any executive officer or member of the Board will be immediately reported to the Compliance Officer for review, inquiry, and/or investigation. Should the Compliance
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Officer be implicated in the complaint, the complaint will be reported to the Chief Executive Officer for review, inquiry, and/or investigation. Those handling the review, inquiry, and/or investigation will do so in accordance with applicable laws and regulations.
- The Compliance Officer will review, inquire into, and investigate complaints received from employees of Inventiva or third parties, either directly or through a subcommittee or independent third parties. A written record of the complaint or disclosure and how it is handled will be prepared by or at the direction of the Compliance Officer and retained by outside counsel until the matter is closed.
- Following the review, inquiry, or investigation, the Compliance Officer may make changes to Inventiva's Anti-Corruption Policy, practices and procedures, and recommend disciplinary actions for wrongful acts to Inventiva's Executive Committee. Such disciplinary actions may include termination of employment or removal from office, termination of the business relationship, or reporting to appropriate governmental authorities.
- The Compliance Officer will retain the complaint and recommendations in confidence unless disclosure is required by law or is in the best interests of Inventiva.
- The Compliance Officer will periodically review this Policy, and if applicable, make recommendations for changes to Inventiva’s Executive Committee. The Compliance Officer will notify Inventiva personnel, the works council, the health and safety committee, the work inspector, and third parties promptly if any changes that affect Inventiva personnel or third-parties are made to this Policy or the procedures that are put into place.
- This Policy will be enforceable as from May 16, 2019.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Date: May 15, 2026
This Insider Trading Policy (the “Policy”) sets out the good practice guidelines of Inventiva SA (the “Company”) with respect to trading in its securities by the members of its Board of Directors and its executive officers and senior managers. It also applies to trading in the Company’s securities by employees, representatives or consultants who, by virtue of their functions, have access to Inside Information (as defined below) concerning the Company. All directors, officers, employees, representatives and consultants of Inventiva must therefore familiarize themselves and comply with this Policy. Please report all questions or concerns regarding this Policy to Inventiva’s Compliance Officer, or if a Compliance Officer has not been appointed, to Inventiva’s General Counsel. Non-compliance with the rules set out in this Policy and, in general, with the applicable regulations, may cause serious harm to the Company and put the Company and/or the persons concerned, at risk of civil, criminal or administrative sanctions which are described in this Policy.
I.
Legal Framework
As the Company securities are traded on both Euronext Paris (represented by ordinary shares, or “Shares”) and the Nasdaq Global Market in the United States (represented by American Depositary Shares, or “ADSs”), both French and U.S. laws and regulations on insider trading are applicable to the Company, including certain provisions of French and U.S. criminal law, the General Regulation of the French stock market authorities (the “AMF”) and European Regulation (EU) No 596/2014 (the “Market Abuse Regulation” or “MAR”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act” and, together, the “Stock Market Rules”). These provisions state that a person with Inside Information who is a Company director, officer, employee, representatives or consultant must not: •
•
carry out or allow to be carried out, directly or through intermediaries, one or more trades in the Company’s securities (including shares, ADSs, debt instruments, bonds or other financial instruments or derivatives ,or any instruments issued in context of equity incentive plans, including free shares, options or warrants (together, “Company Securities”)) while he/she has Inside Information (as defined below) at his/her disposal; or communicate Inside Information to any other person, particularly under circumstances that would be likely to allow this person to carry out one or more trades in Company Securities.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
II.
Transactions Subject to this Policy
III.
Persons Subject to this Policy
The Policy applies to all transactions in Company Securities issued by the Company, as well as derivative securities that are not issued by the Company. The latter category can include, for example, exchange traded options or swaps relating to Company Securities. Accordingly, for purposes of this Policy, the terms “trade,” “trading” and “transactions” include not only purchases and sales of Company Securities in the public market but also any other purchases, sales, transfers, gifts or other acquisitions and dispositions of ordinary or preferred equity, options, warrants and other securities (including debt securities) and other arrangements or transactions that affect economic exposure to changes in the prices of these securities. This Policy applies to you and all other directors, officers, employees, representatives and consultants of the Company and its subsidiaries, regardless of where they are physically located. This Policy also applies to members of your family who reside with you, any other persons you live with, any family members who do not live with you but whose transactions are managed or directed by you or are subject to your influence, and any entities whose transactions in securities you control (including, e.g., a venture or other investment fund, if you control transactions by the fund). However, this Policy does not apply to any entity that invests in securities in the ordinary course of its business (e.g., a venture or other investment fund) if (and only if) such entity has established its own insider trading controls and procedures in compliance with applicable securities laws with respect to trading in Company Securities. Such persons who are deemed subject to this Policy are referred to in this Policy as “Related Persons.” You are responsible for making sure that your Related Persons comply with this Policy. In the event of disclosure of Inside Information outside the Company, you must take every step necessary to ensure that the persons to whom you have passed the information (which must in any case only be in compliance with the Disclosure Policy) do not carry out any transactions in Company Securities. You must also ensure that Related Persons do not carry out transactions in Company Securities during quarterly blackout trading periods and eventspecific trading blackout periods (each as discussed below).
IV.
Inside Information
Inside information (also referred to as material non-public information) (“Inside Information”) is information that has not been made publicly available. It’s not always easy to figure out if the information you have is Inside Information. A simple test is this: if made public, would the information have a significant effect (upward or downward) on Company Securities? This means that a reasonable investor might use such information to decide whether to buy or sell Company Securities.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
For example, common types of Inside Information include: • • • • • • • • • • • • • • • • • • • • •
financial results or forecasts; earnings estimates and guidance, including updates, changes or confirmation of previous guidance; significant changes to the Company’s financial situation or operating income; status of product or product candidate development or regulatory approval; clinical data relating to products or product candidates; timelines for pre-clinical studies or clinical trials; significant external growth transactions or significant acquisitions or dispositions of (buying or selling) assets, divisions or entire companies; entry into new material contracts or amendments; public or private sales of debt or equity securities; stock splits, dividends or changes in dividend policy; gaining or losing a major partner, such as a significant licensor, licensee or supplier, or changes or new corporate partner relationships or collaborations; developments regarding the Company’s material intellectual property (including issuance or denial of patents); regulatory developments; changes in senior leadership or other significant personnel or control changes; employee layocs; a disruption in the Company’s operations, including security breaches of facilities or IT systems; tender ocers, repurchase programs or proxy fights; change in auditors or auditor notifications that the Company may no longer rely on an auditor’s audit report; corrections to previously issued financial statements (accounting restatements); significant lawsuits or settlements; and possible bankruptcy.
Information, whether positive or negative, may be significant if it is likely to have an effect on the rise or fall of the price of Company Securities or could influence an investor’s decision to buy or sell Company Securities.As it can be difficult to determine whether information is Inside Information, in case of doubt please discuss with the Compliance Officer.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
V.
When Insider Information is considered public
You may only trade in Company Securities once the relevant Inside Information has been publicly disseminated. For Inside Information to be considered publicly disseminated, it must be widely disseminated through a press release distributed through a professional information provider (diffuseur professionnel), a filing with the AMF and the Securities and Exchange Commission (the “SEC”), or other widely disseminated announcement. The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. After the Inside Information is made public, investors need time to review and understand the information. For purposes of this policy, a “trading day” shall mean a day on which both Euronext Paris and the Nasdaq Global Market are open for regular trading, and shall begin at the time that regular trading begins on Euronext Paris and end at the time that regular trading ends on the Nasdaq Global Market.
VI.
Insider trading policy of Inventiva SA
The Company has adopted this Policy relating to trading in Company Securities in order to ensure that all Company directors, officers, employees, representatives and consultants conform to applicable regulations on insider trading. In addition to this Policy, you are responsible for complying with all the legal and statutory provisions that are applicable to you, including the stock exchange regulations and securities regulations applicable to insider trading briefly summarized in this Policy.
- Trading in Company Securities
The carrying out of one or more transactions on the basis of Inside Information is forbidden at all times. You must not, directly or indirectly: •
• • • •
Trade in Company Securities (including the sale of Company Securities through the exercise of options or other rights to buy or subscribe to Company Securities) while in possession of Inside Information relating to the Company or any other entity, including Company competitors, suppliers, customers or persons with whom the Company has business relation, except as otherwise specified under the heading “Exceptions to this Policy” below; disclose Inside Information to any person within the Company who does not “need to know” that information; disclose Inside Information to any other person outside the normal scope of your duties or employment or for purposes other than those that for which you received such Inside Information, unless the disclosure is authorized by the Company; recommend to, or ask, a third party to buy or sell Company Securities - whether on your behalf or not; or assist anyone engaged in the above activities.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
The prohibition against insider trading is absolute. It applies even if the decision to trade is not based on such Inside Information. It also applies to transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) and also to very small transactions. All that matters is whether you are aware of any Inside Information relating to the Company at the time of the transaction. The securities laws do not accept any excuses for insider trading. In addition, you must avoid any action that could look wrong to others, to protect the Company’s reputation for following the highest ethical standards. Sometimes this means you may need to cancel or delay a planned transaction after you learn material nonpublic information. Even if this delay may cause a loss or prevent a gain, you must wait. The laws prohibiting insider trading are not limited to trading by the insider alone; advising others to trade on the basis of Inside Information is also illegal and never allowed under this Policy. Liability in such cases can extend both to you, as the “tipper” and to the person who received the information from you (the “tippee”). You can be held liable for your own transactions but also for transactions by a tippee and even the transactions of a tippee’s tippee.
VII.
Blackout Periods
Even if you do not hold any Inside Information, directors, executive officers or senior managers, and certain notified employees, representatives and consultants (“Covered Insiders”) and their Related Persons may not trade in Company Securities: • • •
for a period of thirty calendar days prior to the date on which the Company publishes its annual and half-yearly results, including the date of publication; and for a period of fifteen calendar days prior to the date on which the Company voluntarily publishes quarterly financial information, including the date of publication. These periods are referred to as “quarterly blackout trading periods.”
Of course, even during an open trading window period, you may not (unless an exception applies) conduct any trades in Company Securities if you are otherwise in possession of Inside Information. The Company may start a quarterly blackout trading period early or extend it if, the [Chief Executive Officer, Chief Financial Officer or [Compliance Officer / General Counsel]] believes that trading by Covered Insiders would be inappropriate because of undisclosed information. It is important to note that the fact that the quarterly trading blackout period starts early or has been extended is itself Inside Information that should not be shared with anyone. A Covered Insider who believes that special circumstances require them to trade during a quarterly trading blackout period should consult the Compliance Officer. Permission to trade
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
during a quarterly trading blackout period will be granted only where the circumstances are extenuating, the Compliance Officer concludes that the person is not aware of any Inside Information relating to the Company or its securities, and there appears to be no significant risk that the trade may subsequently be questioned.
VIII.
Event-Specific Blackout Periods
From time to time, an event may occur that is material to the Company and is known by only a few directors, officers and/or employees. So long as the event remains material and nonpublic, the persons designated by the [Compliance Officer] may not trade in Company Securities. In that situation, the Company will notify the designated individuals that neither they nor their Related Persons may trade in Company Securities. The existence of an eventspecific trading blackout should also be considered Inside Information and should not be communicated to any other person. Even if you have not been designated as a person who should not trade due to an event-specific trading blackout, you should not trade while aware of Inside Information. Exceptions will not be granted during an event-specific trading blackout. Outside of the quarterly blackout trading periods and event-specific trading blackout periods, you may still not trade in Company Securities if you are in possession of Inside Information. The quarterly blackout trading periods and event-specific trading blackouts do not apply to those transactions to which this Policy does not apply, as described under the heading “Exceptions to this Policy” below.
IX.
Trading in securities of other companies
You may also not purchase or sell securities (or forward transaction) of another company if you have Inside Information, and that information could affect the share price of another company, if such purchase or sale is based on Inside Information acquired in the context of your duties or your relationship with the Company. For example, any purchase or sale of the securities of a company that the Company is planning to acquire is strictly forbidden for a period expiring ten trading days following the public announcement of the acquisition.
- Exceptions to this Policy. This Policy does not apply in the case of the following transactions, except as specifically noted: •
•
Option Exercises. You may exercise options or warrants granted under the Company’s equity compensation plans for cash, or by using a net-exercise method (where permitted under the grant), without restrictions under this Policy. However, this Policy still applies if you sell any of the shares in the market, including sales made through a broker-assisted cashless exercise, even if the purpose of the transaction is to generate the cash needed to pay the exercise price or taxes. Tax Withholding Transactions. You are permitted to surrender shares directly to the Company to satisfy tax withholding obligations that result from vesting or exercise of restricted stock units, free shares, options or other equity awards granted under the
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
•
• •
•
•
•
Company’s equity compensation plans, without restrictions under this Policy. However, this Policy still applies if you sell any of the shares received upon exercise or vesting of such equity awards, even if the purpose of the transaction is to generate the cash needed to pay the exercise price or taxes. Sell-to-Cover Transactions. This Policy does not restrict sales of shares of the Company for the limited purpose of covering tax withholding obligations (and any associated broker or other fees) (a “sell-to-cover transaction”) if (i) prior to such sale, you elect to sell such shares to cover tax withholding obligations in a manner approved by the Company or (ii) such sell-to-cover transaction is ecected pursuant to a sell-to-cover program mandated by the Company. Sales in a Registered Public Ocering. This Policy does restrict sales of Company Securities as a selling shareholder in a registered public ocering in accordance with applicable securities laws. 10b5-1 Trading Plans. Under Rule 10b5-1 of the Exchange Act, directors, ohcers, employee and consultants may establish a trading plan under which a broker is instructed to buy and sell Company Securities based on pre-determined criteria (a “Trading Plan”). So long as a Trading Plan is properly established, purchases and sales of Company Securities pursuant to that Trading Plan are not subject to this Policy. To be properly established, a director’s, ohcer’s, employee’s, or consultant’s Trading Plan must be established in compliance with the requirements of Rule 10b5-1 of the Exchange Act at a time when the Company was not in a trading blackout period and they were not otherwise aware of any Inside Information relating to the Company. Moreover, all Trading Plans must be reviewed and approved by the Company before being established to confirm that the Trading Plan complies with all pertinent company policies and applicable securities laws. Mutual Funds and Exchange-Traded Funds (“ETFs”). This Policy does not apply to investments in mutual funds or ETFs that follow a broad index (such as the S&P 500) and/or have holdings comprised of less than 10% of Company Securities. However, if a mutual fund or ETF consists of 10% or more of Company Securities, your investment in that mutual fund or ETF are treated as if they are Company Securities. Domestic Relations Order. This Policy does not restrict the transfer of Company Securities under a domestic relations order, as defined in the Internal Revenue Code of 1986, as amended, or Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder. Administrative Transfers. This Policy does not apply to non-market transfers of Company Securities where there is no change in beneficial ownership, provided that the transfer does not involve any market sale of Company Securities.
- Special and Prohibited Transactions •
Inherently Speculative Transactions. Company directors, employees and consultant, and their Related Persons, may not engage in short sales, transactions in options or other derivative securities on an exchange or in any other organized market, or in any other inherently speculative transactions with respect to Company securities.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
•
•
•
•
Hedging Transactions. Hedging or monetization transactions are financial tools—like prepaid variable forwards, equity swaps, collars, and exchange funds—that let a person keep their Company Securities but reduce or eliminate the normal risks of owning them, such as the usual gains or losses. When this happens, the investor may not have the same goals as other shareholders. Because of this, directors, employees, consultants, and their Related Persons are not allowed to use any of these hedging or monetization tools. Margin Accounts and Pledged Securities. If you keep Company Securities in a margin account, the broker can sell them without asking you if you do not meet a margin call. If you use Company Securities as collateral for a loan, the lender can also sell them if you do not repay the loan. Because these sales may happen at times when they have Inside Information and are not allowed to trade, directors, employees, and consultants are not allowed to keep Company Securities in a margin account or use them as collateral for any loan. Standing and Limit Orders. Standing and limit orders (unless under an approved Trading Plan) are risky because you cannot control when your broker will complete the trade. The trade could happen when you have Inside Information. The Company therefore discourages using standing or limit orders. If you must use one, it should last only a short time, and you must cancel it right away if a quarterly or event-specific blackout period starts. Managed Accounts. If you have a managed account (where another person has been given discretion or authority to trade without your prior approval), you should advise your broker or investment advisor not to trade in Company Securities at any time.
- Notification of Transactions
Covered Insiders and their Related Persons face a further restriction: even during an open trading window, they must obtain pre-clearance from the Compliance Officer (or an individual designated by the Compliance Officer) at least two business days before making any trade or changing any trading instruction involving Company Securities. This includes buying, selling, exercising options, giving shares as gifts, transferring shares, or any similar action, whether for their own account or any account they control. The request for preclearance should identify (i) the name of the person who wants to trade, (ii) the type of the proposed transaction (for example, open market purchase or sale, privately negotiated purchase or sale, shares option exercise), (iii) the proposed transaction date and (iv) the type and number of securities involved. Unless the Compliance Officer decides otherwise, the person who will engage in the proposed transaction must also confirm in writing (in a form acceptable to the Compliance Officer) that they do not have Inside Information. After reviewing the request, the Compliance Officer will decide whether the trade may proceed. The Compliance Officer will also assist with any required reporting requirements under applicable regulations. Pre-cleared transactions not completed within two business days will require new pre-clearance.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
The Company intends to advise all relevant persons if and when the reporting requirements under applicable regulations become applicable. Following the date specified in that notice, the Covered Insider or Related Person must notify the Compliance Officer immediately after completing a transaction so the Company can help with the required reporting requirements.
- Stock Market Rules and Reporting Obligations AMF Requirements for PDMRs
Under the Stock Market Rules, Persons Discharging Managerial Responsibilities (“PDMR”) and all “persons closely associated with them”, are required to notify the Company and the AMF electronically, within three working days of the transaction date of any trades they make in Company Securities if such trades exceed EUR 50,000 in a calendar year. The Company is required to draw up a list of all PDMRs and such “persons closely associated with them”. Who is concerned by this obligation The following persons are concerned by this obligation: •
•
X.
any person who is a PDMR, meaning a member of the Board of Directors of the Company or a senior executive or manager who has access to Inside Information or has the power to make managerial decisions acecting the future development and business prospects of the Company; and any person who is “closely associated” to a PDMR, namely a family member or relative of the PDMR or a company, trust or partnership, which is managed by, directly or indirectly controlled by, or set up for the benefit of a PDMR or by a person closely associated with a PDMR or whose economic interests are substantially equivalent to those of a PDMR or person closely associated with a PDMR.
Transactions concerned
All transactions involving the purchase, sale, subscription or exchange of Company Securities, including warrants (BSA), founder warrants (BSPCE), stock options, etc. If you are unclear as to whether or not a transaction is required to be disclosed, please
Date: May 1, 2026
Inventiva SA (the “Company”) is a publicly traded company listed on Euronext Paris in France and the Nasdaq Global Market in the United States. The Company is required to comply with applicable French stock market rules, including the “Code Monétaire et Financier” (the French Financial and Monetary Code), the “Règlement Général” (the “General Regulations”) of the “Autorité des Marchés Financiers” (the “AMF”), and the European Regulation (EU) No 596/2014 (the “Market Abuse Regulation” or “MAR”) (together, the “French Stock Market Rules”). These rules impose certain periodic and ongoing disclosure obligations in the interest of investor protection and reputation of the market. Additionally, for as long as the Company qualifies as a foreign private issuer, the Company may choose to voluntarily comply with Regulation Fair Disclosure (“Regulation FD”) under the Securities Exchange Act of 1934, as amended, to avoid potential liability that could arise from selective disclosures (e.g., from “tipping” securities analysts or select shareholders intentionally or unintentionally) of important nonpublic information by issuers before the information is more broadly released to the general public. The Company is committed to meeting its disclosure obligations in accordance with these principles in order to support investor confidence in the integrity of the Company. This disclosure policy (the “Policy”) is intended to allow the Company to comply with its obligations in respect of the protection and disclosure of “Inside Information” or “Material Non-Public Information” (as defined below) concerning the Company, as well as its continuous disclosure obligations concerning all other important non-public information. It is intended to ensure required announcements are made in a timely manner, are factual, do not omit any material elements and are expressed in a clear and objective manner, as well as to help prevent market abuse, inadvertent selective disclosure, insider dealing and other similar offences. Accordingly, all directors, officers and employees of Inventiva must familiarize themselves and comply with this Policy. The Compliance Officer is responsible for monitoring compliance and safeguarding confidentiality of Inside Information. Please direct all questions or concerns regarding this Policy to Inventiva’s Compliance Officer, or if a Compliance Officer has not been appointed, to Inventiva’s Chief Legal Officer (“CLO”). Non-compliance with the rules set out in this Policy and, in general, with applicable regulations, may cause serious harm to the Company and subject the Company to penalties and other sanctions. This Policy should be read in conjunction with, and supplements, Inventiva’s other policies, including its Insider Trading Policy, and the terms of any applicable agreement between you and the Company, including any confidentiality provisions therein.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
THE REQUIREMENTS French Stock Market Rules
Under the French Stock Market Rules, any Inside Information or other material information which concerns the Company must, as soon as possible, be disclosed to: • the public; and • the AMF. All communications to the public must be simultaneously released through the primary information provider selected by the Company from the list of AMF providers.
US Securities Laws
Unless otherwise authorized by the Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”) and CLO (the “Authorized Officers”), no persons acting on behalf of the Company may disclose Inside Information to an Outside Person (as defined below). For purposes of this Policy, an “Outside Person” is defined as: • broker dealers and their associated persons, such as analysts; • investment advisors, institutional investment managers and each of their associated persons; • investment companies, hedge funds and each of their aaliated persons; and • any holder of the Company’s securities if it is reasonably foreseeable that the holder will purchase or sell the Company’s securities on the basis of the information. The following communications are exempt from the Regulation FD disclosure requirements: • communications made to a person who owes the Company a duty of trust or confidence, such as attorneys, investment banks or accountants; • communications made to any person who expressly agrees to maintain the information in confidence, even if the express agreement is given after the disclosure of Inside Information, but must be before the recipient discloses or trades on the basis of the information; and • communications made in connection with registered securities ocerings by means of specifically approved forms of written or oral communications other than ocerings expressly excluded under Regulation FD.
Inside Information
Inside Information is information that has not been made publicly available. Nonpublic information, whether positive or negative, may be significant or material if it is likely to have an effect on the price of the Company’s securities or could influence an investor’s decision to buy or sell the Company’s securities. It is not always easy to figure out if the information you have is Inside Information. A simple test is this: if the information is made public, would the information have a significant effect (upward or downward) on the Company’s securities? If the answer is “yes,” then this means that a reasonable investor might use such information to decide whether to buy or sell the Company’s securities and it is Inside Information. For example, common types of Inside Information include: • financial results, plans or forecasts; • earnings estimates and guidance, including updates, changes or confirmation of previous guidance;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • • • • • • • • • • • • • • • • • •
significant changes to the Company’s financial situation, strategy or operating income; status of product or product candidate development or regulatory approval; clinical data relating to products or product candidates; timelines for pre-clinical studies or clinical trials; significant external growth transactions or significant acquisitions or dispositions of (buying or selling) assets, divisions or entire companies; entry into new material contracts or amendments; public or private sales of debt or equity securities; stock splits, dividends or changes in dividend policy; gaining or losing a major partner, such as a significant licensor, licensee or supplier, or changes or new corporate partner relationships or collaborations; developments regarding the Company’s material intellectual property (including issuance or denial of patents); regulatory developments; changes in management, senior leadership or other significant personnel or control changes; employee layocs; a disruption in the Company’s operations, including security breaches of facilities or IT systems; tender ocers, repurchase programs or proxy fights; change in auditors or auditor notifications that the Company may no longer rely on an auditor’s audit report; corrections to previously issued financial statements (accounting restatements); significant lawsuits or settlements; and possible bankruptcy.
As it can be difficult to determine whether information is material, please discuss with the Compliance Officer in case of doubt.
PRIMARY PROCEDURE
All directors, officers, employees, representatives and consultants of the Company must familiarize themselves with this Policy and the importance of compliance. Authorized Officers must be informed immediately when any potential Inside Information or other material information becomes available. The Authorized Officers will determine if such information is Inside Information and will decide how and when to disclose such information (or to delay disclosure of Inside Information if appropriate). The Authorized Officers may consult with other directors, officers or employees of the Company, the Company's external lawyers and/or its financial adviser(s) in making this decision. If disclosure is required or advisable, an Authorized Officer will authorize the necessary disclosure (unless a delay in making an announcement is permitted) and also ensure publication of such information on the Company’s website as required. If disclosure of certain Inside Information is not required, it is the Company’s policy not to release such information, unless: • the Company has regularly disclosed that type of information in the past or the Authorized Oacers have otherwise determined that it is advisable to disclose such information in order
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
•
to ensure market integrity; and such release is made in compliance with this Policy.
The Company will follow a “No Comment” policy. The Company will not respond to inquiries about rumors, potential transactions or unusual market activity in the Company’s securities. In performing your duties on behalf of the Company, you must ensure that: • the number of people with access to confidential information is limited; • confidential documents are locked up and code names are used if necessary; and • all employees, representatives and consultants are educated about the need to keep certain information confidential, not discuss confidential information which may be overheard, and not discuss investments in the Company’s securities. If a Company director, officer, employee or consultant who is not a spokesperson believes that they may have disclosed Inside Information, or believes Inside Information has been leaked, such person must immediately notify an Authorized Officer of the information disclosed, the person to whom the information was disclosed, and any other pertinent information regarding the disclosure. After notification, the Authorized Officers will determine whether to disclose the information in the manner prescribed in this Policy.
METHODS OF PUBLIC DISCLOSURE Public disclosure will be made by:
filing or furnishing a report with the Securities and Exchange Commission (“SEC”); or another method (or combination of methods) of disclosure reasonably designed to provide broad, non-exclusionary distribution of information to the public, such as: a press release distributed through a widely disseminated news or wire service; or an announcement made at a press conference, webcast or conference call, if the public is given adequate advance notice of the conference, webcast or call and the public is granted simultaneous access to the conference, webcast or call either by telephonic and/or electronic transmission, which is reasonably designed to provide broad, non-exclusionary distribution of the information to the public.
ANNOUNCEMENTS Contents of Announcements
If you are responsible for preparing an announcement, you must ensure that: • the statements, figures, forecasts or other information provided in such announcement are not misleading, false or deceptive and do not omit anything which might acect the meaning of such statement, forecast or information; • • • •
the announcement complies with all requirements set out in the applicable rules on publicly listed securities, for example, in relation to dealings by persons discharging managerial or directorship responsibilities (and their related persons); the announcement complies with all other applicable legal or regulatory obligations; the announcement does not include any statements designed to market or promote the Company's activities that would result in the announcement becoming misleading, e.g. where an adverse event or circumstance is obscured by other more positive matters; and you have verified the contents of the announcement. The nature and extent of verification will depend upon the subject matter of the announcement but should include confirmation as to
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
the accuracy of facts, where necessary from management.
Vetting and Authorization Processes
The Company’s procedure for review and release of Company announcements and press releases is as follows: • Save in exceptional circumstances, all external communications, including announcements, press releases, presentations, and website and social media postings and other digital communications must be reviewed and authorized by an Authorized Oacer who will consult with the Company’s Medical, Legal, and Regulation Review Committee pursuant to the Company’s compliance policies. • The following external advisers should also be consulted as appropriate: • financial advisers; o PR/IR firm or consultants; o Regulatory advisers; o lawyers; and o auditors. • Unless otherwise instructed by an Authorized Oacer, all persons named in the announcement should be given the opportunity to review the announcement prior to its release to confirm all information is factually correct, material information is not omitted, and it is expressed in a clear and objective manner that allows investors to assess the impact of the information when making investment decisions. • An Authorized Oacer must authorize the final release.
Financial Statements •
All annual financial statements, half-year financial statements and quarterly financial information are reviewed by the audit committee of the Company’s Board of Directors and all annual financial statements, half-year financial statements and quarterly financial information are approved by the Board of Directors, or by duly designated members of the Board of Directors.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Release of Public Announcements • •
•
Only an Authorized Oacer can authorize public announcements for release. All announcements must be available publicly on the Company’s website and the Company must ensure of the complete and ecective dispatch of all announcements. The Company may rely on a professional dispatcher (including a primary information provider or “di#useur professionnel” within the meaning of article 221-4 IV of the General Regulations of the AMF) to whom it shall send such announcements for dispatch through electronic means. The Company must notify Nasdaq’s MarketWatch Department prior to the public release of Inside Information or other news in accordance with Nasdaq listing rules.
DELAYED ANNOUNCEMENTS
As an exception to the prompt disclosure requirement set forth above, the Authorized Officers may delay disclosure of Inside Information if all the following conditions are satisfied: • immediate disclosure is likely to prejudice the legitimate interests of the Company; • delay of disclosure is not likely to mislead the public and the deferred information is not in contradiction with the last publicly disclosed information; and • the Company is able to ensure the confidentiality of the information. For example, the Company may delay disclosure (provided that the conditions referred to above are satisfied) in the following situations: • the Company is conducting negotiations and the outcome of such negotiations would likely be jeopardized by disclosure (e.g., M&A transactions, spin-ocs, disposal of major assets, etc.); or • the Company has developed a product, product candidate or a technological invention and the immediate public disclosure of that information is likely to jeopardize the intellectual property rights of the Company. • If disclosure of Inside Information is delayed, the Company must keep a record of the following information: • the dates and times when: o the Inside Information first existed; o the decision to delay disclosure was made; and o the Company is likely to disclose the Inside Information; • the identity of the persons responsible for: o making the decision to delay disclosure; o monitoring the conditions for the delay; o making the decision to publicly disclose the Inside Information; and • providing information and explanations about the delay to the authorities; • proof that the conditions for delayed disclosure have been met, and of any change of these conditions, including the means implemented to ensure protection of the Inside Information for which disclosure is delayed. When the delayed Inside Information is disclosed, the Company must send the following information to the AMF by email at [email protected]: • the identity of the Company;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • • • •
the identity and contact details of the person making the notification: name, surname, position within the Company, work email and phone number; identification of the Inside Information that was subject to delayed disclosure: title of the disclosure statement; the reference number where the system used to disseminate the Inside Information assigns one; date and time of the public disclosure of the Inside Information; date and time of the decision to delay the disclosure of Inside Information; and the identity of all persons responsible for the decision to delay the public disclosure.
ONGOING DISCLOSURE Company Spokesperson and Media Enquiries
All public disclosures of information and communications and all contacts with analysts, existing investors, potential investors, the media or the general public must be made in accordance with the following: • All public disclosures of information and communications shall be made by an authorized spokesperson of the Company. No other individual is authorized to communicate about the Company or disclose Inside Information regarding the Company to any third party without the prior consent of an Authorized Oacer. The Company shall keep the number of spokespersons authorized to speak on behalf of the Company to a minimum. • The Company has designated the following individuals as the Company’s authorized spokespersons: o the Company’s CEO; o the Company’s CFO; o the Company’s Chief Medical Oacer; and o the Company’s EVP External and Corporate Acairs o the Company’s Head of IR • With regards to any queries from the media, the primary spokesperson for the Company is the CEO. If you are contacted directly by a journalist or other media representative, do not answer their questions but take the name and contact details and refer the information to the CEO and/or EVP External and Corporate Acairs. • The CEO is also the primary spokesperson in responding to enquiries from institutional and other large shareholders, stockbrokers and analysts as well as enquiries from small shareholders. Accordingly, all enquiries from such persons must be directed to the CEO and the CFO. When the CEO is not available to answer a particular enquiry, the CFO then takes responsibility for that enquiry as appropriate. • The CEO is responsible for ensuring that public disclosures of information relating to the Company are constantly monitored and is responsible for the accuracy of such information. In addition, the CEO will ensure that copies of material public announcements of the Company are distributed on a timely basis to the Board of Directors as well as relevant Board committees.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Conference Calls
The Company may schedule conference calls from time to time to discuss financial results or other information that may be material to the investing public and the securities industry. The procedures applicable to such conference calls are: • A reasonable time prior to the call, the Company will issue a press release announcing the time, date and dial-in information of the call and a description of the Inside Information to be discussed. • The Company will not selectively disclose any additional Inside Information after a conference call and will only disclose new information on a conference call if the conference call is held in compliance with the French Stock Market Rules and Regulation FD. • A transcript or audio file of the conference call, including any other summaries of the conference call, may be posted on the Company’s website.
Private Meetings
Authorized spokespersons of the Company may engage in private meetings with financial market analysts and investors solely for the purpose of clarifying previously disclosed information, provided that these meetings are authorized in advance by the CEO. These private meetings must not involve the disclosure of Inside Information and it is best practice for at least two individuals to attend every such meeting. The spokesperson will not confirm any previous financial guidance or forecasts under facts and circumstances that make the confirmation itself material, unless such information, update or confirmation is contemporaneously made available to the public in a manner consistent with this Policy. If Inside Information is inadvertently disclosed, you must immediately inform an Authorized Officer to enable them to announce the information publicly immediately. If an analyst asks a question which touches on a price-sensitive area, you may only answer with publicly available information. You must take all reasonable measures to ensure that all statements, forecasts or other information you provide are not inaccurate, misleading, false or deceptive. Where this is not possible, you must decline to answer the question, or take it on notice and refer the matter to the CEO.
Presentations
An Authorized Officer must approve all of the Company’s financial, regulated or other public disclosures and audiovisual engagements covered by this Policy in advance. If you are presenting in a capacity on behalf of the Company, you must ensure that all presentations: • do not contain Inside Information unless such information is also being simultaneously publicly announced; • have been verified; and • where any of them is made in support of an announcement or contains information that will be announced, that such presentation and the announcement are aligned. You must ensure that relevant management and external advisers have been allowed to review and comment on the document at appropriate stages during its preparation. Scripts & Q&As should generally be prepared and subject to the same scrutiny as presentations. The Company should ensure equal and concomitant access to the information made available to
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
financial analysts. In practice, this will be done through webcasts of presentations to analysts and postings of slideshows made available on the Company’s website.
Review of draft Analysts’ Reports / Articles
You may sometimes be requested to review draft analysts’ reports and articles on the Company prior to publication. In such instance, you must use utmost care in any review and preferably decline any input. Any input shall in any case in such instances be restricted to amending factual errors. Under no circumstances may you expressly or impliedly approve or disapprove the financial projections or other information outside the information that is publicly available.
Annual Reports, Periodic Reports and Company Literature
The Company must regularly provide an annual report on the Company’s financial condition and related business performance following fiscal-year end. Interim reporting of the Company’s financial and business performance may be provided quarterly or half-yearly between annual reports or at such other interval as is required by applicable law or otherwise advisable. Annual reports and interim reports, if any, will be made available in a manner reasonably designed to provide broad, non-exclusionary distribution of the information to the public.
The Company Website and Social Media Channels
The Company intends to use its website and certain other social media channels to provide access to: • public announcements; • company presentations; • company contacts; and • other relevant information. The Company endeavours to ensure that no inappropriate information is placed on its corporate website and to keep the website maintained and up-to-date. Written materials placed on the website shall include a reference to appropriate cautionary disclosures and/or disclaimers in order to take advantage of the U.S. safe harbor under the Private Securities Litigation Reform Act of 1995. You may not use social media, including corporate blogs, chat rooms, chat boards, Facebook, LinkedIn, Instagram, Reddit, Clubhouse, TikTok, Medium, X, Youtube, the Motley Fool, Raging Bull, Yahoo! Finance and other non-traditional means of communication to disclose information about the Company or other companies with which the Company does business, even if done so anonymously, without the prior approval of an Authorized Officer. This prohibition applies regardless of whether the posting is made in an individual capacity or if the social network is accessed at an individual’s home or at the office or anywhere else. The Company may use approved social media channels from time to time to disclose information management believes is important to be disseminated or of use to the public. All information disseminated on Company accounts on any social media channel (e.g., X, Facebook, Instagram, Medium, TikTok, etc.) must be approved by an Authorized Officer prior to posting. All postings to any Company account on any social media channel, other than ordinary course marketing or advertising or responses regarding customer experience, must be reviewed and approved by an Authorized Officer prior to posting.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
In addition, the following guidelines apply to social media posts and digital communications by the Company: • each post and digital communication must be dated and electronically archived; • if space is limited (e.g., character limitations), the post and digital communication must provide hyperlinks to the full text of the communication and to appropriate cautionary statements in connection with any forward-looking statements and reference the cautionary language in the post; • social media posts may not include any confidential information, trade secrets or other similar information; • links included in Company posts or digital communications are considered part of the communication itself. If hyperlinks are included to third-party content, such posts and digital communications must include a notification that users are leaving the Company-controlled channels and that the Company is not responsible for and neither endorses nor approves such content (or provide an intermediary link page that includes such notification); and • any Company responses to comments or other responses to such post, other than ordinary course responses regarding customer experiences, must be reviewed and approved by an Authorized Oacer. Language should be included on the Company website and communications to notify investors publicly that the Company intends to use its website and specific social media channels, if any, as channels of distribution of material information about the Company.
Market Surveillance Queries / Market Rumors
Any information relating to market rumors, leaks or false information relating to the Company must be brought to the attention of the Authorized Officers as soon as possible. The Authorized Officers will then take steps to ascertain as far as practicable the veracity of the leak or rumor and the degree that the leak or rumor exists in the marketplace. You must not directly respond to such market rumors, leaks or false information without the prior authorization of the CEO. The Authorized Officers will assess whether it is appropriate for the Company to respond to the leak or rumor. If considered appropriate, the leak or rumor will be responded to by the Company through an announcement. If the AMF or Nasdaq verbally queries the Company on a leak or rumor, only the Authorized Officers may respond to the AMF or Nasdaq. The Authorized Officers will consult on such query and decide on an appropriate response to such enquiries as soon as possible.
INSIDER LIST
The Compliance Officer will maintain an insider list in accordance with the applicable rules. The list will comprise persons employed or engaged by the Company, Board members, and third parties acting on behalf or for the account of the Company, who have access to inside information relating to the Company. The Compliance Officer may appoint other persons within the Company to administer the establishment of insider lists relating to employees within particular divisions or geographical locations. Insider lists must include: • the name of each person who has access to Inside Information (for third parties, the entities’ names should be included in the insider list);
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • •
the reason why such person is on the insider list; the date on which the person first had access to the Inside Information; and where a person no longer has access to Inside Information, the date on which this occurred.
The Company shall inform the persons named on the list of their inclusion on such list, their legal and regulatory duties in respect thereof, and the sanctions applicable to insider dealing and unlawful disclosure of inside information. Such persons must acknowledge receipt thereof.
AMENDMENT OF THIS POLICY
This Policy has been adopted by the Board of Directors of the Company. Amendments to it can only be approved by the Board of Directors. The Compliance Officer is responsible for reviewing this policy to ensure compliance with the applicable laws and regulations as well as corporate governance best practices.
SANCTIONS
The AMF may, pursuant to article L.621-15-III of the French Monetary and Financial code, impose fines of up to EUR 100,000,000 (one hundred million Euros) or ten times the amount of any profit made. This amount may be increased to up to 15% of the revenues of the Company. In addition to the Company itself, executive officers may be found liable (and therefore subject to the fines referred to above) in the event of failure to disclose inside information in a timely manner. Additionally, violations of US securities laws may result in SEC enforcement actions, which can result in civil monetary or criminal penalties. Any person who communicates about the Company’s business with analysts, existing investors, potential investors, shareholders, the media or the general public without the express approval of an Authorized Officer, or who otherwise discloses the Company’s information in violation of this Policy, will be subject to disciplinary action, which may include termination of employment.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
May 2026
Introduction
Inventiva S.A. and its affiliates (“Inventiva”) are committed to building relationships with healthcare professionals (“HCPs”) and healthcare organizations (“HCOs”) that are grounded in integrity and a shared commitment to patients. Transparent, accurate, and fair interactions with the healthcare community are not only a regulatory expectation, but they are essential to ensuring that patients, HCPs, and HCOs can make well-informed decisions. Most countries in which we operate have implemented laws and regulations governing interactions with HCPs and HCOs. Industry associations such as the European Federation of Pharmaceutical Industries Associations (“EFPIA”) and the Pharmaceutical Research and Manufacturers of America (“PhRMA”), also maintain guidelines in this respect. Inventiva is committed to complying with all Applicable Laws pertaining to interactions with HCPs and HCOs. This Code of Conduct (the “Code”) has therefore been adopted by Inventiva to provide guidelines for all interactions between Inventiva Personnel and HCPs or HCOs. This Code addresses common types of interactions with HCPs and HCOs, including events, hospitality, donations, grants, sponsorship, services agreements, medical samples, gifts, informational or educational materials and items of medical utility. However this Code is not exhaustive. It should be read together with all other Inventiva policies and procedures and does not represent a complete statement of every rule or requirement that governs our interactions with HCPs and HCOs. Local laws and applicable industry codes may impose heightened or additional requirements beyond those expressly stated in this Code. As a general rule, all interactions with HCPs and HCOs must be conducted in an ethical, fair, objective, truthful and transparent manner and in accordance with all Applicable Law and Inventiva policies. You must avoid interactions that are deceptive or that create conflicts of interest or bias. All Inventiva Personnel must comply with this Code. Failure to follow this Code may trigger large fines for Inventiva and sanctions such as business shutdown, withdrawal of an approved product or marketing authorization and reputational loss. Inventiva Personnel who are found to be non-compliant also run the risk of individual fines or imprisonment. Due to the severity of the consequences, in order to protect our rights, Inventiva may take whatever steps are required against Inventiva Personnel who do not comply with this Code including disciplinary action, including termination. If you have any questions about this Code or about any additional requirements that may apply in a particular situation, please contact your supervisor or Inventiva’s Legal Department. This Code provides: • general guidelines on permitted activities; • general guidelines on prohibited activities; and • references to Inventiva’s procedures to guide specific types of interactions.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
This Code applies to all Inventiva Personnel who engage in or support interactions with HCPs or HCOs on behalf of Inventiva, irrespective of where you or the HCPs are located, including: •
interactions with HCPs that occur outside the territory in which such HCPs are admitted to practice;
•
live interactions (e.g., face-to-face) and interactions in a virtual setting (e.g., exchanging information over audio or video conferencing).
Such interactions include, but are not limited to: •
Services provided by HCPs, including participation in clinical trials or Advisory Boards, consulting services provided under Consulting Agreements, and other services; and
•
Scientific exchanges with HCPs in any form whatsoever, including but not limited to, written, oral, or printed exchanges and digital communications including social media.
The definition of the term “HCP” may vary from one jurisdiction to another. You are required to verify the scope of the term HCP in the applicable jurisdiction before pursuing activities involving HCPs in the jurisdiction where the activities are to take place and the jurisdiction where the HCPs are admitted to practice. For multi-jurisdictional interactions, determination of which country rules apply is based: •
primarily on the country in which the HCPs is admitted to practice; and
•
the rules of the country in which the HCP Service will take place.
Please note: some countries have more stringent requirements than others -- where the requirements of two countries could apply, you must follow the most stringent of these rules. Please refer to Inventiva’s country-specific guidance and requirements, available at on Sharepoint at Compliance - Policies & Training - Tous les documents or from the Compliance Officer, for further information regarding local requirements.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
II.
Definitions and Abbreviations
Term Advisor
Advisory Board
Applicable Laws
Bona Fide Competent Authorities Consultant
Consulting Agreement Donations and Grants
Educational Items
Definition Investigator, academic personnel, clinical expert, or other healthcare professionals whose expertise can be relied upon by Inventiva in relation to emerging company scientific and, where permitted, business issues that may have implications for: • Understanding of diseases, epidemiology, existing therapies, and treatments • Clinical development plans and clinical study designs • Clinical gaps and generation of related plans • Planned disease state education • Product launch plans, Product strategy, and positioning within relevant markets • Other strategic issues facing Inventiva Forum in which discussions can take place between Advisors or Consultants that may have implications on: • Understanding of diseases, epidemiology, existing therapies, and treatments • Clinical development plans and clinical study designs • Clinical gaps and generation of related plans • Planned disease state education • Product launch plans, Product strategy, and positioning within relevant markets All applicable international, federal, state, national and local laws, statutes, laws, regulations, statutory instruments and legally binding guidance relating to interactions with HCPs or HCOs, including without limitation; (i) anti-bribery and anti-corruption laws, (ii) laws governing inducements, gifts, hospitality, sponsorships, fees for services and other transfers of value, (iii) laws governing transparency and transfer-of-value disclosure and reporting requirements, (iv) fair market value standards, (v) laws governing the promotion of medicinal products and scientific exchange, and (vi) data protection and privacy laws, in each case as enacted, amended, or reinterpreted from time to time in any jurisdiction in which Inventiva operates. In good faith, without fraud or deceit. The competent authorities in the countries where Inventiva carries out its activities responsible for, among other things, regulating and supervising, medicinal products and clinical trials. Third Party Vendor, including an HCP, engaged for the purpose of providing guidance, information, or feedback to Inventiva to meet legitimate business needs when such information is not reasonably available internally or not readily available through other means. Written business arrangement with an HCP who is compensated by Inventiva, in accordance with applicable internal company policies, Fair Market Value, and all Applicable Laws for Services rendered on a fee-for-service basis. Collectively, mean providing funds, assets, benefits in-kind or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient to provide goods or services to the benefit of the donor in return. In general, donations include remuneration that is provided to not-for-profit, charitable organisations; and grants include: (i) educational grants (i.e., remuneration that is provided to support a bona fide, independent educational program), or (ii) research grants (i.e., remuneration that is provided to third parties to support the advancement of medical or scientific knowledge). Items related to human health and diseases which are aimed directly at the education of HCPs, enhancing the provision of medical services and patient care.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Entertainment Events
Fair Market (“FMV”)
Value
Fee-for-service Gift Hospitality Healthcare Organization (“HCO”)
Healthcare (“HCP”)
Professional
Inventiva Officer
Compliance
Inventiva Personnel Meal Medical Sample Patient (“PO”) Personnel
Product Service
Organization
Entertainment includes, but is not limited to, dancing or arrangements where live music is the main attraction, sight-seeing trips, theatre excursions, sporting events (e.g. skiing, golf or football match) and other leisure arrangements. All professional, promotional, scientific, educational meetings, congresses, conferences, symposia, and other similar events (including, but not limited to, Advisory Board meetings, and planning, training or investigator meetings for clinical trials and non-interventional studies) organized or sponsored by or on behalf of Inventiva or by a Third Party. The price that a disinterested buyer (meaning a buyer without a vested or conflicting interest in the matter) would be willing to pay and a seller would be willing to accept on the open market or in an arms' length transaction assuming a reasonable period of time for an agreement to arise. Engagement of a qualified HCP as a Consultant, Advisor or Speaker to perform a Service for Inventiva, including, but is not limited to consultation on product development, research, participation at Advisory Boards or Speaker Programs. A monetary or in-kind advantage, benefit, favor. Provision of food, beverage, accommodation, transportation and other amenities at Inventiva’s expense to HCPs. Any organization, institution, association, or other legal person or entity that is involved in the delivery, financing, administration, oversight, or support of healthcare services, or that is managed by, run by or comprised of HCPs. Such entities may include but are not limited to hospitals, pharmacies, medical practices, physician groups, nursing homes, laboratories, group purchasing organizations, insurers, and health plans. Any natural person that provides health care services, including but not limited to a n y member of the medical, d e n t a l paramedical, pharmaceutical, or nursing professions, any medical or healthcare students or any other person who in the course of his or her professional activities may prescribe, purchase, r e c o m m e n d , r e f e r , supply, administer, or arrange for the purchase of a medicinal product. The Inventiva Compliance Officer is a person to whom you can address any questions or concerns related to this Code or any other matters relating to regulatory compliance. In the absence of a designated Compliance Officer, Inventiva’s Compliance Officer is Inventiva’s Chief Legal Counsel. The Inventiva Compliance Officer may also designate additional individuals to assist in the performance of the duties of the Inventiva Compliance Officer. All Inventiva officers, directors, employees, representatives, agents, or other individuals and entities providing services on Inventiva’s behalf. Refers to all food and beverages, including snacks, being provided to HCPs that is directly related to the services that they provide to Inventiva. Means a sample of medicinal product free of charge provided to persons qualified to prescribe or supply them so that they can familiarize themselves with new products and acquire experience in dealing with them. A non-for-profit legal person/entity (including the umbrella organization to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers. Inventiva’s officers, directors, employees, including Third-Party Vendors (“TPV”), agents, consultants, and any other individual or entity providing services/conducting activities on Inventiva’s behalf. Includes persons employed by Inventiva either on a full-time or part-time basis and includes all workers or temporary workers. Any of Inventiva’s products, including product candidates in development. Any function or activity provided for or on behalf of Inventiva by an HCP. Examples include, but are not limited to: (1) participation on an Advisory Board, (2) promotional or nonpromotional speaking, (3) medical or scientific support or guidance in connection with
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Speaker Speaker Program Sponsorship Third Party (“TPV”) Unsolicited Abbreviations
Vendor
clinical or other biomedical research, or (4) other functions or activities in which an HCP is engaged by or on behalf of Inventiva on a fee-for-service basis. For the purposes of this Code, a Service does not include functions or activities performed by a bona fide employee of Inventiva, or by any other person or entity who or which devotes substantially their full professional or business time or effort to performing functions or activities for or on behalf of Inventiva. Podium speaker, moderator and/or chair, who presents during a Speaker Program sponsored by the Company or a Third Party Event (Poster- and abstract-presenters are not considered speakers). An activity during which an approved HCP under contract with the Company presents information on Products, disease states or other healthcare topics to a group of HCPs and/or other appropriate attendees, as applicable, in accordance with Applicable Laws. Support provided by or on behalf of Inventiva, when permitted by Applicable Laws, as a contribution to support an activity (including an Event) performed, organized or created by a Healthcare organization, a Patient Organization or a Third Party. Individual or entity, such as an agent, contractor, subcontractor, consultant, supplier, outside marketing representative, or other vendor or persons authorized by written contract to engage in work on behalf of Inventiva and performing business activities, or providing services, for Inventiva or on behalf of Inventiva or its divisions. Not prompted, either directly or indirectly, solicited, or initiated by Inventiva. “EU” - European Union “EUR” - Euro “VAT” - Value Added Tax
III. Fee-For-Services Arrangements Inventiva periodically obtains Services from HCPs in connection with legitimate Inventiva business needs and compensates HCPs for such Services. Even when such an engagement and the compensation is appropriate, paying or providing other compensation to an HCP to provide a Service can be perceived as an attempt by Inventiva to inappropriately influence the HCP to prescribe or use, or influence the prescription or use, of an Inventiva Product. As such, you must take caution to ensure that such engagements are consistent with this Code, all Inventiva policies, and Applicable Laws.
GENERAL RULES FOR ENTERING INTO CONSULTANCY AGREEMENTS WITH HCPS Inventiva may engage a qualified HCP to perform a Service for Inventiva. This may include, but is not limited to consulting on product development, research, participation at Advisory Boards or Speaker Programs. Inventiva may not engage an HCP, directly or indirectly, to perform or provide a Service with the intention to: •
induce the HCP to use, purchase, order, price, or prescribe an Inventiva Product; or
•
influence or arrange for the use, purchase, order, pricing, or prescription; or
•
reward the HCP for the use, purchase, order, price, or prescription of an Inventiva Product.
Consulting Agreements: minimum standards
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
All Inventiva Consulting Agreements must meet the following requirements and be otherwise permitted by Applicable Laws and all Inventiva policies, SOPs and Guidelines: • • • • • •
•
•
•
•
•
The Service must be provided for the purpose of supporting healthcare, research or education and must not constitute an inducement to recommend and/or prescribe, purchase, supply, sell or administer specific Products. A legitimate Inventiva business need for the Service must be demonstrated and documented in accordance with the Inventiva Business Needs Assessment Form before engaging an HCP. Consulting Agreements and the related Service must be documented: in a written agreement signed by the parties and approved by the Legal Department before any Service is commenced or any payment for the Service is provided; based on Inventiva’s HCP Consultancy Services template agreement to which no revisions shall be made without the prior written approval of the Legal Department. The HCP must be qualified to provide the Service and all necessary information must be available to demonstrate the HCP’s qualifications before an agreement is signed. o Inventiva Personnel selecting the Consultant must: o select the Consultant based on clearly defined objective business criteria; o evaluate whether the Consultant meets the criteria and confirm in writing whether the related objective business criteria have been fulfilled; o have the necessary expertise to evaluate whether the Consultant meets the legitimate business needs for the Service and whether the criteria for selecting the Consultant are met; and o select the Consultant based on independent decision-making to prevent any potential bribery and corruption risks arising in connection with use of Consultants. Where required by Applicable Laws or employment rules, the Consultant must obtain, document and provide their employer’s approval to Inventiva in writing before any written agreement is concluded in relation to the Consulting Service. In case of doubt as to whether this is required, please contact the Inventiva Legal Department. Many public authorities or institutions place strict limitations on Consulting Agreements. Competent Authority o_cials or other public authority o_cials or institution personnel may be prohibited from providing Consulting Services to Inventiva or may be required to document their eligibility to provide Consulting Services to Inventiva or seek prior authorization from their employers. Consulting Agreements with public authority o_cials or institution personnel must therefore be: o reviewed by the Inventiva Compliance O_cer prior to any related agreement being concluded; o approved by the Inventiva Compliance O_cer in writing in advance of entering into the Consulting Agreement. Meetings attended by Consultants: o must take place at venues that are conducive to the Services being performed, modest and appropriate taking into account Applicable Laws; and o the Consulting Services and activities related to the Services must be the focus of any meeting at which Consultants are present. Communications with Consultant:
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Consulting Agreements for the purpose of speaking to Inventiva Personnel at Company meetings: o are only permitted subject to prior review and approval by the Inventiva Compliance O_cer; o the subject of such speaking engagements must be approved in accordance with the Promotional Materials Policy; and o the Consultant must disclose that they will receive remuneration from Inventiva for their presentation at the beginning of the presentation. o Product specific information provided to a Consultant must be limited in scope to facilitate the bona fide service being provided. Compensation and payments provided in relation to the Consultant’s services: o must be reasonable and based on their qualifications, expertise, and experience; o must reflect Fair Market Value (“FMV”) for the Services being provided; o must be aligned with the Inventiva FMV guidance and documented in accordance with Inventiva’s policies and procedures; and o may include reimbursement of reasonable documented expenses provided that: o expenses are reasonable and justified under the circumstances; o expenses are consistent with the Business Travel, Accommodation and Meals section below and Applicable Laws (including prior notification/approval by Competent Authorities, if applicable); o expenses are approved by the Inventiva Compliance O_cer in advance; and o adequate invoices and proof of expenses are provided by the Consultant. Inventiva must never compensate Consultants for personal expenses associated with Consulting Agreements, such as Entertainment, or expenses associated with a spouse or other guest traveling with the Consultant. All payments and other transfers of value must be: o based on required documentation, both internal and external; o documented in records maintained in relation to the service; paid only into the HCP’s professional bank account, if required by Applicable Laws; and subject to full disclosure in accordance with Applicable Laws. o
•
• • • •
Additional specific local laws and regulations may be applicable in some countries, including research agreements (research and development, non-interventional studies, clinical studies).
for
Prohibited Activities
Inventiva must never use Consulting Agreements to try to induce an HCP/HCO to use, prescribe, purchase, or recommend Inventiva Products, reward past purchases, or influence research results. Examples of prohibited activities include, without limitation: • entering into Consulting Agreements for the purpose of influencing principal investigators or prescribers; • entering into multiple or repetitive agreements to obtain Services which would duplicate Services or information that the Company has already obtained;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
•
• • •
providing information to or requesting information from a Consultant about Products which have not yet been authorized by Competent Authorities unless this is either as part of a clinical trial or in response to an Unsolicited request and has been approved in accordance with the Promotional Materials Policy in advance; entering into a Consulting Agreement with any supranational, national, public, governmental or local authority o_cial or institution employee without prior written approval by the Inventiva Compliance O_cer; providing payments to a Consultant by directing the payment to a charity or charitable organization on Consultant’s behalf, or for Services that have not been rendered or before Services have been rendered; obering or agreeing to payments that make the assessment of FMV impossible or challenging (such as provision of shares or stock options in Inventiva or a monthly or yearly retainer).
Additional Rules For Advisory Boards
An Advisory Board is a forum in which Inventiva can obtain advice from Advisors and Consultants whose expertise meets Inventiva’s legitimate business needs on emerging scientific and, where permitted, business issues that may have implications on the following: • understanding of diseases, epidemiology, existing therapies and treatments relevant to Inventiva’s field of interest; • clinical development plans and study designs; • other strategic issues facing the Company, including market access and reimbursement; • planned disease education; and • product launch plans.
Advisory Boards: Minimum Standards
All Consulting Agreements with Advisors in relation to Advisory Boards must meet the following requirements and be otherwise permitted by Applicable Laws and Inventiva policies: •
•
Consulting Agreements for Advisory Boards must: o meet the minimum standards for Consultancy Agreements; o always have a legitimate scientific or, where permitted, business need to seek advice, which shall be determined and documented in advance in accordance with the Inventiva Business Needs Assessment Form; o be the best way to satisfy the legitimate scientific or business need, and designed to do so in an e_cient and ebective manner o be based on Inventiva’s Advisory Boards Template Agreement to which no revisions shall be made without the prior written approval of the Legal Department. Rules on Communications During Advisory Boards: o information about Inventiva Products that are provided at Advisory Board meetings must be consistent with data from Inventiva’s clinical development programs, product authorizations, public disclosures or otherwise relevant to Inventiva’s current or future clinical development or other strategic plans;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
o o o o o
all materials presented or provided as part of any Advisory Board meeting must be approved in writing and in accordance with Inventiva’s Promotional Materials Review Policy before being provided; information provided by Inventiva at Advisory Board meetings must be limited to that which is necessary for the Advisors to perform their contracted Services; only Medical Abairs or Clinical Development Personnel may present data at an Advisory Board and solely to the extent the data fulfills all Minimum Standards for Consideration when Conducting Advisory Boards; Marketing and Commercial Personnel should not present data at an Advisory Board; any information provided in hard copy during an Advisory Board must be returned to Inventiva by Advisory Board participants at the end of the related meeting.
Prohibited Activities
Advisory Boards are not an opportunity for Product demonstrations, marketing presentations or other activities intended to influence the market. Advisory Boards may not be used for presentation of data that are not necessary for the Advisors to perform their contracted Services as part of the Advisory Board. Additionally, the following activities are not permitted: • •
• • •
use of materials that have not been approved in writing in accordance with the Promotional Materials Review Policy prior to the meeting; attendance by any guest of a Consultant, including a significant other, with whom Inventiva has not contracted and who is not legitimately attending any Event related to the Advisory Board in their own right and on the basis of an agreement individually concluded in writing between them and Inventiva; attendance by Inventiva Personnel at an Advisory Board meeting that is not based on legitimate Inventiva business needs; attendance by Inventiva Personnel where the number of Inventiva representatives is excessive and unreasonable based on the number of Advisors attending the event; attendance by Inventiva Personnel for any reason other than to moderate, present, monitor or obtain first-hand feedback, and/or manage the meeting (i.e., it would not be appropriate for an Inventiva employee to attend an Advisory Board merely to develop or maintain relationships with the Advisors).
IV. Events And Hospitality WHAT IS AN EVENT? Events include all professional, promotional, scientific, educational meetings, congresses, conferences, symposia, and other similar events (including, but not limited to, Advisory Board meetings, and planning, training or investigator meetings for clinical trials and non-interventional studies) organized or sponsored by or on behalf of Inventiva or organized by a Third Party.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
EVENTS: MINIMUM STANDARDS Inventiva may hold, sponsor or, in certain jurisdictions, support delegates to attend a wide range of Events, including meetings, provided such Events meet the requirements of this Code. This may include, where permitted by Applicable Law, support of HCPs now known to Inventiva via an HCO in accordance with Inventiva’s policies and as approved in advance by the Compliance Officer. •
•
• • • •
• •
Scientific, Educational or Promotional objectives: The purpose and focus of any and all invitations to Events organized by Inventiva or a third party must be to provide scientific or educational information and/or to inform HCPs about Inventiva’s Products. It should be the program content that attracts delegates to attend and not any associated Hospitality or venue. Appropriate and relevant content: the content of the Event must be appropriate and relevant to attendees. The Event program shall directly relate to the specialty and/or medical practice of the HCPs who attends the Event or be su_ciently relevant to justify the HCP’s attendance and sponsorship, where permitted by Applicable Laws. Appropriate venue: the venue must be appropriate and conducive to the main purpose of the Event. Lavish, extravagant or deluxe venues must not be used. Venues that are renowned for their entertainment facilities must not be used. With the exception of congresses, Events must be held where it makes the most sense from a logistics standpoint to hold the event (ie in the country or state where the majority of the participants are located) International Events: Sponsorship of an HCP is subject to both the Applicable Laws of the country where the HCP is admitted to practice and the Applicable Laws of the country in which the Event takes place. Prohibition of Sponsorship of US-Licensed HCPs: Given Applicable Laws in the U.S., direct Sponsorship of US-licensed HCPs is prohibited. In such instances, Sponsorships shall be limited to third-party organizations in accordance with Inventiva’s policies governing Sponsorships and as approved in advance by Inventiva’s Compliance O_cer. Entertainment: no Entertainment or other leisure or social activities shall be provided or paid for by Inventiva. Selection of HCPs: The purpose and focus of all invitations to Events organized by Inventiva or a third party shall be to provide scientific or educational information and/or to inform HCPs about Inventiva’s Products. o The Event program shall directly relate to the specialty and/or medical practice of the HCP who attends the Event or be su_ciently relevant to justify the HCP’s attendance and sponsorship, where permitted by Applicable Laws. To the extent permitted by Applicable Laws, Inventiva may select HCPs to receive Sponsorship funding if the following conditions are met: o Inventiva must not base the selection of HCPs to whom Sponsorship is provided on the actual or potential volume of business that such HCPs could generate. o Inventiva Personnel must use the following criteria in the selection of such HCPs:
- Inventiva must provide Sponsorship to HCPs only in response to a related written Unsolicited request and in order to support the scientific and medical education and professional development of the HCPs;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
the Sponsorship provided must have a direct relationship with the medical practice of the HCPs; and
- Inventiva must not provide frequent Sponsorship to the same HCP or give the impression that recurrent support can be expected. Sponsorship provided to HCPs: o must be documented in detail and governed by a written agreement signed by the HCP prior to provision of the Sponsorship, setting out what has been agreed, and the categories of costs covered such as registration fees, accommodation and/or travel; o the rationale for the decision to provide support to an HCP to attend a meeting should be documented prior to the provision of support; and o where required by Applicable Laws, the arrangements must be approved by the Competent Authorities, professional organizations and the employer of the HCP.
•
Guests: Inventiva shall not pay any costs associated with individuals accompanying invited HCPs or for any other person who does not qualify as a participant in their own right. • • • • • •
• • • • •
No payment may be obered or paid to individuals to compensate merely for the time spent in attending events/meetings. Reasonable Hospitality: Inventiva may pay for costs associated with the HCP attending the Event. Hospitality extended in connection with Events must be: limited to travel, meals, accommodation and genuine registration fees; not exceed the monetary thresholds of the relevant jurisdiction; where an Event takes place in a country other than the country in which the HCP is admitted to practice, the monetary threshold for meals (food and beverages) set in the country where the Event takes place (the "Host Country Principle") shall prevail. only be extended to persons who qualify as participants in their own right. o In exceptional cases of established health needs (e.g. disability or injury), the travel, meals, accommodation and genuine registration fee costs of an accompanying person can be reimbursed within the same parameters. “reasonable” in level and strictly limited to the main purpose of the Event; “Reasonable” means moderate in value. as a general rule, the Hospitality provided must not exceed what those individuals would normally be prepared to pay for themselves; strictly limited to the main purpose of Event, of secondary consideration and not out of proportion to the occasion Inventiva may only pay for costs associated with Reasonable Hospitality that comply with Applicable Laws and are in line with the Inventiva Restrictions on Hospitality hospitality provided in connection with Events may not include the sponsoring or organising of entertainment, sporting, or leisure events.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
V.
Bussiness Travel, Accommodation And Meals
Inventiva may from time to time in connection with Consulting Agreements, research arrangements and certain educational activities, provide modest accommodations, travel, and Meals to HCPs to facilitate appropriate meetings and interactions with HCPs. Individual countries may establish individual requirements regarding permissible values and circumstances in which modest accommodations, travel, and Meals may be provided to HCPs. Inventiva Personnel must ensure that any proposed interaction, activity, or arrangement does not breach Applicable Laws. Please refer to Inventiva’s country-specific guidance and requirements, available on Sharepoint at Compliance - Policies & Training - Tous les documents for further information regarding national requirements of individual countries. Personnel should consult with the Inventiva Compliance Officer on any question about such activity.
Business Travel, Accommodation And Meals: Minimum Standards
Any provision of accommodations, travel, and Meals must meet the following requirements and be otherwise permitted by Applicable Laws and Inventiva policies: • • • • • •
there must be a documented and approved legitimate and bona fide business purpose for the expense; any prior notification or authorization that is required by Competent Authorities must be provided and/or obtained in writing before the engagement; when interacting with HCPs, the location for such interaction must be conducive and appropriate to the purpose of the meeting; meetings that require significant travel for the attendees must only be undertaken where there is a legitimate purpose for conducting the meeting at such location instead of holding it where the majority of attendees are located; modest accommodation, travel, and Meal expenses directly incurred during the legitimate performance of authorized services to Inventiva may, on provision of documentary evidence, be paid or reimbursed by the Company; and expenses submitted for reimbursement by the HCP must be incurred by the HCP and be reasonable and incidental to the legitimate Services provided to Inventiva. o Unnecessary expenses such as lodging or Meals past or outside of the engagement are prohibited. o Moreover, the HCP is expected to arrive as close to the beginning of the engagement and leave as close to the end of the last engagement as can be reasonably expected.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Meals
Reasonable and occasional Meals may be provided as a courtesy to an HCP when incidental to a legitimate business purpose and in compliance with this Code. Meals may be provided by Inventiva representatives provided that: • •
• • •
• • • • •
the Meal is provided to the HCPs on an occasional basis only; the Meal is obered in conjunction with a bona fide informational presentation or discussion that provides a recognizable and legitimate business purpose: o the informational presentation must provide scientific or educational value, such as discussion of Products or disease states relevant to Inventiva Products, or, where permitted, other legitimate business discussions related to an Inventiva Product; and o the Meal is not in conjunction with an Entertainment or recreational event. the Meal is incidental to the informational presentation or scientific or business discussion and may not distract from or overshadow the focus of the business or educational discussion; the number of HCPs who consume the Meal is conducive to the presentation of such information; the Meal is modest as defined by local standards and the amount spent for the Meal does not exceed the monetary threshold value permitted by Applicable Laws in the country or region where the HCP is admitted to practice or in which the Meal is provided, and defined in Inventiva’s country-specific guidance and requirements, available on Sharepoint at inventiva Travel Guidelines_v02_2026.pdf - Tous les documents ; the Meal is limited to in-o_ce or in-hospital/clinic settings or in its nearest neighborhood (i.e. no “to go” meals); at least one Inventiva representative participates in the program or meeting during the Meal (either live or virtually); the Meal is provided to HCPs who attend the majority of the informational or educational component of the meeting; under no circumstances should an HCP's spouse or other guest be present during the meal, even if the HCP or guest agrees to pay for the cost of the meal, unless the spouse or guest is otherwise qualified to attend and is invited in advance, where applicable; and the Meal is not provided in cash or in cash equivalents (e.g., gift certificates for restaurant), and shall not include food gifts (e.g., box of chocolates or cookies, fruit basket, bottle of wine etc).
Business Travel, Accommodation And Meals: Inventiva Restrictions
Permitted levels of hospitality vary country-by-country. Please refer to the relevant country-specific guidance for information regarding local requirements, including the definition of “reasonable” in the relevant jurisdiction and limits on hospitality. Country specific guidance is available on Sharepoint at: Compliance - Policies & Training - Tous les documents. If the requirements of two countries, e.g. the country where the HCP is admitted to practice and the country where the event takes place could apply, you must apply the most stringent of these rules.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
In the event that the country specific guidance does not cover the type of hospitality you wish to provide, or there is no guidance for the country in consideration, hospitality must be limited to the values established in the table below. Travel : Train
1st class rates Economy for short & medium haul flights
Flight
Business for long haul flights (more than 6 hours) AND if the HCP is presenting at the event the next morning
Car
Rental cars: only when justified by the length of stay and geographic area
Taxi
Only for transfers to or from the airport to the hotel or to the event
Meals (food and beverages)*
No alcoholic beverages outside of meals
Breakfast
Maximum of 15€ including tax and tips if not included in accommodation
Lunch
Maximum of 40€ per meal, including tax and tips
Dinner
Maximum of 60€ per meal, including tax and tips
Snacks
Maximum of 10€ per snack including tax and tips limited 2 snacks per day
Accommodation* (includes breakfast)
Must be absolutely necessary, related to and focus on the Event purpose Shall not cover a period of stay beyond the official duration of the Event Shall not be at top category or luxury hotels Maximum 200€ per night, tax included
Actual registration fees
Linked to the Event and local regulations
*Amounts include all taxes
VI. Gifts, Non-Educational Items, Entertainment And Recreation
The giving or receiving of gifts, invitations and hospitality may be perceived or construed negatively and may negatively impact the reputation of the individual and Inventiva. Interactions with HCPs must be geared towards educating and informing HCPs about diseases and, where relevant, Inventiva research and development programs. Relationships with HCPs must remain professional and must not convey the appearance of impropriety. Applicable Laws limit or prohibit the provision of items of value to HCPs out of concern that such items will impact independent medical decision-making and unduly influence HCP prescribing or referral decisions. Can Inventiva Personnel offer or provide Gifts, non-Educational Items, Entertainment, or recreation to HCPs? No, Inventiva Personnel may not offer, arrange for, or provide any Gifts, non-Educational Items, Entertainment, recreational, or leisure items to any HCP in any circumstances. Examples of prohibited items include, but are not limited to the following:
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • • • • • • • •
cash or cash equivalents (e.g., gift cards) any transfers of value to HCPs that could be perceived as a Gift non-Educational Items (e.g., pens, note pads, mugs, etc.) medical equipment and supplies (e.g., stethoscopes, tongue depressors, ice packs, etc.)1 personal items (e.g., birthday gifts, flowers, wine, concert tickets, etc.) items with an independent value (e.g., DVD or CD player, flash drives, etc.) free services directly (or through a vendor) to any HCP with the intent of saving an HCP time or increasing profits or business for an HCP business referrals Promotional aids — i.e., non-monetary items given for a promotional purpose
These Items shall not be offered to HCPs/HCOs or members of their staff, even if they are of minimal value, accompanied by patient or physician Educational Items, with or without Inventiva or product logo.
VII. Informational or Educational Materials and Items of Medical Utility Can we provide Informational or Educational Materials ? Yes, BUT the materials must be: • • •
modest in value; directly relevant to the practice of medicine or pharmacy; and directly beneficial to the care of patients.
Can we provide Items of Medical Utility ? Yes, BUT the Items must: • • •
be modest in value; be aimed directly at the education of HCPs and patient care; and not obset the routine business practices of those who receive them.
In addition, the Informational or Educational Materials and Items of Medical Utility provided must: • •
not constitute a circumvention of the prohibition on Gifts set forth in this Code, not constitute an inducement to recommend and/or prescribe, purchase, supply, sell, or administer a Product.
NOTE: This does not include clinical trial equipment provided to support clinical trials or clinical investigations when provided consistent with applicable law, Inventiva’s applicable policies and procedures and supported by a related written agreement. 1
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • • • •
be modest in value: less than 30 euros TVA cumulative on an annual basis or as otherwise defined in Inventiva’s country-specific guidance and requirements available on Sharepoint at: Compliance - Policies & Training - Tous les documents ; not be given in the form of cash or cash equivalents; be obered only on an occasional basis; not be product branded, unless the Product name is essential for the correct use of the material or item by the patient. Informational or Educational Materials and Items of Medical Utility may include the Inventiva name; not have any independent value to the HCP outside of their professional responsibilities.
Examples of permissible Informational or Educational Items include: • • • • •
medical textbooks; examination room anatomical models; journal subscriptions; copies of clinical treatment guidelines; and other written informational materials.
VIII. Medical Samples
Can We Provide Directly Or Indirectly Samples To Hcps?
Samples shall not, in principle, be provided to HCPs, except on an exceptional basis and in accordance with the conditions set forth below. Samples must not be given as an inducement to recommend and/or prescribe, purchase, supply, sell or administer specific Products, and must not be given for the sole purpose of treating patients. (1) BEFORE Inventiva has a duly authorized product on the market Inventiva may NOT provide samples to HCPs. (2) AFTER Inventiva has a duly authorized product on the market But only if the Samples meet ALL of the following conditions: • • • • •
The Inventiva Product for which Samples are supplied is authorized in the country of distribution The Samples are provided to an HCPs to enable them to familiarise themselves with Inventiva’s authorized product and acquire experience dealing with it Maximum of 4 samples per product, per HCP, per year Only take place during the first 2 years after the HCP first requested Samples (the "4x2" standard) On an exceptional basis, a longer period than 2 years may be permitted where required by local healthcare conditions and permitted by the applicable national code
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • • • • •
Only be given upon receipt of a dated and signed written request from an HCP authorized to prescribe such product Be no larger than the smallest package form of the medicinal product in the country of distribution Be marked “free medical sample - not for sale” & accompanied by a copy of the Summary of Product Characteristics Be recorded – Inventiva must maintain adequate systems of control and accountability for Samples distributed, including a record for each HCP of the names of persons receiving samples, dates on which Samples were provided, and the number and type of Samples distributed Not be provided directly by Inventiva to patients Be made in accordance with local law
IX. Donations, Grants and Sponsorship Inventiva Personnel must never: • •
solicit requests for Donations, Grants, Sponsorship, investigator-initiated studies or other similar support; directly respond to Unsolicited requests for Donations, Grants, Sponsorship, investigatorinitiated studies or other similar support to HCPs, HCOs or POs.
Inventiva Personnel must submit any Unsolicited requests for Donations, Grants, Sponsorship, investigator-initiated studies or other similar support to Inventiva Medical Affairs for review and approval. Only Inventiva Medical Affairs may respond to such Unsolicited requests for Donations, Grants, Sponsorship, investigator-initiated studies or other similar in accordance with Inventiva Policies on Funding, related SOPs and Guidelines.
X.
Communications With HCPs
General Rules Regarding Communications With Hcps All Inventiva Personnel are responsible for communicating in a truthful and ethical manner with HCPs. Inventiva Products that have not been authorized in the respective jurisdiction may not be promoted in such jurisdiction. This includes promotion to the general public and to HCPs. Information may, however, be exchanged with HCPs either: (1) In response to a related Unsolicited request from the HCP, within the context of a clinical investigation, or (2) Within the context of scientific exchange. Communications with HCPs regarding Inventiva Products must comply with all Applicable Laws and Inventiva policies, including, but not limited to Inventiva’s Promotional Materials Review Policy, and fulfill the following requirements:
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • • • • •
be accurate, balanced, fair, objective, up to date, and su_ciently complete to enable the HCP to form their own opinion of the therapeutic value of the Product concerned; present material facts about the Product being discussed, including facts about negative clinical outcomes that could result from participation in a clinical trial or other use (e.g., data cannot be omitted or selectively chosen); be adequately substantiated by clinical data; for an approved product, be consistent with the scope of relevant marketing authorization granted by the European Commission, Competent Authorities or other regulatory authorities, and the clinical data relied upon by these regulatory authorities to grant an authorization; be appropriate for the targeted audience; be approved in accordance with the Promotional Materials Review Policy for use or distribution.
Communications: Prohibited Activities Unless otherwise approved by an Authorized Officer, Inventiva Personnel must never: •
• • • • •
distribute or use materials or messages that have not been approved in writing by in accordance with Inventiva’s Disclosure Policy, Promotional Materials Review Policy and other policies (e.g., posting messages containing Inventiva business or confidential information to social media accounts); alter or modify materials approved in accordance with such policies, such as by highlighting, deleting, editing or adding notes or other material; provide medical advice to a patient; interact with patients unless specifically authorized in writing by Medical Abairs to do so and trained as needed; engage in pre-authorization promotion (e.g., represent in a promotional context that an investigational Product or pipeline Product is safe or ebective for the purposes for which it is not yet authorized or is still under investigation); solicit, prompt, encourage, suggest, or otherwise cause an HCP to submit a request for oblabel information, ask a question about an ob-label use, or enter into a discussion about oblabel information.
Unsolicited Requests For Off-Label Information : Questions About Unapproved Products And Uses Inventiva Personnel must never directly respond to Unsolicited requests for information for Off-Label Information from HCPs. If Inventiva Personnel receives an Unsolicited request from an HCP for off-label information, Inventiva Personnel must submit the Unsolicited request to Medical Affairs for response. Examples of such requests may include: • •
requests for disease information that go beyond the disease definition used in Inventiva’s clinical trials; questions about clinical trial design or data from Inventiva’s clinical trials or interpretation thereof; and
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• •
questions about unauthorized Products or uses including investigational or pipeline Products; Questions about uses or variations to existing marketing authorizations that have not yet been authorized in a particular jurisdiction, as applicable.
Only Medical Affairs may respond to Unsolicited request. When responding to such requests, Medical Affairs must assure that: • •
No sales representatives are involved or participate in the discussion or exchange; The information shared in response to an Unsolicited request or question is: o limited to objective, factual, balanced, su_ciently complete to enable the HCP to form their own opinion of the therapeutic value of the Product concerned, up-to-date information that is substantiated by scientific data, including: factual and objective presentation of the results of clinical trials; reprints of peer-reviewed articles and scientific conference posters that have been approved for dissemination in accordance with Company procedures o non-promotional and should not include or make reference to Promotional Materials; o tailored to answer or address only the specific Unsolicited question or request received and does not go beyond the information needed to answer the question or request; o directed only to the specific individual who requested the information as a private, individual communication; and o a prominent statement notifying the recipient that the Products or the use addressed in the response provided, as applicable, has not been authorized by the competent authorities in relevant jurisdiction, as applicable; o All responses to Unsolicited requests must be in writing and documented.
Scientific Information Scientific information relating to unauthorized Products or uses, including an investigational Product, may be shared between Inventiva and HCPs who act as investigators involved in clinical trials in relation to which Inventiva is acting as the sponsor, provided that the information: • • • • • •
clearly discloses the investigational status of the Product (e.g., it is under investigation and is not approved by the relevant competent authorities, and it is not a “new treatment” or “new medicinal product”); is communicated in an accurate, balanced, fair, objective, up to date, and su_ciently complete to enable the HCP to form their own opinion of the information that is provided in relation to the investigational Product concerned; does not draw any conclusions suggesting that the Product is safe or ebective for any investigational use; provides a fair and balanced disclosure of safety data and risk information; is not false or misleading in any respect, but truthfully and accurately presents all material information; is non-promotional in intent, tone, and context;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Examples of this type of scientific exchange are: • • • •
presentations and discussions of study protocols with investigators and study teams; in so far as is permitted by Applicable Laws, publication of results from scientific studies in peer reviewed journals; scientific presentations of clinical study results within the context of scientific exchange; exchanges of medical and scientific information within the context of Advisory and Consulting activities provided by HCPs within the context of activities led by medical or scientific departments.
Adverse Events & Product Complaint Reporting Inventiva is required to report adverse event information associated with the use of Products to Competent Authorities in compliance with Applicable Laws. If, during the course of any interaction with an HCP, any Inventiva Personnel becomes aware of adverse events or receive a complaint involving a Product, they must report this information in writing consistent with Inventiva’s policies for Reporting Adverse Events and handling complaints. Other Communications All Unsolicited requests from HCPs about potential Consulting Agreements shall be forwarded to Medical Affairs for their review. No Inventiva Personnel shall offer, promise, solicit, or encourage HCPs to request such engagements. XI. Transparency Inventiva is required by Applicable Laws governing transparency to track and report certain payments or other transfers of value to HCPs. All Inventiva Personnel must comply with this obligation and track and submit all applicable payments or transfers of value accurately and in a timely manner, including those activities and expenses managed by a third party service provider on behalf of Inventiva.
XII. Compliance And Procedures
To support compliance with this Code, Inventiva is implementing training and review as part of our broader compliance programs overseen by the Legal Department. The Inventiva Compliance Officer is a person to whom you may address any questions or concerns related to this Code or any other matters relating to legal or regulatory compliance. Please note that relationships with HCOs, HCPs and POs are also governed by other Inventiva rules and procedures, in particular rules on Anti-Bribery, Code of Business Conduct and Data Protection. Please refer to Inventiva's policies on these issues for further details. If you have a question or concern about an activity or conduct that could potentially be in breach of law or Inventiva policy, contact the Inventiva Compliance Officer.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Adopted by the Board of Directors on June 15, 2020
Introduction The Board of Directors (the “Board”) of Inventiva S.A. (together with any subsidiaries that may exist from time to time, the “Company”) has adopted this Code of Business Conduct and Ethics (the “Code”) to aid directors, officers, and all employees of the Company in making ethical and legal decisions when conducting the Company’s business and to cause the Company to comply with applicable rules and regulations of all French, U.S. and other governmental entities and other private and public regulatory agencies to which the Company is subject, including The Nasdaq Stock Market, Euronext Paris, and any other exchanges on which the Company’s securities may be listed. The Board is responsible for administering the Code. The Board has delegated day-to-day responsibility for administering and interpreting the Code to the Company’s Compliance Officer, or in the absence of a Compliance Officer, to the Company’s General Counsel (the “Compliance Officer”), who has been appointed as the Company’s compliance officer under this Code. One of the Company’s most valuable assets is its reputation for integrity, professionalism and fairness. We must strive to foster a culture of accountability, and our commitment to the highest level of ethical conduct should be reflected in all of the Company’s business activities. All employees, officers and directors must conduct themselves according to the language and spirit of this Code, exercise reasonable judgment when conducting business and seek to avoid even the appearance of improper behavior. Even well-intentioned actions that violate the law or this Code may result in negative consequences for the Company and the individuals involved. While covering a wide range of business practices and procedures, the standards set forth in this Code cannot and do not cover every issue that may arise, or every situation where ethical decisions must be made, but rather set forth key guiding principles that represent Company policies and establish certain conditions for employment at the Company. From time to time, we may adopt additional policies and procedures with which our employees, officers and directors are expected to comply, if applicable to them. It is the responsibility of each employee to apply common sense, together with his or her own highest personal ethical standards, in making business decisions where there is no stated guideline in the Code. All employees, officers and directors generally have other legal and contractual obligations to the Company. This Code is not intended to reduce or limit the other obligations that any such individual may have to the Company. Instead, the standards in this Code should be viewed as minimum standards that we expect all employees, officers and directors to adhere to in the conduct of our business. Actions by members of your family, significant others or other persons who live in your household (referred to in the Code as “family members”) also may potentially result in ethical issues to the extent that they involve the Company’s business. For example, acceptance of inappropriate gifts
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
by a family member from one of our commercial partners could create a conflict of interest and result in a Code violation attributable to you. Consequently, in complying with the Code, you should consider not only your own conduct, but also that of your family members, significant others and other persons who live in your household. Employees are notified that this Code has been approved by the Company’s Works Council, and accordingly shall be integrated as part of the internal rules (règlement intérieur) of the Company. In addition, all directors, executive officers and employees must certify in writing that they have read and intend to comply with this Code and complete the acknowledgment attached hereto as Annex A. References in the Code to employees are intended to cover executive officers and, as applicable, directors. You should not hesitate to ask questions about whether any conduct may violate the Code, voice concerns or clarify areas that are unclear. Questions regarding the Code should be directed to your supervisor or the Compliance Officer (as described in Section 17 below).
Honest and Ethical Conduct
Legal Compliance
It is the Company’s policy to promote high standards of integrity by conducting our affairs in an honest and ethical manner. The integrity and reputation of the Company depends on the honesty, fairness and integrity brought to the job by each person associated with us. Unyielding personal integrity is the foundation of corporate integrity. Obeying the law, both in letter and in spirit, is the foundation of this Code. The Company seeks to conduct its business in compliance with all applicable laws, rules and regulations in the jurisdictions where it does business. Our success depends upon each employee operating within legal guidelines and cooperating with local, national and international authorities. We expect employees to understand the legal and regulatory requirements applicable to their business units and areas of responsibility. We hold or provide access to periodic training sessions or relevant education in order to ensure that all employees comply with the relevant laws, rules and regulations associated with their employment, including laws prohibiting insider trading (which are discussed in further detail in Section 3 below). While we do not expect you to memorize every detail of these laws, rules and regulations, we want you to be aware of and understand the main laws that apply to your work and to be able to determine when to seek advice from others. If you do have a question in the area of legal compliance, it is important that you not hesitate to seek answers from your supervisor or the Compliance Officer (as described in Section 17 below). Disregard of the law will not be tolerated. Violation of domestic or foreign laws, rules and regulations may subject an individual, as well as the Company, to civil and/or criminal penalties. You should be aware that conduct and records, including emails, are subject to internal and external audits in accordance with applicable law and to discovery by third parties in the event of a government investigation or civil litigation. It is in everyone’s best interests to know and comply with our legal and ethical obligations.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Insider Trading
All material and non-public information about the Company, its subsidiaries or about companies with which we do business is considered confidential information. Using non-public Company information in connection with buying or selling securities, or providing a family member or any other person with a “tip,” is illegal. Employees must exercise the utmost care when handling material inside information. We have adopted a separate Insider Trading Policy which also forms part of the internal rules (règlement intérieur of the Company with which you will be expected to comply as a condition of your employment with the Company. You should consult our Insider Trading Policy for more specific information on the definition of “inside/material and non-public” information and on buying and selling our securities or securities of companies with which we do business.
Regulatory Compliance
International Business Laws
The Company’s business is subject to, or may in the future be subject to, a number of legal and regulatory requirements, including standards related to ethical research procedures and proper scientific conduct. We expect employees to comply with all such requirements. Our employees are expected to comply with the applicable laws in all countries to which they travel, in which they operate and where we otherwise do business, including laws prohibiting bribery, corruption or the conduct of business with specified individuals, companies or countries. In addition, we expect employees to comply with all laws, rules and regulations of France, the United States and of each other jurisdiction where the Company carries on business governing the conduct of business by its citizens and corporations outside France, the United States and each such other jurisdiction. These laws, rules and regulations, which extend to all our activities outside France and the United States, include: •
Anti-Corruption and Anti-Bribery laws, addressed in further detail in the Company’s AntiCorruption Policy which has been adopted by the Company and forms part of the internal rules (règlement intérieur) and including the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits directly or indirectly giving anything of value to a government oIcial to obtain or retain business or favorable treatment, and requires the maintenance of accurate books of account, with all company transactions being properly recorded; Article 435-1 et seq. of the French Criminal Code concerning international corruption and Articles 432-11 et seq., 433-1 et seq., and Article 445-1 et seq. of the French Criminal Code concerning domestic corruption; and other applicable anti-corruption, anti-bribery, or money laundering laws or regulations in any other relevant jurisdictions;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
•
• •
Embargoes and Trade Sanctions, which generally prohibit companies, their subsidiaries and their employees from doing business with, or traveling to, certain countries subject to sanctions, as well as specific companies and individuals identified on lists published by governmental authorities; Export Controls, which restrict exports and re-exports of goods, software and technology to many countries, and prohibit transfers to prohibited persons and entities; and Anti-Boycott Regulations and Blocking Statutes, which prohibit companies and their employees from taking any action that has the eWect of furthering or supporting an unauthorized restrictive trade practice or boycott imposed by another country.
If you have a question as to whether an activity is restricted or prohibited, seek assistance before taking any action, including giving any verbal assurances that might be regulated by international laws.
Antitrust and Competition
Antitrust and competition laws are designed to protect the competitive process. These laws are based on the premise that the public interest is best served by vigorous competition and will suffer from illegal agreements or collusion among competitors. Antitrust and competition laws generally prohibit: • • •
agreements, formal or informal, with competitors that harm competition or customers, including price fixing and allocations of customers, territories or contracts; agreements, formal or informal, that establish or fix the price at which a customer may resell a product; and the acquisition or maintenance of a monopoly or attempted monopoly through anti-competitive conduct.
Certain kinds of information, such as pricing, production and inventory, should not be exchanged with competitors, regardless of how innocent or casual the exchange may be and regardless of the setting, whether business or social. Antitrust and competition laws impose severe penalties for certain types of violations, including criminal penalties and potential fines and damages of millions of dollars, which may be tripled under certain circumstances. Understanding the requirements of antitrust and unfair competition laws of the various jurisdictions where we do business can be difficult, and you are urged to seek assistance from your supervisor or the Compliance Officer whenever you have a question relating to these laws.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Environmental Compliance
Conflicts of Interest
It is our policy to conduct our business in an environmentally responsible way that minimizes environmental impacts. We are committed to minimizing and, if practicable, eliminating the use of any substance or material that may cause environmental damage, reducing waste generation and disposing of all waste through safe and responsible methods, minimizing environmental risks by employing safe technologies and operating procedures, and being prepared to respond appropriately to accidents and emergencies. We respect the rights of our employees to manage their personal affairs and investments and do not wish to impinge on their personal lives. At the same time, employees should avoid conflicts of interest that occur when their personal interests may interfere in any way with the performance of their duties or the best interests of the Company. A “conflict of interest” occurs when an employee’s personal interest interferes in any way, or even appears to interfere, with the Company’s interests. A conflicting personal interest could result from an expectation of personal gain now or in the future or from a need to satisfy a prior or concurrent personal obligation. We expect our employees to be free from influences that conflict with the best interests of the Company or might deprive the Company of their undivided loyalty in business dealings. Even the appearance of a conflict of interest where none actually exists can be damaging and should be avoided. Whether or not a conflict of interest exists or will exist can be unclear. Conflicts of interest are prohibited unless specifically authorized as described below. If you have any questions about a potential conflict or if you become aware of an actual or potential conflict, and you are not an officer or director of the Company, you should discuss the matter with your supervisor or the Compliance Officer. Supervisors may not authorize conflict of interest matters or make determinations as to whether a problematic conflict of interest exists without first seeking the approval of the Compliance Officer and providing the Compliance Officer with a written description of the activity. If the supervisor is involved in the potential or actual conflict, you should discuss the matter directly with the Compliance Officer. Officers and directors must seek any authorizations and determinations from the Audit Committee (the “Audit Committee”) of the Board, depending on the nature of the conflict of interest. Factors that may be considered in evaluating a potential conflict of interest are, among others: • • • • • •
whether it may interfere with the employee’s job performance, responsibilities or morale; whether the employee has access to confidential information; whether it may interfere with the job performance, responsibilities or morale of others within the organization; any potential adverse or beneficial impact on the Company’s business; any potential adverse or beneficial impact on the Company’s relationships with its customers, suppliers or other service providers; whether it would enhance or support a competitor’s position;
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
• • •
the extent to which it would result in financial or other benefit (direct or indirect) to the employee; the extent to which it would result in financial or other benefit (direct or indirect) to one of the Company’s customers, suppliers or other service providers; and the extent to which it would appear improper to an outside observer.
Although no list can include every possible situation in which a conflict of interest could arise, the following are examples of situations that may, depending on the facts and circumstances, involve problematic conflicts of interests: • Working in any capacity for, including service on the board of, a competitor, customer or supplier or other service provider while employed by the Company. Activity that enhances or supports the position of a competitor to the detriment of the Company is prohibited, including employment by or service on the board of a competitor. Employment by or service on the board of a customer, supplier or other service provider is generally discouraged. • Owning, directly or indirectly, a significant financial interest in any entity that does business, seeks to do business or competes with us. In addition to the factors described above, persons evaluating ownership in other entities for conflicts of interest will consider the size and nature of the investment, the nature of the relationship between the other entity and the Company, the employee’s access to confidential information and the employee’s ability to influence the Company’s decisions. • Soliciting or accepting gifts, favors, or any other benefit or benefits (including reputational), loans or preferential treatment from any person or entity that does business or seeks to do business with us. See Section 12 for further discussion of the issues involved in this type of conflict. • Soliciting contributions for any charity or for any political candidate from any person or entity that does business or seeks to do business with us. • Taking personal advantage of corporate opportunities. See Section 9 for further discussion of the issues involved in this type of conflict. • Conducting Company business transactions with your family member or a business in which you have a significant financial interest. Material related party transactions approved by the Board or a committee thereof and involving any executive oIcer or director will be publicly disclosed as required by applicable French and U.S. laws and regulations.
Loans to, or guarantees of obligations of, employees or their family members by the Company could constitute an improper personal benefit to the recipients of these loans or guarantees, depending on the facts and circumstances. Some loans are expressly prohibited by U.S. and French law and applicable law requires that the Board approve all loans and guarantees to employees.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
In addition, we have adopted the Related Person Transactions Policy to set forth the procedures applicable to transactions involving the Company and its directors, officers, significant shareholders and their family members. For more information on our Related Person Transactions Policy, please contact the Compliance Officer.
Corporate Opportunities
You may not take personal advantage of opportunities for the Company that are presented to you or discovered by you as a result of your position with us or through your use of corporate property or information, unless authorized by your supervisor, the Compliance Officer, the Board or a committee thereof, as described in Section 8. Even opportunities that are acquired privately by you may be questionable if they are related to our existing or proposed lines of business. Participation in an investment or outside business opportunity that is directly related to the Company’s lines of business must be pre-approved by the Board or a committee thereof. You may not use your position with the Company or any corporate property or information for improper personal gain, nor should you compete with the Company in any way, except as otherwise agreed to by the Company.
- Maintenance of Corporate Books, Records, Documents and Accounts; Financial Integrity; Public Reporting
The integrity of our records and public disclosure depends upon the validity, reliability, accuracy and completeness of the information supporting the entries to our books of account. Therefore, our corporate and business records should be completed accurately and honestly. The making of false, artificial or misleading entries, whether they relate to financial results or test results, is strictly prohibited. Our records serve as a basis for managing our business and are important in meeting our obligations to customers, suppliers, creditors, employees and others with whom we do business. As a result, it is important that our books, records and accounts accurately and fairly reflect, in reasonable detail, our assets, liabilities, revenues, costs and expenses, as well as all transactions and changes in assets and liabilities. We require that: •
• •
• •
no entry be made in our books and records that intentionally hides or disguises the nature of any transaction or of any of our liabilities or misclassifies any transactions as to accounts or accounting periods; transactions be supported by appropriate documentation; the terms of sales and other commercial transactions be reflected accurately in the documentation for those transactions and all such documentation be reflected accurately in our books and records; employees comply with our system of internal controls; and no cash or other assets be maintained for any purpose in any unrecorded or “oW-the-books” fund.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Our accounting records are also relied upon to produce reports for our management, shareholders and creditors, as well as for governmental agencies. In particular, we rely upon our accounting and other business and corporate records in preparing the reports and documents we file with or submit to the French Autorité des Marchés Financiers (“AMF”) or the U.S. Securities and Exchange Commission (“SEC”), and in our other public communications. French and U.S. securities laws require that these reports provide fair, accurate, timely and understandable disclosure and fairly present our financial condition and results of operations. Employees who collect, provide or analyze information for or otherwise contribute in any way in preparing or verifying these reports should strive to ensure that our financial disclosure is accurate and transparent and that our reports contain all of the information about the Company that would be important to enable shareholders and potential investors to assess the soundness and risks of our business and finances and the quality and integrity of our accounting and disclosures. In addition: •
•
•
no employee may take or authorize any action that would intentionally cause our financial records or financial disclosure to fail to comply with generally accepted accounting principles, the rules and regulations of the AMF or the SEC or other applicable laws, rules and regulations; all employees must cooperate fully with our Accounting Department, as well as our independent statutory auditors and legal counsel, respond to their questions with candor and provide them with complete and accurate information to help ensure that our books and records, as well as our reports filed with the AMF or the SEC, are accurate and complete; and no employee should knowingly make (or cause or encourage any other person to make) any false or misleading statement in any of our reports filed with the AMF or the SEC or knowingly omit (or cause or encourage any other person to omit) any information necessary to make the disclosure in any of our reports accurate in all material respects.
Any employee who becomes aware of any departure from these standards should report his or her knowledge promptly to a supervisor, the Compliance OIcer, the Audit Committee or one of the other compliance resources described in Section 17.
- Fair Dealing
We strive to outperform our competition fairly and honestly through superior performance and not through unethical or illegal business practices. Acquiring proprietary information from others through improper means, possessing trade secret information that was improperly obtained, or inducing improper disclosure of confidential information from past or present employees of other companies is prohibited, even if motivated by an intention to advance our interests. If information is obtained by mistake that may constitute a trade secret or other confidential information of another business, or if you have any questions about the legality of proposed information gathering, you must consult your supervisor or the Compliance Officer, as further described in Section 17.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Accordingly, it is the Company’s policy that you must endeavor to deal ethically, fairly and lawfully with the Company’s customers, commercial partners, suppliers, competitors and anyone else with whom you have contact in the course of performing your job in all business dealings on the Company’s behalf. Employees involved in procurement have a special responsibility to adhere to principles of fair competition in the purchase of products and services by selecting suppliers based exclusively on normal commercial considerations, such as quality, cost, availability, service and reputation, and not on the receipt of special favors.
- Bribes, Kickbacks and Other Improper Payments
No bribes, kickbacks or other improper payments, transfers or receipts in any form shall be made, directly or indirectly, to or for anyone for the purpose of obtaining or retaining business or obtaining any other favorable action. Occasional business gifts to and entertainment of nongovernment employees in connection with business discussions or the development of business relationships are generally deemed appropriate in the conduct of Company business, provided that these are infrequent and their value is modest. Gifts or entertainment in any form that would likely result in a feeling or expectation of personal obligation should not be extended or accepted. All employees, officers and directors are directed to the Company’s Anti-Corruption Policy for additional guidance regarding business gifts and entertainment. Further, practices that are acceptable in commercial business environments may be against the law or applicable policies governing government employees. Therefore, no gifts or business entertainment of any kind may be given to any government employee, except in strict compliance with the Company’s AntiCorruption Policy.
- Protection and Proper Use of Company Assets
Loss, theft and misuse of the Company’s assets has a direct impact on the Company’s business and its profitability. Protecting Company assets against loss, theft or other misuse is the responsibility of every employee. Employees are expected to take particular care in protecting Company assets that are entrusted to their care. Employees are also expected to take steps to ensure that the Company’s assets are only used for legitimate business purposes.
- Confidentiality
One of our most important assets is our confidential information. As an employee of the Company, you may learn of information about the Company that is confidential and proprietary. You also may learn of information before that information is released to the general public. Employees who have received or have access to confidential information should take care to keep this information confidential. Protecting this information plays an important role in the Company’s continued growth and success. Confidential information includes non-public information that might be of use to competitors or harmful to the Company or its suppliers, vendors or partners if disclosed, such as business,
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
marketing and service plans, financial information, product development, scientific data, manufacturing, laboratory results, designs, databases, customer lists, pricing strategies, personnel data, personally identifiable information pertaining to our employees, patients or other individuals (including, for example, names, addresses, telephone numbers and social security numbers), and similar types of information provided to us by our customers, suppliers and partners. This information may be protected by patent, trademark, copyright and trade secret laws. Employees may not disclose or distribute the Company’s confidential information, except when disclosure is authorized by the Company or required by applicable law, rule or regulation. Employees shall use confidential information solely for legitimate business purposes. Employees must return all of the Company’s confidential and/or proprietary information in their possession to the Company when they cease to be employed by, or to otherwise serve, the Company. Unauthorized use or distribution of proprietary information violates Company policy and could be illegal. Such use or distribution could result in negative consequences for both the Company and the individuals involved, including potential legal and disciplinary actions. In addition, because we interact with other companies and organizations, there may be times when you learn confidential information about other companies before that information has been made available to the public. You must treat this information in the same manner as you are required to treat our confidential and proprietary information. There may even be times when you must treat as confidential the fact that we have an interest in, or are involved with, another company. This policy requires you to refrain from discussing confidential or proprietary information with outsiders and even with other Company employees, unless those fellow employees have a legitimate need to know the information in order to perform their job duties. Unauthorized use or distribution of this information could also be illegal and result in civil liability and/or criminal penalties. You are expected to keep confidential information and proprietary information confidential unless and until that information is released to the public through approved channels (usually through a press release, a filing with the AMF or the SEC or a formal communication from a member of senior management) as further described in Section 15. Every employee has a duty to refrain from disclosing to any person confidential or proprietary information about us or any other company learned in the course of employment with us, until that information is disclosed to the public through approved channels. You should also take care not to inadvertently disclose confidential information. Materials that contain confidential information, such as memos, notebooks, computer disks, mobile devices and laptop computers, should be stored securely. Except where expressly allowed under French or U.S. law, as applicable, unauthorized posting or discussion of any information concerning our business, information or prospects on the Internet is prohibited, including on Internet forums, message boards, social media sites, “chat rooms” or blogs, regardless of whether you use your own name
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
or a pseudonym. Be cautious when discussing sensitive information in public places like elevators, airports, restaurants and “quasi-public” areas within the Company. All Company emails, voicemails and other communications are presumed confidential and should not be forwarded or otherwise disseminated outside of the Company, except where required for legitimate business purposes. In addition to the above responsibilities, if you are handling information protected by any privacy policy published by us, then you must handle that information in accordance with the applicable policy.
- Public Disclosures; Media/Public Discussions
The Company is committed to providing its shareholders with information about its financial condition and results of operations as required by applicable French and U.S. securities laws. It is our policy that the reports and documents we file with or submit to the AMF or the SEC, and our earnings releases and similar public communications made by us, include fair, timely and understandable disclosure. Employees who are responsible for these filings and disclosures, including the Company’s principal executive, financial and accounting officers, must use reasonable judgment and perform their responsibilities honestly, ethically and objectively in order to ensure that this disclosure policy is fulfilled. It is our policy to disclose material information concerning the Company to the public only through specific limited channels to avoid inappropriate publicity and to ensure that all those with an interest in the Company will have equal access to information. All inquiries or calls from the press and financial analysts should be referred to the Company’s head of investor relations, the Company’s Chief Financial Officer or the Company’s Chief Executive Officer. We have designated our Chief Executive Officer, Chief Financial Officer and head of investor relations as our official spokespersons for questions concerning the financial performance, strategic direction or operating performance of the Company, and operational issues including research and development, regulatory developments, and sales and marketing. Unless a specific exception has been made by the Chief Executive Officer or Chief Financial Officer, these designees are the only persons who may communicate with the press on behalf of the Company.
- Waivers and Amendments
Any waiver of this Code for executive officers (including, where required by applicable laws, our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions) or directors may be authorized only by the Board, and will be disclosed as required by applicable French and U.S. laws, rules and regulations. Any waivers of the Code for other employees may be made by the Compliance Officer, the Board or, if permitted, a committee thereof. All amendments to the Code must be made in compliance with applicable laws, be approved by the Board or a committee thereof and, if applicable, must be promptly disclosed to the Company’s
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
shareholders in accordance with applicable French and United States securities laws and/or the rules and regulations of The Nasdaq Stock Market, Euronext Paris, or any other exchanges on which the Company’s securities may be listed.
- Compliance Standards and Procedures Compliance Resources To facilitate compliance with this Code, we have implemented a program of Code awareness, training and review that is part of our broader compliance programs overseen by our Compliance Officer. The Compliance Officer is a person to whom you can address any questions or concerns related to this Code or any other matters relating to legal or regulatory compliance. In addition to fielding questions or concerns with respect to potential violations of this Code or any other matters relating to legal or regulatory compliance, the Compliance Officer is responsible for: • • • • •
•
•
investigating possible violations of the Code; training new employees in Code policies; conducting annual training sessions to refresh employees’ familiarity with the Code; distributing copies of the Code annually via email to each employee with a reminder that each employee is responsible for reading, understanding and complying with the Code; updating the Code as needed and alerting employees to any updates, with appropriate approval of the Board, to reflect changes in the law, the Company’s operations and in recognized best practices; overseeing the Company’s compliance program and reporting to the Board or a committee thereof material matters that may arise relating to the Company’s legal and regulatory compliance eWorts; and otherwise promoting an atmosphere of responsible and ethical conduct.
Your most immediate resource for any matter related to the Code is your supervisor. He or she may have the information you need or may be able to refer the question to another appropriate source. There may, however, be times when you prefer not to go to your supervisor. In these instances, you should feel free to discuss your concern with the Compliance Officer. If you are uncomfortable speaking with the Compliance Officer because he or she works in your department or is one of your supervisors, please contact the Company’s Chief Executive Officer. Monitoring Compliance and Disciplinary Action The Code will be strictly enforced throughout the Company and violations will be dealt with immediately. The Company’s management, under the supervision of the Board or a committee thereof or, in the case of accounting, internal accounting controls, auditing or securities law matters, the Audit
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Committee, shall take reasonable steps from time to time to (i) monitor compliance with the Code and (ii) when appropriate, impose and enforce appropriate disciplinary measures for violations of the Code. Disciplinary measures for violations of the Code will be determined in the Company’s sole discretion and may include, but are not limited to, counseling, oral or written reprimands, warnings, suspension with or without pay, demotions and/or termination of employment. Violations of the Code that involve illegal behavior will be reported to the appropriate authorities. The Company’s management shall periodically report to the Board or a committee thereof on these compliance efforts including, without limitation, periodic reporting of alleged violations of the Code and the actions taken with respect to any such violation. Clarifying Questions and Concerns You are expected to act proactively by asking questions, seeking guidance and reporting suspected violations of the Code and other policies and procedures of the Company, as well as any violation or suspected violation of applicable law, rule or regulation arising in the conduct of the Company’s business or occurring on its property. If you encounter a situation or are considering a course of action and its appropriateness is unclear, discuss the matter promptly with your supervisor or the Compliance Officer; even the appearance of impropriety can be very damaging and should be avoided. Reporting Possible Violations If you are aware of a suspected or actual violation of Code standards or any law, rule or regulation applicable to the Company by others, you must bring the matter to the attention of the Company. You should consult our Whistleblower Policy for more information regarding how to report possible violations.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
ANNEX A
ACKNOWLEDGMENT OF RECEIPT AND REVIEW I_________________________, acknowledge that I have received and read a copy of the Code of Ethics and Business Conduct (the “Code”) of Inventiva S.A. I understand the contents of the Code and I hereby undertake to comply with the policies and procedures set out in the Code. I understand that I should approach my supervisor or the Company’s Compliance Officer if I have any questions about the Code generally. I understand that I should consult the Company’s Whistleblower Policy for more information about how to report suspected conflicts of interest or violations of the Code.
[NAME]
[PRINTED NAME]
[DATE] [To be signed and returned by each director, executive officer and employee to the Company’s Human Resources Department]
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
MAY 16, 2019
Purpose
One of Inventiva SA’s (“Inventiva”) core values is the need to operate with integrity, and Inventiva expects that all areas of its business be conducted in an honest and ethical way by all employees and third parties. Inventiva is committed to complying with all applicable anti-corruption laws and regulations, standards, controls and practices, and therefore has implemented this policy (the “Anti-Corruption Policy”) to ensure compliance with all anti-bribery and anti-corruption laws applicable where we do business (the “Anti-Bribery Laws”). These laws include, but are not limited to, the U.S. Foreign Corrupt Practices Act of 1977 as amended (the “FCPA”), the U.S. Travel Act, the U.S. Domestic Bribery Statute, Article 435-1 et seq. of the French Criminal Code concerning international corruption and Articles 432-11 et seq., 433-1 et seq., and Article 445-1 et seq. of the French Criminal Code concerning domestic corruption, the UK Bribery Act 2010, the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions and all other anti-corruption laws and s regulations applicable to Inventiva’s business anywhere in the world. This Anti-Corruption Policy applies to all directors, officers and employees of Inventiva and any of its subsidiaries. We also expect all persons with whom we do business, including our agents, consultants, representatives, lobbyists, suppliers/vendors, resellers, distributors, customs or other brokers, contractors, advisors, and other business partners, to comply with the principles contained in this policy. Please report all questions or concerns regarding this policy to Inventiva’s Compliance Officer, or if a Compliance Officer has not been appointed, to Inventiva’s General Counsel.
General Policy Statements
You may not promise, offer, provide, or authorize cash payments (such as bribes or kickbacks) or anything else of value directly or indirectly to any person to achieve an improper purpose related to Inventiva’s business. You may not request, agree to receive, or accept money or anything else of value from any person to achieve an improper purpose related to Inventiva’s business. You must comply with all of Inventiva’s internal controls, especially those designed to (i) ensure accurate and complete books and records or (ii) prevent corruption, self-dealing, embezzlement, fraud, money laundering, or other improper activities. There are no exceptions to this policy, even if our competitors engage in improper behavior or corruption is an accepted practice in a country where we operate. You must strictly follow this policy with respect to our business anywhere in the world.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Specific Anti-Bribery Prohibitions
This policy requires you to adhere to high ethical standards and to comply with all applicable laws in the course of performing services for Inventiva. Neither you nor Inventiva may promise, offer, provide, or authorize the provision of money (including bribes and kick-backs) or anything of value directly or indirectly to a government official, any employee, official, or representative of a stateowned or affiliated entity, political party, public international organization, nongovernmental organization, private company, or other persons anywhere in the world to achieve an improper purpose. “Improper purposes” means trying to obtain, retain, or direct regulatory approvals, contracts, business or other benefits, by: i. ii. iii. iv.
influencing any act or decision of the recipient in his/her o5cial capacity; inducing the recipient to do or omit to do any act in violation of his/her lawful duty; inducing the recipient to influence any act or decision of a government or instrumentality of a government, or securing any improper advantage.
The scope of “government officials” is very broad and includes (i) doctors, administrators, researchers, or other healthcare professionals employed by state-affiliated hospitals as well as (ii) individuals responsible for classifying our products as eligible for government-subsidized medical reimbursements. This policy prohibits you from providing bribes or other improper benefits to any person to achieve any improper purpose. For example, you may not provide a bribe or other improper benefit in exchange for i. ii. iii. iv. v. vi. vii. viii. ix.
the award of a contract, sponsorship opportunity, research grant, or other business; the issuance or renewal of a concession, license, or business, construction, or other permit or registration (including an export permit); a favorable government classification of our products; an impermissible reduction in duties or other taxes; the successful filing of a patent, trademark, or other intellectual property application; avoiding mandatory inspections; gaining access to environmental waste disposal sites; obtaining a favorable regulatory, environmental, or other inspection certificate; or securing a favorable court decision.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
A violation of this policy occurs even if the bribe is not successful. This means that the providing an improper payment or benefit to a recipient violates this policy even if the recipient does not grant any business or other advantage in return. In addition, the mere offer or promise of a bribe or other improper benefit violates this policy, even if the bribe or improper benefit is not given. All of the Anti-Bribery Laws apply irrespective of whether you use Inventiva funds or your personal funds to finance improper payments or other benefits. This policy also prohibits you from soliciting or accepting bribes, kickbacks, or other improper payments/benefits from Inventiva vendors or other persons in relation to our business. For instance, a violation of this policy will occur if you cause Inventiva to overpay a vendor and that vendor then shares all or a portion of that overpayment with you. Anti-Bribery Law violations typically involve circumstances that also result in violations of other laws, including those that address money laundering, embezzlement, fraud, export controls, and sanctions/embargoes. Guilty persons can face multiple charges based on the same set of facts.
Conflicts Of Interests/Relatives Of Officials
You are strongly encouraged to disclose any actual or potential conflicts of interest to Inventiva’s Compliance Officer. For example, you must notify the Compliance Officer if you are aware of any (i) Inventiva employee or contractor (or potential employee or contractor) who is a government official or customer (including doctors or other healthcare professionals) regulating or working with Inventiva or (ii) Inventiva vendor (or potential vendor), if they are wholly or partially owned by you, a member of your family, a personal friend, or other Inventiva employee/contractor. You are strongly encouraged to also notify Inventiva’s Compliance Officer if you become aware of any current or potential employee or contractor who is an immediate relative (parent, sibling, child, or spouse) of a government official or customer employee. Inventiva may not hire a relative of a government official or customer as an employee or contractor in exchange for a regulatory approval or business opportunity. Please note that persons who are related to government officials or customer employees will not be automatically disqualified from working for Inventiva. However, it is important that the Compliance Officer review their circumstances in advance to ensure that i. ii.
iii.
they are properly qualified to serve Inventiva; are not related to a person who will improperly award government approvals or any business to Inventiva or otherwise exert undue influence over matters relevant to Inventiva’s business; and local legal requirements (such as disclosures) are fulfilled.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Facilitating, Expediting Or Speed Payments
You may not provide any corrupt payments or benefits, including so-called grease, speed or facilitating payments to government officials in their personal capacity to expedite or secure routine government actions (collectively, “Facilitating Payments”). Please note that in some cases, government agencies may impose official fees that may be paid directly in the name of a governmental entity or enterprise itself, as set out in published fee schedules or other official documents. These official government fees can be paid to expedite passports, licenses, or other services, provided that they are deposited in the treasury of a government, an official government receipt is collected, and the expense is accurately recorded in Inventiva’s books. However, Facilitating Payments provided for the benefit of government officials in their personal capacity (i.e., are not deposited in an official treasury account belonging to a government) will violate this policy.
Accounting Requirements
Inventiva adheres to certain accounting requirements. Specifically, Inventiva must maintain books, records, and accounts, which, in reasonable detail, accurately and fairly reflect Inventiva’s transactions, expenses, and asset dispositions. Inventiva is also committed to maintaining a system of internal accounting controls to provide reasonable assurances that transactions are properly authorized by management, executed, and recorded. This means that you must comply with our internal controls and avoid unauthorized activities or expenses. Violations of the above accounting standards can occur if you conceal bribes or falsify other transactions or expenses, no matter how little the amount and even if they are not related to a bribe, in Inventiva’s ledgers or other records. Failure to comply with these accounting requirements can result in fines and penalties of hundreds of millions of dollars.
Intermediaries/Business Partners/Associated Persons
You may not provide bribes or other improper benefits directly or indirectly through third parties or associated persons anywhere in the world. This risk can arise in cases where Inventiva works with contract research organizations, key opinion leaders, clinical investigators, agents, consultants, representatives, lobbyists, suppliers/vendors, resellers, distributors, customs or other brokers, contractors, advisors, law/accounting firms, collaborators, or other business partners that interact with government officials, doctors/healthcare professionals at state hospitals, or customers in relation to our business (collectively “Intermediaries”). You and Inventiva can be held liable under the Anti-Bribery Laws even if you do not expressly authorize an Intermediary to engage in corruption, but they do so anyway. This can occur if you (i) have actual knowledge or a firm belief that an Intermediary will engage in corruption or
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
(ii) consciously disregard, deliberately ignore, or are willfully blind to the Intermediary’s corrupt or improper practices. As a result, Inventiva must understand the ownership, identity of key personnel, reputation, and role of its Intermediaries. Given these risks, you may not use or pay any Intermediary responsible for government or customer interactions unless you have first consulted Inventiva’s Compliance Officer and the Compliance Officer has approved the use of or payment to the Intermediary, and (ii) the Intermediary has executed a written agreement containing anti-corruption compliance clauses to the satisfaction of the Compliance Officer. You are responsible for (i) monitoring the performance of all Intermediaries to ensure that they do not engage in activities that raise Anti-Bribery Law concerns and (ii) ensuring that all payments to Intermediaries or other vendors are approved by Inventiva management in accordance with our internal procedures and are completely and accurately reported in our books and records. You are strongly encouraged to also notify the Compliance Officer if you learn of any Inventiva Intermediary or other contractor that (i) is owned or affiliated with a government or (ii) engages in corrupt or other improper practices. The Compliance Officer will assess how such relationships will need to be handled in compliance with applicable law.
Gifts & Hospitality
Gifts and hospitality are an area of potential anti-bribery concern. You must therefore ensure that only reasonably priced gifts, meals, entertainment, travel, and other benefits are provided, and that they are: • • • •
provided for non-corrupt business promotion or goodwill purposes, of reasonable, moderate value, made in the normal course of a business relationship, and in accordance with applicable laws and Inventiva’s policies on business expenses and relations with healthcare professionals.
You must also ensure that the provision of a gift or other benefit (irrespective of value) is authorized by local laws or policies that apply in the country where the recipient is located. Some countries impose express limits on the value of gifts/benefits that a recipient can accept; other countries ban such gifts/benefits altogether even if they have a nominal value and are given with no corrupt or improper intention. You must obtain the approval of the Compliance Officer prior to providing gifts, meals, travel benefits, and other hospitalities to employees, officials, or agents of any government, political party, state-owned entity, public international organization, or customer of Inventiva. The Compliance Officer will help you determine whether the provision of such benefits is permissible under the Anti-Bribery Laws. If the expense is approved, its value and business purpose must be
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
recorded accurately in Inventiva’s books. Cash gifts are strictly prohibited, as are gift cards or gift certificates that can easily be converted into cash. You must also notify our Compliance Officer if you learn that our Intermediaries provide gifts or other benefits to government officials with respect to our business.
Special Concerns In The Healthcare Sector
The healthcare sector has received significant attention with respect to anti-corruption concerns. Several leading companies in this industry have been the subject of investigations and other enforcement actions for violating Anti-Bribery Laws. In light of this risk, please note the following: • •
• •
•
•
Improper payments made in exchange for clinical trial permits, product approvals, or other government permits are strictly prohibited. Researchers, doctors, other healthcare professionals, or certain other individuals may be considered government o5cials for purposes of the Anti-Bribery Laws by virtue of their employment by government-a5liated hospitals, universities, laboratories, research institutions, or other organizations. Employees or o5cials of public international organizations such as the World Health Organization are considered as government o5cials for purposes of the Anti-Bribery Laws. In certain cases, private persons acting in an o5cial capacity (such as a prime contractor) on behalf of a government hospital or other health agency or a public international organization are considered as government o5cials. Special care must be exercised when Inventiva retains doctors, other healthcare professionals, key opinion leaders, or government o5cials as conference representatives, advisory board members, investigators, consultants, or contractors, especially if their employers are current or prospective customers or regulators of Inventiva’s business. Please ensure that these relationships comply with Inventiva’s policy on relations with healthcare professionals. Anti-corruption concerns can arise in the context of research grants or sponsorships provided by Inventiva to persons or organizations at the request of, or otherwise a5liated with, government o5cials. No grant may be used to confer a personal benefit on a healthcare professional, other government o5cial, or other person in exchange for regulatory approvals, business, or other improper advantages. Grant/sponsorship requests must be reviewed by the Compliance O5cer to ensure that appropriate anti-corruption standards are followed.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
- Violations And Consequences
A violation of this policy will result in appropriate disciplinary action, including demotion, reassignment, additional training, probation, suspension, or even termination of employment, office or contract. In addition, both Inventiva and you may be subject to substantial fines and penalties for violating the Anti-Bribery Laws. For example, in serious cases, even if you are a non-U.S. citizen, you may face imprisonment for up to five years for each FCPA anti-bribery violation and up to 20 years for each FCPA accounting violation. In addition, Inventiva may face suspension or debarment from government contracts, the loss of import/export privileges, and certain other consequences. These results can be devastating to our business.
- Obligations, Training And Materials You must: o Learn, understand, and comply with the requirements of this Policy; o Apply the requirements of this Policy in performing all job related responsibilities and activities; o Monitor compliance with this Policy by agents, consultants, distributors, sales representatives, joint venture partners and other third party representatives; o Maintain and retain any specific required evidence of compliance, such as receipts; and o Cooperate fully in any audit or investigation related to possible violations of this Policy.
Managers and supervisors have an additional responsibility to: o Ensure that every member of their team knows and understands this Policy; o Take a5rmative steps to prevent violations; o Establish proactive methods to determine if violations have occurred; and o Assure that any employee who reports a suspected violation is protected from retaliation. Regular and formal certification of compliance with the requirements of this Policy will be requested.
All personnel must undergo anti-corruption training provided by Inventiva. The attendees, nature, content, and frequency of that training will be determined by the Compliance Officer. We encourage all of our business partners to provide training to their personnel as well.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
- Status
This policy does not form part of any employment contract with you and may be amended at any time. This policy should be read in conjunction with Inventiva’s other policies and procedures.
- Certification
Please sign the certificate that appears in Attachment 1 after you have read this policy. Inventiva may require you to recertify your compliance with this policy on a periodic basis. If you are aware of any facts that contradict the content of our compliance certificate, please notify our Compliance Officer immediately.
- Reporting/Questions
You have an affirmative obligation to report all violations of this policy to the Compliance Officer as set forth in the Whistleblowing Policy.
- Date Of Enforceability
This Policy will be enforceable as from May 16, 2019.
Inventiva Pharma — Proprietary and Confidential | inventivapharma.com | 50 Rue de Dijon · 21121 Daix · France
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohort
Topline results of NATiV3 expected in Q4 2026
September investor conference participation and timing of H1 2026 financial results update
Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate and advanced fibrosis.
NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort. With the last patient having completed their final visit, all patients have completed the 72-week treatment period.
Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicines for launch and integrating cross-functional operations, Mr. Benecchi will lead Inventiva's operational readiness as the Company approaches its pivotal NATiV3 Phase 3 topline study results of lanifibranor, in MASH, expected in Q4 2026, and prepares for potential commercialization.
With a potential U.S. launch of lanifibranor, subject to regulatory approval, anticipated in 2028, Inventiva is strategically building the organization, infrastructure, and commercial capabilities needed to support a successful launch and long-term market adoption.
Andrew Obenshain, Chief Executive Officer, Inventiva: “This is a defining moment for Inventiva.
Number of Shares and Voting Rights
Statement of total voting rights and shares forming the company’s share capital on August 31, 2026 Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Market: Euronext Paris ISIN code / Mnemo: FR0013233012/ IVA
Web site: www.inventivapharma.com
DATE
NUMBER OF SHARES OUTSTANDING
TOTAL VOTING RIGHTS, GROSS1
TOTAL VOTING RIGHTS, NET2
31 August 2026
236 280 202
245 178 845
245 178 845
- The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
- The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
pg. 1
Number of Shares and Voting Rights
Statement of total voting rights and shares forming the company’s share capital on July 31, 2026 Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Market: Euronext Paris ISIN code / Mnemo: FR0013233012/ IVA
Web site: www.inventivapharma.com
DATE
NUMBER OF SHARES OUTSTANDING
TOTAL VOTING RIGHTS, GROSS1
TOTAL VOTING RIGHTS, NET2
31 July 2026
236 280 202
245 331 845
245 331 845
- The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
- The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
pg. 1
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026
Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the press release remains unchanged. As a result, the corrected version shall read as follows:
Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 2026, including its cash, cash equivalents and revenues.
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026
Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 2026, including its cash, cash equivalents and revenues.
Preliminary Financial Results
As at June 30, 2026, the Company’s cash and cash equivalents amounted to €166.1 million and €67.8 million in short-term deposits2, compared to cash and cash equivalents at €99.3 million and €131.6 million in short-term deposits as at December 31, 2025.
Net cash used in operating activities amounted to (€48.7) million for the first half of 2026, compared to (€53.7) million for the same period in 2025. The lower cash consumption mainly reflects the working capital change of €8.8 million between the two periods.
Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the “Combined Transaction”) through the issuance of approximately 15.7 million new warrants (bons de souscription d’actions) (the "New EIB Warrants") to the European Investment Bank (the "EIB") and the surrender and cancellation of all remaining warrants originally issued to the EIB in January 2024 (the “Legacy EIB Tranche B Warrants”) that were not repurchased in the Combined Transaction.
Andrew Obenshain, CEO of Inventiva, commented: " The completion of this EIB warrant restructuring is an important step in strengthening Inventiva’s capital structure and improving alignment with our shareholders.
Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting.
The Combined Shareholders' Meeting was held on Tuesday June 30, 2026, at 2 p.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Andrew Obenshain, Chief Executive Officer of Inventiva.
Mr. Andrew Obenshain proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mrs Susan Coles and Mr. Jean Volatier, as tellers, as well as Mr. Abel Colomb, as secretary of the general meeting.
All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 31st resolution, which had been the subject of a negative recommendation by the Board of Directors.
COMMUNIQUE DE PRESSE
Assemblée Générale Mixte du 30 juin 2026 Modalités de mise à disposition des documents préparatoires Daix (France), New York City (New York, United States), le 9 juin 2026 – Inventiva ((Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui les modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 30 juin 2026.
Les actionnaires d'Inventiva sont invités à participer à l’Assemblée Générale Mixte qui se tiendra le 30 juin 2026 à 14 heures à l'Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Paris (France). L’avis de réunion, comportant l’ordre du jour et les projets de résolutions ainsi que les principales modalités de participation et de vote à l’Assemblée Générale Mixte, a été publié au Bulletin des Annonces Légales et Obligatoires (BALO) n°61 du 22 mai 2026 et une traduction a été déposée auprès de la Securities and Exchange Commission le 22 mai 2026. Les actionnaires sont invités à se reporter à l’ordre du jour et au texte des résolutions disponibles sur le site internet de la Société, sous l’onglet « Assemblées générales », étant précisé que l’ordre du jour de l’Assemblée générale mixte a notamment été complété par une 39ᵉ résolution faisant suite à la conclusion, par la Société, en date du 1ᵉʳ juin 2026, d’un accord (master agreement) avec la Banque européenne d’investissement (BEI), relatif au remboursement intégral des prêts existants consentis par la BEI à la Société et au rachat par la Société d’une partie des bons de souscription émis au profit de la BEI dans le cadre de ces prêts, sous réserve du respect ou de la renonciation aux conditions qui y sont énoncées (les « Opérations BEI »)1. Précisément, la Société rachètera et annulera les BSA Tranche A BEI ainsi qu’une partie des BSA Tranche B BEI précédemment émis au profit de la BEI pour un prix de rachat total de 50 millions d’euros et émettra de nouveaux bons de souscription au profit de la BEI, à des conditions plus usuelles, en substitution du solde des BSA BEI Tranche B précédemment émis au profit de la BEI (les « BSA BEI Restants »), lesquels BSA BEI Restants seront remis en vue de leur annulation dès l’émission des Nouveaux BSA BEI, sous réserve de l’approbation des actionnaires de la Société lors de l’Assemblée générale mixte ou, si cette approbation n’est pas obtenue, lors d’une assemblée générale ultérieure qui devra se tenir au plus tard le 31 octobre 2026. En outre, les plafonds des résolutions 33 à 35, relatives aux attributions gratuites d’actions, aux options de souscription ou d’achat d’actions et à l’émission de bons de souscription, ont été ajustés afin de prendre en compte les décisions récentes du Conseil d’administration. Vous pouvez consulter et télécharger les informations et documents relatifs à l’Assemblée Générale Mixte sur le site internet de la Société (www.inventivapharma.com, rubrique « Investisseurs » / « Assemblées Générales »). Conformément aux articles R. 225-83 et R. 225-89 du Code de commerce, les documents qui doivent être tenus à la disposition des actionnaires dans le cadre des Assemblées Générales seront disponibles au siège social de la Société, 50, Rue de Dijon, 21121 Daix (France), à partir du quinzième jour précédant l’Assemblée Générale.
1
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 30 juin 2026 Daix (France), New York City (New York, United States), le 2 juillet 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui les résultats des votes de son Assemblée Générale Mixte. L’Assemblée Générale Mixte s’est tenue le mardi 30 juin à 14 heures à l'Hôtel Villa M – 24-30 Bd Pasteur - 75015 Paris, France, sous la présidence de Monsieur Andrew Obenshain, Directeur Général d’Inventiva. Monsieur Andrew Obenshain a procédé aux formalités d’usage d’ouverture de la séance, notamment à la constitution du Bureau en désignant Madame Susan Coles et Monsieur Jean Volatier, en qualité de scrutateurs, ainsi que Monsieur Abel Colomb en qualité de secrétaire de l’Assemblée générale. Toutes les résolutions soumises au vote ont été adoptées par ses actionnaires, à l'exception de la 31e résolution qui avait fait l’objet d’une recommandation défavorable du Conseil d’Administration. La 31e résolution aurait donné compétence au Conseil d’Administration pour décider la réalisation d'augmentations de capital social réservées aux adhérents d’un plan d’épargne d’entreprise à instituer par la Société. En application de l’article R. 22-10-14 IV du Code de commerce, l’Assemblée Générale Mixte a notamment approuvé, sans modification, la politique de rémunération des mandataires sociaux telle que décrite dans le Document d’enregistrement universel 2025 (partie 3.5.1, pages 134 et suivantes) et, pour ce qui concerne spécifiquement le président du conseil d’administration, dans la brochure de convocation à l’Assemblée Générale Mixte, mise en ligne sur le site internet de la Société sous la rubrique « Assemblées Générales ». Les informations relatives au résultat des votes sont présentées ci-dessous : •
Nombre total d’actions : 236 280 202
•
Nombre total d'actions ayant le droit de participer au vote : 236 280 202 PARTIE ORDINAIRE
PARTIE EXTRAORDINAIRE
ACTIONNAIRES
ACTIONS
VOIX
ACTIONNAIRES
ACTIONS
VOIX
Actionnaires présents
5
318 490
519 790
5
318 490
519 790
Pouvoir à des tiers
0
0
0
0
0
0
Pouvoir au Président
214
21 380 077
21 505 444
214
21 380 077
21 505 444
Votes par correspondance
221
148 125 573
155 342 788
221
148 125 573
155 342 788
TOTAL
440
169 824 140
177 368 022
440
169 824 140
177 368 022
QUORUM
71,874 %
71,874 % pg. 1
COMMUNIQUE DE PRESSE
RESULTATS DU SCRUTIN : Résolutions Ordinaires
Votes
%
Votes
%
Votes
%
Total des voix prises en compte
Adoptée
177 222 228
99,92 %
133 103
0,08 %
12 691
177 355 331
Actions représentées par les voix exprimées 169 824 140
2
Adoptée
177 221 334
99,92 %
134 197
0,08 %
12 491
177 355 531
169 824 140
71,874 %
3
Adoptée
177 221 057
99,92 %
134 109
0,08 %
12 856
177 355 166
169 824 140
4
Adoptée
177 218 663
99,92 %
138 566
0,08 %
10 793
177 357 229
5
Adoptée
169 001 759
99,80 %
333 429
0,20 %
8 475
6
Adoptée
142 101 931
80,13 %
35 235 606
19,87 %
30 485
7
Adoptée
142 260 329
80,22 %
35 075 808
19,78 %
8
Adoptée
142 242 043
80,21 %
35 094 119
9
Adoptée
142 260 377
80,22 %
10
Adoptée
171 116 568
11
Adoptée
12
Pour
Contre
Abstention
Proportion du capotal social Voix hors resprésente par les vote voix exprimées 71,874 % 0
Voix nulles
Quorum
0
71,874 %
0
0
71,874 %
71,874 %
0
0
71,874 %
169 824 140
71,874 %
0
0
71,874 %
169 335 188
161 799 781
68,477 %
8 024 359
0
71,874 %
177 337 537
169 824 140
71,874 %
0
0
71,874 %
31 885
177 336 137
169 824 140
71,874 %
0
0
71,874 %
19,79 %
31 860
177 336 162
169 824 140
71,874 %
0
0
71,874 %
35 075 785
19,78 %
31 860
177 336 162
169 824 140
71,874 %
0
0
71,874 %
96,49 %
6 233 151
3,51 %
18 303
177 349 719
169 824 140
71,874 %
0
0
71,874 %
142 115 577
80,14 %
35 219 585
19,86 %
32 860
177 335 162
169 824 140
71,874 %
0
0
71,874 %
Adoptée
142 256 741
80,22 %
35 077 573
19,78 %
33 708
177 334 314
169 824 140
71,874 %
0
0
71,874 %
13
Adoptée
143 403 465
80,86 %
33 943 220
19,14 %
21 337
177 346 685
169 824 140
71,874 %
0
0
71,874 %
14
Adoptée
170 745 845
96,28 %
6 604 810
3,72 %
17 367
177 350 655
169 824 140
71,874 %
0
0
71,874 %
15
Adoptée
172 576 402
97,31 %
4 763 296
2,69 %
28 324
177 339 698
169 824 140
71,874 %
0
0
71,874 %
16
Adoptée
174 294 992
98,28 %
3 044 831
1,72 %
28 199
177 339 823
169 824 140
71,874 %
0
0
71,874 %
17
Adoptée
151 354 591
85,35 %
25 987 080
14,65 %
26 351
177 341 671
169 824 140
71,874 %
0
0
71,874 %
18
Adoptée
151 353 927
85,35 %
25 987 714
14,65 %
26 381
177 341 641
169 824 140
71,874 %
0
0
71,874 %
19
Adoptée
151 170 758
85,24 %
26 170 883
14,76 %
26 381
177 341 641
169 824 140
71,874 %
0
0
71,874 %
20
Adoptée
145 764 550
82,20 %
31 566 386
17,80 %
37 086
177 330 936
169 824 140
71,874 %
0
0
71,874 %
40
Adoptée
177 215 321
99,93 %
127 471
0,07 %
25 230
177 342 792
169 824 140
71,874 %
0
0
71,874 %
Résolution
Résultat
1
pg. 2
COMMUNIQUE DE PRESSE
RESULTATS DU SCRUTIN : Résolutions Extraordinaires
Votes
%
Votes
%
Votes
%
Total des voix prises en compte
Adoptée
175 557 047
98,99 %
1 790 590
1,01 %
20 385
177 347 637
Actions représentées par les voix exprimées 169 824 140
22
Adoptée
144 164 252
81,28 %
33 194 352
18,72 %
9 418
177 358 604
169 824 140
71,874 %
23
Adoptée
143 103 408
80,69 %
34 255 067
19,31 %
9 547
177 358 475
169 824 140
24
Adoptée
143 083 973
80,68 %
34 256 866
19,32 %
27 183
177 340 839
25
Adoptée
143 090 257
80,69 %
34 253 657
19,31 %
24 108
26
Adoptée
143 086 234
80,68 %
34 257 680
19,32 %
24 108
27
Adoptée
143 090 519
80,69 %
34 251 194
19,31 %
28
Adoptée
143 260 260
80,77 %
34 099 506
29
Adoptée
143 162 737
80,73 %
30
Adoptée
143 245 142
31
Rejetée
32
Pour
Contre
Abstention
Proportion du capotal social Voix hors resprésente par les vote voix exprimées 71,874 % 0
Voix nulles
Quorum
0
71,874 %
0
0
71,874 %
71,874 %
0
0
71,874 %
169 824 140
71,874 %
0
0
71,874 %
177 343 914
169 824 140
71,874 %
0
0
71,874 %
177 343 914
169 824 140
71,874 %
0
0
71,874 %
26 309
177 341 713
169 824 140
71,874 %
0
0
71,874 %
19,23 %
8 256
177 359 766
169 824 140
71,874 %
0
0
71,874 %
34 180 406
19,27 %
24 879
177 343 143
169 824 140
71,874 %
0
0
71,874 %
80,77 %
34 096 744
19,23 %
26 136
177 341 886
169 824 140
71,874 %
0
0
71,874 %
81 472 089
45,94 %
95 870 777
54,06 %
25 156
177 342 866
169 824 140
71,874 %
0
0
71,874 %
Adoptée
177 054 574
99,83 %
307 309
0,17 %
6 139
177 361 883
169 824 140
71,874 %
0
0
71,874 %
33
Adoptée
142 122 037
80,13 %
35 237 007
19,87 %
8 978
177 359 044
169 824 140
71,874 %
0
0
71,874 %
34
Adoptée
142 066 660
80,10 %
35 284 507
19,90 %
16 855
177 351 167
169 824 140
71,874 %
0
0
71,874 %
35
Adoptée
143 260 220
80,78 %
34 095 970
19,22 %
11 832
177 356 190
169 824 140
71,874 %
0
0
71,874 %
36
Adoptée
177 186 176
99,91 %
153 411
0,09 %
28 435
177 339 587
169 824 140
71,874 %
0
0
71,874 %
37
Adoptée
177 211 214
99,93 %
132 881
0,07 %
23 927
177 344 095
169 824 140
71,874 %
0
0
71,874 %
38
Adoptée
143 381 185
80,85 %
33 961 896
19,15 %
24 941
177 343 081
169 824 140
71,874 %
0
0
71,874 %
39
Adoptée
143 934 896
81,16 %
33 415 428
18,84 %
17 698
177 350 324
169 824 140
71,874 %
0
0
71,874 %
Résolution
Résultat
21
pg. 3
A propos d'Inventiva Inventiva est une société biopharmaceutique en phase clinique spécialisée dans la recherche et développement d’une petite molécule administrée par voie orale pour le traitement de patients atteints de la MASH. La Société évalue actuellement le lanifibranor, un nouvel agoniste pan-PPAR, dans le cadre de l’étude clinique pivot de phase 3 NATiV3 pour le traitement de patients adultes atteints de la MASH, une maladie hépatique chronique courante et progressive. Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole: IVA, ISIN: FR0013233012) et sur le Nasdaq Global Market aux États-Unis (symbole: IVA). https://www.inventivapharma.com
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva Rapport des commissaires aux comptes sur l’autorisation d’attribution d'options de souscription ou d’achat d’actions
Assemblée générale mixte du 30 juin 2026, résolution n° 34 Inventiva 50, rue de Dijon - 21121 Daix
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 14-30080101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais (« private company limited by guarantee »).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva 50, rue de Dijon - 21121 Daix Rapport des commissaires aux comptes sur l’autorisation d’attribution d'options de souscription ou d’achat d’actions Assemblée générale mixte du 30 juin 2026, résolution n° 34 A l’assemblée générale mixte, En notre qualité de commissaires aux comptes de votre société et en exécution de la mission prévue par les articles L. 225-177 et R. 225-144 du code de commerce, nous vous présentons notre rapport sur l’autorisation d’attribution d'options de souscription ou d'achat d’actions au bénéfice des mandataires sociaux et salariés de votre société ou de sociétés du groupe, opération sur laquelle vous êtes appelés à vous prononcer. Le nombre total des options ainsi consenties ne pourra donner droit à souscrire ou acquérir un nombre total d'actions représentant plus de 8,1% du capital social à la date de la décision de leur attribution par le conseil d'administration, étant précisé que le montant nominal de toutes augmentations de capital susceptibles d’être réalisées en application de la présente résolution s’impute sur le plafond commun fixé au 2) de la 33ème résolution de la présente Assemblée générale. Votre conseil d’administration vous propose, sur la base de son rapport, de l’autoriser pour une durée de 38 mois à attribuer des options de souscription ou d'achat d'actions. Il appartient au conseil d’administration d'établir un rapport sur les motifs de l'ouverture des options de souscription ou d'achat d'actions ainsi que sur les modalités proposées pour la fixation du prix de souscription ou d'achat. Il nous appartient de donner notre avis sur les modalités proposées pour la fixation du prix de souscription ou d'achat des actions.
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 14-30080101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais (« private company limited by guarantee »).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
Nous avons mis en œuvre les diligences que nous avons estimé nécessaires au regard de la doctrine professionnelle de la Compagnie nationale des commissaires aux comptes relative à cette mission. Ces diligences ont consisté notamment à vérifier que les modalités proposées pour la fixation du prix de souscription ou d'achat des actions sont précisées dans le rapport du conseil d’administration et qu'elles sont conformes aux dispositions prévues par les textes légaux et règlementaires. Nous n'avons pas d'observation à formuler sur les modalités proposées pour la fixation du prix de souscription ou d'achat des actions.
Paris La Défense, le 8 juin 2026
Paris, le 8 juin 2026
KPMG SA [sc_sign.KPMG.signature]
LCA Audit
Philippe Grandclerc Associé
Lison Dahan Chouraki Associée
Lison Dahan Chouraki
Signature numérique de Lison Dahan Chouraki Date : 2026.06.08 20:42:32 +02'00'
Inventiva S.A. Rapport des commissaires aux comptes sur l’autorisation d’attribution d'options de souscription ou d’achat d’actions Assemblée générale mixte du 30 juin 2026 - résolution n° 34 3
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva Rapport des commissaires aux comptes sur l’autorisation d’attribution d’actions gratuites existantes ou à émettre
Assemblée générale mixte du 30 juin 2026, résolution n° 33 Inventiva 50, rue de Dijon - 21121 Daix
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 14-30080101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais (« private company limited by guarantee »).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva 50, rue de Dijon - 21121 Daix Rapport des commissaires aux comptes sur l’autorisation d’attribution d’actions gratuites existantes ou à émettre Assemblée générale mixte du 30 juin 2026, résolution n° 33 A l’assemblée générale mixte, En notre qualité de commissaires aux comptes de votre société, et en exécution de la mission prévue par l’article L. 225-197-1 du code de commerce, nous vous présentons notre rapport sur le projet d’autorisation d’attribution d'actions gratuites existantes ou à émettre au profit des membres du personnel salarié et/ou des mandataires sociaux de votre société et des sociétés qui lui sont liées, opération sur laquelle vous êtes appelés à vous prononcer. Le nombre total d’actions ainsi attribuées gratuitement ne pourra dépasser 8,1% du capital social à la date de la décision de leur attribution par le conseil d'administration, étant précisé que le montant nominal de toutes les augmentations de capital susceptibles d’être réalisées en application de la présente résolution, de la 34ème résolution et de la 35ème résolution, ne pourra excéder un plafond de 8,1% du capital social sur une base pleinement diluée constaté à la date de la présente Assemblée Générale. Votre conseil d’administration vous propose, sur la base de son rapport, de l’autoriser, pour une durée de 38 mois à attribuer des actions gratuites existantes ou à émettre. Il appartient au conseil d’administration d'établir un rapport sur cette opération à laquelle il souhaite pouvoir procéder. Il nous appartient de vous faire part, le cas échéant, de nos observations sur les informations qui vous sont ainsi données sur l’opération envisagée.
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 14-30080101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais (« private company limited by guarantee »).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
Nous avons mis en œuvre les diligences que nous avons estimées nécessaires au regard de la doctrine professionnelle de la Compagnie nationale des commissaires aux comptes relative à cette mission. Ces diligences ont consisté notamment à vérifier que les modalités envisagées et données dans le rapport du conseil d’administration s’inscrivent dans le cadre des dispositions prévues par la loi. Nous n'avons pas d'observation à formuler sur les informations données dans le rapport du conseil d’administration portant sur l’opération envisagée d’autorisation d’attribution d’actions gratuites. Paris La Défense, le 8 juin 2026
Paris, le 8 juin 2026
KPMG SA [sc_sign.KPMG.signature]
LCA Audit Signature numérique
[/sc_sign.KPMG.signature]
Lison Dahan Lison Dahan de Chouraki Date : 2026.06.08 Chouraki 20:43:02 +02'00'
Philippe Grandclerc Associé
Lison Dahan Chouraki Associée
Inventiva S.A. Rapport des commissaires aux comptes sur l’autorisation d’attribution d’actions gratuites existantes ou à émettre Assemblée générale mixte du 30 juin 2026 - résolution n° 33
3
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva Rapport des commissaires aux comptes sur l’émission d’actions ordinaires ou de diverses valeurs mobilières de la société réservée aux adhérents d’un plan d’épargne d’entreprise
Assemblée générale mixte du 30 juin 2026, résolution n° 31 Inventiva 50, rue de Dijon - 21121 Daix
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 14-30080101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais (« private company limited by guarantee »).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva 50, rue de Dijon - 21121 Daix Rapport des commissaires aux comptes sur l’émission d’actions ordinaires ou de diverses valeurs mobilières de la société réservée aux adhérents d’un plan d’épargne d’entreprise Assemblée générale mixte du 30 juin 2026, résolution n° 31 A l’assemblée générale mixte, En notre qualité de commissaires aux comptes de votre société et en exécution de la mission prévue par les articles L. 228-92 et L. 225-135 et suivants du code de commerce, nous vous présentons notre rapport sur la proposition de délégation au conseil d’administration de la compétence de décider l’émission d’actions ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme avec suppression du droit préférentiel de souscription, réservée aux salariés et anciens salariés adhérents d’un plan d’épargne d’entreprise de votre société, pour un montant maximum de 4 300 euros, opération sur laquelle vous êtes appelés à vous prononcer. Il est précisé que le montant nominal des augmentations de capital susceptibles de résulter de la présente résolution s’impute sur le plafond global de 2.000.000 euros fixé à la 22ième résolution. Cette émission est soumise à votre approbation en application des dispositions des articles L. 225-1296 du code de commerce et L. 3332-18 et suivants du code du travail. Votre conseil d’administration vous propose, sur la base de son rapport, de lui déléguer pour une durée de 26 mois la compétence pour décider une émission et de supprimer votre droit préférentiel de souscription aux actions ordinaires ou valeurs mobilières à émettre. Le cas échéant, il lui appartiendra de fixer les conditions définitives d’émission de cette opération. Il appartient au conseil d’administration d'établir un rapport conformément aux articles R. 225-113 et suivants du code de commerce. Il nous appartient de donner notre avis sur la sincérité des informations chiffrées tirées des comptes, sur la proposition de suppression du droit préférentiel de souscription et sur certaines autres informations concernant l'émission, données dans ce rapport. Nous avons mis en œuvre les diligences que nous avons estimées nécessaires au regard de la doctrine professionnelle de la Compagnie nationale des commissaires aux comptes relative à cette mission. Ces diligences ont consisté à vérifier le contenu du rapport du conseil d’administration relatif à cette opération et les modalités de détermination du prix d'émission des titres de capital à émettre.
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 14-30080101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais (« private company limited by guarantee »).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
Sous réserve de l'examen ultérieur des conditions de l'émission qui serait décidée, nous n'avons pas d'observation à formuler sur les modalités de détermination du prix d'émission des titres de capital à émettre données dans le rapport du conseil d’administration. Les conditions définitives dans lesquelles l’émission serait réalisée n’étant pas fixées, nous n'exprimons pas d'avis sur celles-ci et, par voie de conséquence, sur la proposition de suppression du droit préférentiel de souscription qui vous est faite. Conformément à l'article R. 225-116 du code de commerce, nous établirons un rapport complémentaire, le cas échéant, lors de l’utilisation de cette délégation par votre conseil d’administration.
Paris La Défense, le 8 juin 2026
Paris, le 8 juin 2026
KPMG SA [sc_sign.KPMG.signature]
LCA Audit Signature numérique
Lison Dahan Lison Dahan de Chouraki Date : 2026.06.08 Chouraki
[/sc_sign.KPMG.signature] Philippe Grandclerc Associé
20:43:33 +02'00'
Lison Dahan Chouraki Associée
Inventiva S.A. Rapport des commissaires aux comptes sur l’émission d’actions ordinaires ou de diverses valeurs mobilières de la société réservée aux adhérents d’un plan d’épargne d’entreprise Assemblée générale mixte du 30 juin 2026- résolution n°31 3
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva Rapport des commissaires aux comptes sur l’émission d’actions et de diverses valeurs mobilières avec maintien et/ou suppression du droit préférentiel de souscription
Assemblée générale mixte du 30 juin 2026, résolutions n° 22 à 30 Inventiva S.A. 50, rue de Dijon - 21121 Daix
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 143008010101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais ( private company limited by guarantee ).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
LCA Audit 22 rue Fourcroy 75017 Paris
KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex
Inventiva S.A. 50, rue de Dijon - 21121 Daix Rapport des commissaires aux comptes sur l’émission d’actions et de diverses valeurs mobilières avec maintien et/ou suppression du droit préférentiel de souscription Assemblée générale mixte du 30 juin 2026, résolutions n° 22 à 30 A l’assemblée générale mixte, En notre qualité de commissaires aux comptes de votre société et en exécution de la mission prévue par les articles L.228-92 et L.225-135 et suivants du code de commerce, nous vous présentons notre rapport sur les propositions de délégation au conseil d’administration de différentes émissions d’actions et/ou de valeurs mobilières, opérations sur lesquelles vous êtes appelés à vous prononcer. Votre conseil d’administration vous propose, sur la base de son rapport :
• de lui déléguer, pour une durée de 26 mois, la compétence pour décider des opérations suivantes et
fixer les conditions définitives de ces émissions et vous propose, le cas échéant, de supprimer votre droit préférentiel de souscription :
émission avec maintien du droit préférentiel de souscription (22ième résolution) d’actions ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme ;
émission avec suppression du droit préférentiel de souscription par voie d'offre au public autre que celles visées au 1° de l'article L.411-2 du code monétaire et financier (23ième résolution) d’actions ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme. Etant précisé que conformément à l’article L. 22-10-52 alinéa 1 du code de commerce, votre conseil d’administration vous propose de l’autoriser à fixer librement le prix d'émission des titres de capital à émettre au titre de la 23ème résolution ;
émission avec suppression du droit préférentiel de souscription par voie d'offres visées au 1° de l'article L.411-2 du code monétaire et financier et dans la limite légale de 30% du capital social par an (24ième résolution) d’actions ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme. Etant précisé que conformément à l’article L. 2210-52 alinéa 1 du code de commerce, votre conseil d’administration vous propose de l’autoriser à fixer librement le prix d'émission des titres de capital à émettre au titre de la 24ème résolution ;
KPMG S.A., société d’expertise comptable et de commissaires aux comptes inscrite au Tableau de l’Ordre des experts comptables de Paris sous le n° 143008010101 et rattachée à la Compagnie régionale des commissaires aux comptes de Versailles et du Centre. Société française membre du réseau KPMG constitué de cabinets indépendants affiliés à KPMG International Limited, une société de droit anglais ( private company limited by guarantee ).
Société anonyme à conseil d’administration Siège social : Tour EQHO 2 avenue Gambetta CS 60055 92066 Paris La Défense Cedex Capital social : 5 497 100 € 775 726 417 RCS Nanterre
LCA Audit Société de commissariat aux comptes Siège social : 22 rue Fourcroy 75017 Paris 512 150 467 RCS PARIS
émission avec suppression du droit préférentiel de souscription en cas d’offre publique d’échange initiée par votre société (29ième résolution) d’actions ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme ;
• de lui déléguer, pour une durée de 18 mois, la compétence pour décider une émission d’actions
ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme et de supprimer votre droit préférentiel de souscription aux actions et aux autres valeurs mobilières au profit des catégories de bénéficiaires suivantes (25ième résolution) : (i) des personnes physiques ou morales, en ce compris des sociétés, trusts ou fonds d’investissement ou autres véhicules de placement, quelle que soit leur forme, de droit français ou étranger, investissant à titre habituel dans le secteur pharmaceutique, biotechnologique, ou des technologies médicales ; et/ou (ii) des sociétés, institutions ou entités quelle que soit leur forme, françaises ou étrangères, exerçant une part significative de leurs activités dans le domaine pharmaceutique, cosmétique ou chimique ou des dispositifs et/ou de la recherche dans ces domaines ; et/ou (iii) des prestataires de services d'investissement français ou étranger ayant un statut équivalent susceptibles de garantir la réalisation d'une émission destinée à être placée auprès des personnes visées au (i) et/ou (ii) ci-dessus et, dans ce cadre, de souscrire aux titres émis.
• de lui déléguer, pour une durée de 18 mois , la compétence pour décider une émission avec suppression
du droit préférentiel de souscription d’actions ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme réservée à une ou à plusieurs personnes nommément désignées et de lui déléguer le pouvoir de désigner ces personnes conformément à l’article L. 22-10-52-1 du code de commerce, dans la limite de 30 % du capital social par an (26ième résolution) ;
• de lui déléguer, pour une durée de 18 mois, la compétence pour décider une émission d’actions
ordinaires à émettre immédiatement ou à terme et de supprimer votre droit préférentiel de souscription aux actions et autres valeurs mobilières au profit des catégories de bénéficiaires suivantes (27ième résolution) : (i) tout établissement de crédit ou tout prestataire de services d’investissement, français ou étranger, ou tout établissement étranger ayant un statut équivalent, intervenant dans le cadre d'un contrat de financement en fonds propres sur le marché américain dit « At-the-market » ou « ATM » mis en place par votre Société (ou tout programme de financement en fonds propres de même nature qui viendrait s'y substituer) et prévoyant, dans ce cadre, de souscrire aux titres émis par votre Société
•
de lui déléguer, pour une durée de 26 mois, les pouvoirs nécessaires à l’effet de procéder à une émission d'actions ordinaires ou de valeurs mobilières donnant accès à des actions ordinaires à émettre immédiatement ou à terme, en vue de rémunérer des apports en nature consentis à la société et constitués de titres de capital ou de valeurs mobilières donnant accès au capital (30ième résolution), dans la limite légale de 20% du capital.
Le montant nominal global des augmentations du capital susceptibles d’être réalisées immédiatement ou à terme ne pourra, selon les 22iéme et 23ième résolutions : •
excéder 2.000.000 euros, au titre des 22ième, 23iéme, 25ième et 30ième résolutions, étant précisé que ce montant s’impute sur le plafond global de 2.000.000 euros fixé à la 22ième résolution ;
•
excéder 1.000.000 euros, au titre des 24ième , 26ième, 27eme et 29ième résolutions, étant précisé que ce montant s’impute sur le plafond global de 2.000.000 euros fixé à la 22ième résolution.
Par ailleurs, le montant nominal global des titres de créance susceptibles d’être émis ne pourra, selon la 22ième résolution, excéder 500.000.000 euros au titre des 22ième à 30ième résolutions. Ces plafonds tiennent compte du nombre supplémentaire de titres à créer dans le cadre de la mise en œuvre des délégations visées aux 22ième, 23iéme, 25ième, 27ième, 29ième et 30ième résolutions, dans les conditions prévues à l’article L.225-135-1 du code de commerce, si vous adoptez la 22ième résolution. Il appartient au conseil d’administration d’établir un rapport conformément aux articles R.225-113 et suivants du code de commerce. Il nous appartient de donner notre avis sur la sincérité des informations chiffrées tirées des comptes, sur la proposition de suppression du droit préférentiel de souscription et sur certaines autres informations concernant ces opérations, données dans ce rapport. Nous avons mis en œuvre les diligences que nous avons estimées nécessaires au regard de la doctrine professionnelle de la Compagnie nationale des commissaires aux comptes relative à cette mission. Ces diligences ont consisté à vérifier le contenu du rapport du conseil d’administration relatif à ces opérations et les modalités de détermination du prix d’émission des titres de capital à émettre. Sous réserve de l'examen ultérieur des conditions des émissions qui seraient décidées, nous n'avons pas d'observation à formuler sur les modalités de détermination du prix d'émission des titres de capital à émettre données dans le rapport du conseil d’administration au titre de la 25ème, 26ème et 27ème résolutions. Par ailleurs, ce rapport ne précisant pas les modalités de détermination du prix d’émission des titres de capital à émettre dans le cadre de la mise en œuvre des 22ème, 29ème et 30ème résolutions, nous ne pouvons donner notre avis sur le choix des éléments de calcul de ce prix d’émission. Les conditions définitives dans lesquelles les émissions seront réalisées n'étant pas fixées, nous n'exprimons pas d'avis sur celles-ci. Conformément à l’article R.225-116 du code de commerce, nous établirons un rapport complémentaire, le cas échéant, lors de l'utilisation de ces délégations par votre conseil d’administration en cas d'émission de valeurs mobilières qui sont des titres de capital donnant accès à d’autres titres de capital ou donnant droit à l’attribution de titres de créance, en cas d’émission de valeurs mobilières donnant accès à des titres de capital à émettre et en cas d'émission d’actions avec suppression du droit préférentiel de souscription. Les commissaires aux comptes
Paris La Défense, le 8 juin 2026
Paris, le 8 juin 2026
KPMG SA [sc_sign.KPMG.signature]
LCA Audit Signature numérique
Lison Dahan Lison Dahan de Chouraki Date : 2026.06.08 Chouraki
[/sc_sign.KPMG.signature] Philippe Grandclerc Associé
20:41:05 +02'00'
Lison Dahan Chouraki Associée
INVENTIVA
French société Anonyme with a Board of Directors
with a share capital of EUR 2,090,074.75
Registered Office: 50, Rue de Dijon, 21121 Daix
Notice of meeting
The shareholders of INVENTIVA are informed that the ordinary and extraordinary general meeting (the “General Meeting”) will be held on June 30, 2026 at 2 p.m., at: l’Hôtel Villa M, 24-30, boulevard Pasteur - 75015 Paris, France.
With respect to the notice of meeting published in the Bulletin des Annonces Légales Obligatoires on 22 May 2026 (bulletin no. 61), resolutions 33, 34 and 35 have been amended, in particular in order to provide for a new common ceiling, and a 39th resolution, entitled “Decision to issue warrants, without shareholders' preemptive subscription rights, to the benefit of the European Investment Bank and delegation of power to the Board of Directors”, has been added.
Consequently, the agenda of the General Meeting and the draft texts of the resolutions on which it is called to deliberate are as follows:
Agenda
Reading of the reports of the Board of Directors and the Statutory Auditors;
On an Ordinary basis
1.
· Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7 million Underlying Shares) for a repurchase price of €50 million
· Issued the Tranche A Convertible Bonds (€35 million) and the Tranche B Amortized Bonds (€40 million), for an initial aggregate drawdown of €75 million under the Debt Financing Transaction3 with funds and accounts managed by BlackRock and Claret Capital Partners
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the completion, on June 12, 2026, of the following key steps of the transactions previously announced on June 2, 2026 (the “Combined Transaction”): (i) the repayment in full of the EIB Loans and the repurchase of a portion of the existing EIB Warrants; and (ii) the issuance of the Tranche A Conver
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of June 30, 2026.
Shareholders are invited to participate in the Combined General Meeting that will be held on June 30, 2026 at 2 p.m. at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Paris (France).
The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n°61 of May 22, 2026 and a translation was filed with the Securities and Exchange Commission on May 22, 2026.
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 3:30 p.m. CEST.
Trading of the ordinary shares of the Company was halted, at the Company’s request, on June 2, 2026 from 9:00 a.m. CEST, in the context of the previously announced Debt Financing Transaction and Offering of American Depositary Shares in the United States (each representing one new ordinary share of the Company with a nominal value of €0.01).
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH.
Optimization including Debt and Equity Financing in
Advance of the Anticipated Phase 3 Readout
· Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an additional uncommitted tranche of up to €20 million, to replace its existing EIB loan ahead of maturity and extend its debt maturity profile to 2030
· Simplifying its capital structure with agreement to repurchase existing warrants issued in favor of the EIB, thereby eliminating 60% of the dilution protected EIB warrants (exercisable into 22.7 million shares), at a 40% discount to intrinsic value, and restructuring the remaining EIB warrants on terms that do not contain dilution protection
· Priced an underwritten offering of $ 120 million American Depositary Shares only in the United States and listed on the Nasdaq Global Market, from both new and existing investors
· Extending cash runway into early first quarter 2028, assuming the completion of the Equity Offering, the EIB transactions, the full exercise of all warrants in the optional tranche 3 of the October 2024 structured financing1, a
Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York, as Depositary (Must be received prior to 12:00 PM Eastern Time June 24, 2026) The undersigned Holder of American Depositary Receipts (“Receipts”) of Inventiva S.A. (the “Company”) hereby requests and instructs The Bank of New York, as Depositary, to vote or cause to be voted the number of ordinary shares represented by such Receipt(s) of the Company, registered in the name of the undersigned on the books of the Depositary as of the close of business May 22, 2026 at the Ordinary and Extraordinary General Meeting of Shareholders to be held on June 30, 2026. Notes: 1. Please direct the Depositary how to vote by placing an X in the box opposite the resolutions on the reverse side. 2. If no instructions are received, a discretionary proxy will be given to a person designated by the Company. Inventiva S.A. PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE Inventiva S.A.
Cash and cash equivalents at €75.0 million, and €121.5 million in short-term deposits2
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first quarter of 2026, including its cash, cash equivalents and revenues.
Key Financial Results
Cash, Cash Equivalents and Deposits
As of March 31, 2026, the Company's cash and cash equivalents amounted to €75.0 million and its short-term deposits2 to €121.5 million, compared to cash and cash equivalents of €99.3 million and short-term deposits of €131.6 million as of December 31, 2025. The net cash used was mainly the result of the Company’s planned operating activities related to its lanifibranor development program.
INVENTIVA
Société Anonyme with a Board of Directors
With a share capital of EUR 2,090,074.75
Registered Office: 50, Rue de Dijon, 21121 Daix
Notice of meeting to the Ordinary and Extraordinary General Meeting dated June 30, 2026
The shareholders of INVENTIVA (the “Company”) are informed that the ordinary and extraordinary general meeting (the “General Meeting”) will be held on June 30, 2026, at 2 p.m., at: Hôtel Villa M, 24-30, boulevard Pasteur – 75015 Paris, France.
The General Meeting will be broadcasted live on the Company's website https://inventivapharma.com/fr/investisseurs/assemblees-generales/.
The Ordinary and Extraordinary General Meeting will have to deliberate on the following agenda:
Agenda
Reading of the reports of the Board of Directors and KPMG S.A. (the “Statutory Auditors”);
Ordinary items
1. Approval of the statutory financial statements for the financial year ended December 31, 2025;
2. Approval of the consolidated financial statements for the financial year ended December 31, 2025;
3. Appropriation of profit/loss for the financial year ended December 31, 2025;
4.
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization.
Axel-Sven Malkomes joins as Chief Financial Officer, bringing more than 30 years of investment banking and corporate leadership experience, including recently playing an instrumental role in CureVac’s acquisition by BioNTech.
Susan Coles joins as Chief Legal Officer, bringing more than 25 years of experience guiding life science companies through growth and transformation.
Pamela Herbster joins as Chief People Officer, bringing over 25 years of biopharmaceutical experience in developing human resource strategies and programs that elevate organizational performance and cultivate high-performing, people-centric cultures.
Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025
Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)
Cash runway expected until the middle of the first quarter of 20273
Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approved
Topline results of NATiV3 Phase 3 clinical trial expected for the fourth quarter of 2026
The Company will host a conference call on March 31, 2026, at 8 a.m. EDT / 2 p.m. CEST
Daix (France), New York City (New York, United States), March 30, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial results for the full year ended December 31, 2025 and also provided a business update.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Inventiva S.A.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.